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David, a shepherd from an early age, developed his courage and fi ghting skills by defending the fl ocks 
from the wild animals that preyed upon them. The free time that being a shepherd provided also allowed 
him to develop two other skills, that of music and poetry. David was a warrior, and a writer of psalms.
When the Israelites were at war with the Philistines, the two armies faced each other from opposite 
hills with the Valley of Elah between them. Every morning for forty days, the mighty Philistine Goliath 
(he may have stood over 9 feet tall) challenged the Israelites for someone to come out and fi ght him, but 
none would go out. One day, David, who was actually then too young for the army, arrived with some 
deliveries for his older brothers. He heard Goliath and immediately volunteered to fi ght him. 
When David explained to King Saul that he had been fi ghting fi erce animals all his life, he convinced 
the king that he could defeat the Philistine. Perhaps by then the king was willing to try anything to 
get out of the embarrassing situation, and even if David were not successful the Israelites could always 
belittle his lack of success with the excuse that David was “just a kid.”
After turning down an off er of the king’s own armor, which was too big for him, David went down to 
the creek and got fi ve suitable stones (fi ve, not just one, as any prudent marksman would do when facing 
a very formidable opponent). He killed Goliath with a single perfectly-accurate shot, perhaps with a little 
help from an angel – the stone didn’t just rebound off  the giant man’s thick skull as would naturally be 
expected, but actually penetrated with the power of a modern high-velocity bullet. Upon seeing their 
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INTRODUCTION
Within medicine there is growing focus on the quality of care delivered. Not only medical 
professionals strive for increased performance. Also patients, politicians and insurance 
companies, each having there own and diff erent interest, aim for optimal care. To illustrate 
the widespread interest for quality, several rank lists have been published in the Dutch 
laymen’s press, qualifying various hospitals to be the “best institution”.1-3 Although the quality 
of medical care is far from easy to defi ne and measure, there is an irreversible tendency of 
governmental institutions to regulate on the basis of quality. In the Netherlands, the Inspec-
tion of Health Care has defi ned a number of “performance indicators” with the intend to 
improve quality. According to the Inspection these indicators are all “quantifi able parameters 
that represent quality, safety, effi  cacy and accessibility of medical care”.4 Indicators include, 
amongst others, hemovigilance for patients undergoing blood transfusion, percentage of 
unscheduled surgical re-interventions, number of patients with a hip fracture that undergoes 
surgery within 24 hours, and the fraction of patients diagnosed with breast cancer within 
fi ve days after presentation. Each hospital is obliged to measure and to disclose its perfor-
mance on the internet. Consumer pressure is an important factor backing up this system. 
Although the introduction of performance indicators seems an attractive option, there may 
be a considerable risk of false interpretation of reported indicators due to methodological 
and statistical pitfalls.5 Moreover, it is argued that performance indicators are determined not 
only by the quality of treatment, but also by patient characteristics such as age, comorbidity 
and complexity of disease at presentation.6,7 Therefore, it has been suggested that investigat-
ing diagnostic and therapeutic processes may gain better insight in the quality of care rather 
than focussing solely on predefi ned treatment endpoints.8
Despite the fact that the current way of measuring quality may not be optimal, it is an 
appealing idea that the quality of care is crucial and infl uences treatment outcome to a con-
siderable extent. However, before any attempt is made to measure quality, it is key to defi ne 
it fi rst. One could arbitrarily state that the quality of a treatment is determined by comparing 
it to a standard that is consensus-based and considered as suffi  cient by medical professionals 
working in a particular area. For example, experts in the fi eld of rectal cancer treatment have 
recently stated that MRI is mandatory in the diagnostic work up to assess mesorectal fascia 
infi ltration by the rectal tumour.9 In line with this statement, omitting a MRI scan would imply 
inferior quality of preoperative work up. Another example may be the leaving out of lymph 
node dissection in the surgical treatment of gastric cancer. Results from a large US random-
ized clinical trial10 showed clearly that surgical undertreatment by removing too few lymph 
nodes is responsible for poor survival.11 Therefore, lymph node dissection should be per-
formed to a certain extent in order to achieve a suffi  cient quality of surgical care. By reaching 
consensus in this manner, a defi nition of acceptable practise emerges that can be referred to 
when evaluating diagnostic and therapeutic strategies. The development of a standard aids 
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in reducing variability of treatment outcome between institutions and individual physicians. 
To develop and maintain a certain standard, a complete set of measures needs to be taken. 
Only then a predefi ned level of care can be realised, ranging from accurate and unanimous 
diagnosis, standardized therapeutic interventions to clear-cut evaluation protocols. All these 
measures taken together constitute the principle of quality assurance (QA).
Treating solid malignancies has become a matter of team work. Key players are the surgi-
cal oncologist, the radiation oncologist and the medical oncologists. Although radiologists 
and pathologist have become increasingly important in the peri-operative care, their con-
tribution to the quality of oncological care is not discussed in this introducing chapter. QA 
programmes have been successfully launched by the European Organisation of Research and 
Treatment of Cancer (EORTC) in the fi eld of both radiation and medical oncology. The EORTC, 
founded in 1962, with its headquarters in Brussels, Belgium is an organisation that develops, 
conducts and coordinates laboratory and clinical research throughout Europe in an attempt 
to improve the management of cancer. The work of the EORTC is funded by the EORTC Foun-
dation, an international association that was established by royal decree under Belgian law. 
In radiation oncology, as early as 1982, a quality assurance programme was activated in the 
EORTC Cooperative Group of Radiotherapy.12 Programmes included dosimetry studies13,14 and 
the development of infrastructure guide-lines in order to implement radiotherapy quality 
assurance programmes.15,16 In medical oncology comparable initiatives were set up: atten-
tion has been successfully focussed on local facilities of hospitals with regard to adequate 
dosing, preparation and administration of cytotoxic drugs.17 Within the context of quality 
programmes centers have been visited and facilities for treatment and data management 
have been reviewed.18,19
Apart from the input by professional organisations, launching new (cytotoxic) drugs is 
backed up by the pharmaceutical industry, willing to invest considerably in an attempt to 
have their drugs released. Also, to ensure safety and quality of new drugs, governmental 
institutions as the US Food and Drug Administration (FDA) and its European counterpart, 
the European Medicines Agency (EMEA) play an important role as well. Despite this govern-
mental interference, withdrawal of promising drugs may become inevitable, as became clear 
from the withdrawal of rofecoxib (VIOXX), a COX2-inhibitor, showing a rise in cardiovascular 
events after a secondary safety analysis in comparison to Naprosyn, another non-steroidal 
infl ammatory drug.20 The withdrawal of this money-making drug from the market caused 
Merck’s stock price to fall by 40%, implying a loss of US$40 billion in market capitalization. 
The resources that are involved in developing and releasing novel drug are enormous. These 
fi nancial investments should be counterbalanced against the possible benefi ts that can be 
obtained when applying these means in other areas of oncological care.
So what about surgical oncology? Surgery has a major impact on treatment outcome and is 
the key to cure in patients with solid malignancies. If it’s agreed that investing in quality is 
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worthwhile, the profi ts of QA programmes are perhaps most pronounced in surgery. However, 
in contrast to medical and radiation oncology, surgery may seem a less attractive candidate 
for QA programmes: every operation may be looked upon as a unique event with numerous 
unpredictable characteristics. Surgery is therapy but not a pill that represents identical tim-
ing and dosing in each patient. This possibly leads to the idea that developing a standard 
of quality of surgical treatment is practically impossible. Meanwhile however, practise has 
proved the opposite. The advances in rectal cancer surgery illustrate clearly the benefi ts of 
surgical QA programmes. From the early days of rectal cancer surgery until recently, local 
recurrences after rectal cancer treatment have been a major problem. Symptoms of local 
failure are severe and include rectal blood loss, incontinence and intractable pain.21 For many 
years, aggressive biological tumour behaviour had been held responsible for local failure 
after rectal cancer surgery. It was Heald who stated for the fi rst time in 1979 that leaving 
behind mesorectal tissue was responsible for local recurrence rather than the inherent nature 
of rectal cancer.22 The principle of total mesorectal excision (TME) was born: removing the 
complete mesorectum with its tumour bearing tissue, resulted in a stunning drop of local 
recurrences. External audit was considered necessary to validate Heald’s results.23 In the 
decades thereafter TME has been successfully introduced in many countries: surgeons have 
been taught in the principles of TME, and local recurrences have dropped and survival has 
improved concomitantly.24-26 Moreover, due to working under vision when enveloping the 
mesorectum, nerves that are important for sexual and bladder function are now spared and 
identifi ed, leading to superior functional outcome after pelvic surgery.27-29 When comparing 
the results of TME to those of conventional surgery which involves blunt dissection of the 
mesorectum, it has to be concluded that there is considerable impact of the type and quality 
of surgery on clinical outcome parameters such as local control and survival. Keeping this in 
mind, surgery needs to be standardized and quality-controlled when testing (neo-)adjuvant 
regimens: only then the role of surgery as a confounding factor can be reduced and the 
impact of radiation and/or chemotherapy regimens can be assessed reliably. To illustrate 
this, in the Norwegian Rectal Cancer Project that involved the introduction of TME among 
surgeons, survival at four years improved substantially from 60% to 73% with a two fold drop 
in local recurrences.25 For comparison, the 5 year survival rate improvement of 5FU based 
chemotherapy in stage III colon cancer patients has been “only” 5% from 45% to 50%.30 These 
fi gures indicate that the impact of surgery on treatment outcome may be more pronounced 
than the eff ect of cytotoxic therapies. Therefore, standardizing and auditing surgery is key in 
studies investigating experimental (neo-)adjuvant regimes. There are not many studies that 
control the surgical act. The “TME trial” has been an exception. This prospective randomised 
trial tested the impact on local control of preoperative short term radiotherapy applying 5x5 
Gy in patients with operable rectal cancer who were treated according tot the principles of 
TME surgery.31 A few years earlier the Swedish Rectal Cancer trial had already shown that 
this radiotherapy regimen was benefi cial in rectal cancer patients who were treated with 
14 Chapter 1
conventional surgery: both local control as well as survival was superior in irradiated patients 
(11% vs. 27%, P <0.001 resp. 58% vs. 48%, P = 0.004).32 The question that had to be answered 
was whether radiotherapy was still benefi cial in TME treated patients. A pilot phase preceded 
the TME trial: Y. Moriya from the National Cancer Center Hospital in Tokyo, Japan operated 
upon 47 Dutch rectal cancer patients obeying the nerve-preserving and TME principles. Local 
recurrence rate was 7.1%, and it was concluded that nerve preserving did not compromise 
radicality.33 In 1996 the TME trial was launched. Running this trial meant introducing the TME 
technique on a national scale. An extensive QA program was executed in order to standardize 
surgical treatment and to reduce variation in the quality of surgery between the 84 partici-
pating centers.31 A unique surgical QA structure was set up: workshops and symposia were 
organised, an instruction video was distributed and a monitoring committee of experienced 
instructor-surgeons was installed that gave instructions on-site. In each center, the fi rst fi ve 
TME operations were supervised by members of the surgical committee. Not only surgery 
was standardised, but also pathological evaluation of the resected specimens took place 
according to well defi ned guidelines as described in the protocol of Quirke et al.34 A panel of 
supervising pathologists reviewed the results of histopathological examinations. Moreover, 
the study coordinators of surgery, radiotherapy and pathology checked trial eligibility, treat-
ment and follow-up data. The Central Data Offi  ce of the surgical department of the Leiden 
University Medical Center ensured the quality of all data.35 By executing this structure of ex-
tensive data collection and reviewing, a rich database has emerged that encompasses major 
opportunities for further research. Early results after a median follow-up of two years showed 
a signifi cant diff erence on local recurrence rates to the benefi t of radiotherapy (2.4% vs. 5.3%, 
P<0.001) without any diff erence in overall survival (82.0% vs. 81.8%, P = 0.84).36 Introduction 
of TME in 84 Dutch hospitals applying the surgical QA program seemed successful.
A similar initiative of quality controlled surgical research was already launched in 1989 
when the Dutch Gastric “D1D2 trial” was started. This trial investigated the benefi ts of ex-
tended (D2) lymph node dissection in gastric cancer patients. As for rectal cancer, surgery 
is considered the mainstay of the treatment of gastric cancer. Being worldwide an impor-
tant cause of cancer mortality37, gastric cancer poses a challenge to oncologists. Not only 
geographic diff erences in the incidence of gastric cancer are of interest, also the worldwide 
discrepancies in treatment outcome furnish food for thought: in Japan where gastric can-
cer is a common disease, excellent results have been obtained by not only removing the 
perigastric lymph nodes (the N1 echelon) but also the regional lymph nodes surrounding 
the great vessels of the celiac axis (N2 echelon, extended (D2) lymph node dissection).38,39 
Locoregional recurrences are seldomly engaged and survival is outstanding according to 
Western standards. Moreover, because regional lymph nodes are removed and subjected to 
pathological examination, gastric cancer patients are better staged as metastases in these 
nodes will not be overlooked. Convinced of the benefi ts of extensive lymph node clearance, 
the Japanese have never been eager to compare it in a prospective randomised fashion to 
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limited surgery as employed in the West. In an attempt to investigate whether the high qual-
ity of the Japanese results could be achieved, the Dutch D1D2 trial was launched.40 Patients 
with histologically proven adenocarcinoma of the stomach without clinical evidence of 
distant disease, aged under 85 years and fi t for surgery were randomised between limited 
and extended surgery. A sample size of 1062 patients was required to detect a 12% diff erence 
in 5 years survival rate between both treatment arms. When comparing two types of surgery 
in a randomised fashion, formulating and controlling the delivered surgical treatment is of 
utmost importance. That is exactly what the protocol of D1D2 trial looked after: patients were 
assigned to one of the two randomisation arms to ensure standardisation of surgery.41 D1 
and D2 dissection were done according to the Guidelines of the Japanese Research Society 
for the Study of Gastric Cancer.42 In these guidelines 16 diff erent lymph node stations are 
discerned surrounding the stomach. D1 dissection involves removal of the involved part of 
the stomach together with the lymph nodes along the lesser (stations 1,3 and 5) and greater 
curvature (2, 4 and 6). D2 dissection implies removal of not only the perigastric (N1) nodes as 
is done when performing a D1 dissection, but also the regional lymph nodes: along the left 
gastric (station 7), the common hepatic (station 8), the celiac (station 9) and the splenic arter-
ies (station 10 and 11). Other nodes involve the extraregional stations 12 (hepatoduodenal 
ligament), 13 (posterior side of the pancreatic head), 14 (the root of the mesenterium), 15 
(the mesocolon of the transverse colon) and 16 (para-aortic) nodes (see also fi gure 1, chapter 
4). Local surgeons, supervised by the trial coordinator, performed the operations in case of 
assignment to D1 dissection. One of the 9 referent surgeons performed the D2 dissections. 
These referent surgeons had been trained in regional nodal dissection by M. Sasako, an 
experienced Japanese surgeon from the National Cancer Center Hospital in Tokyo, Japan.43 
In case of D2 surgery, the surgeon himself divided the specimen into the separate lymph 
node stations that were further investigated by the local pathologist. Despite this unique 
programme of surgical QA, protocol violations were engaged, especially in the early phase 
of trial accrual: non-compliance, i.e. no substantiation of lymphadenectomy by nodal yields 
of indicated stations, and contamination, i.e. extension of lymphadenectomy outside the 
allocated level of nodal clearance. These protocol violations reduced the intended distinc-
tion between the two types of lymphadenectomy. Therefore, sample size was augmented 
from the initial 660 patients to 1062. Moreover, the trial coordinators took additional steps to 
preserve the distinction between limited and extended lymphadenectomy and to improve 
the accuracy of nodal staging.41 A few years ago, the fi nal results of this Dutch Gastric Cancer 
Trial were published: morbidity and mortality were signifi cant higher in the D2 group (25% 
vs. 43%, P<0.001 resp. 4% vs. 10%, P = 0.004). There was no signifi cant diff erence on overall 
survival at 11 years of follow-up (30% vs. 35%, p = 0.53).44 It was concluded that the higher 
postoperative mortality in case of D2 surgery might have off set the long term survival benefi t 
of extended surgery. As for the TME trial, data collection and verifi cation was a vital part of 
this study enabling additional analyses on which this thesis is partly based.
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Oncological research aims for better treatment outcome, ranging from improved locore-
gional control and survival to better functional outcome and improved quality life. In addi-
tion, the identifi cation of high- and low-risk patients is key in order to deliver (multimodality) 
therapy with its toxic side eff ects only to those patient who are most likely to benefi t from it. 
This thesis aims to contribute in meeting this challenge. This thesis was realised with funds 
from the EORTC. The author was the fi rst EORTC fellow focussing on surgical QA aspects of 
the treatment of cancer. The Dutch Gastric Cancer trial and the TME trial, both incorporating 
unique surgical QA programmes, constitute the basis of this thesis.
OUTLINE OF THE THESIS
Chapter 2 reviews the advances in gastric and rectal cancer during the recent decades with 
emphasis on surgical QA programmes. Not only surgery is considered, but also the role of 
(neo-)adjuvant therapy is discussed.
Chapter 3 is based on a editorial that was released together with the publication of a 
prospective randomised Japanese trial that investigated the effi  cacy of postoperative ad-
juvant therapy with mitomycin C, 5-fl uorouracil and cytosine arabinoside followed by oral 
fl uorouracil in serosa negative gastric cancer.45 The excellent results of this Japanese trial with 
only 2 local recurrences out of 252 patients are reviewed, the role of adjuvant chemotherapy 
is discussed and future directions in optimising gastric cancer treatment are considered.
Chapter 4 deals with the prognostic value “Maruyama Index of Unresected Disease” in 
gastric cancer patients. As became clear from the British Medical Research Council (MRC) 
trial46 and the D1D2 trial40 that both compared prospectively extended (D2) to limited 
(D1) lymphadenectomy, postoperative morbidity and mortality was substantial in patients 
assigned to extended surgery. The extent of lymph node dissection was held responsible 
for this rise in complications. Other risk factors were age as well as organ resection (pancre-
atectomy and splenectomy were often performed in order not to compromise dissection of 
stations 10 and 11). At the disclosure of the long-term follow-up data of the D1D2 trial, it was 
speculated that there might be a benefi t of D2 surgery provided that operative mortality 
is reduced. In an attempt to reduce the risk for postoperative complications, organ pres-
ervation is an option, prevention of resecting uninvolved lymph nodes is a possibility too. 
The latter implies preoperative identifi cation of involved nodes. The Maruyama Computer 
program sees to this need. The program consists of Japanese database of 3843 gastric cancer 
patients treated by extensive lymphadenectomy. From all these patients, 7 demographic 
and pathological patients characteristics that are all known pre-/intraoperatively have been 
recorded, as well as nodal involvement of the 16 separate lymph node stations as described 
by the Japanese Research Society for the Study of Gastric Cancer. The program matches cases 
with similar characteristics and thus predicts the likelihood of nodal involvement. From all 
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individual patients included in the D1D2 trial, it was recorded which lymph node stations 
were resected and which were not. Also, the 7 patient characteristics that constitute the 
basis of the Maruyama Computer program, were known in all curatively operated patients. 
Based on this information the “Maruyama Index of Unresected Disease” (MI) was calculated: a 
quantitative measure of residual tumour load in those lymph nodes that were not resected. 
It was hypothesized that patients with a low MI had superior survival rates. This would imply 
that using the Maruyama Program can aid in avoiding resection of uninvolved lymph nodes, 
thus leading to a reduction in postoperative morbidity and mortality without compromising 
locoregional control and survival. The MI, representing the adequacy and quality of surgical 
treatment, had already proved to be a strong independent predictor of survival in a large U.S. 
adjuvant chemo-radiation study.10 In this U.S. study, the completeness of lymphadenectomy 
was questioned: as much as 54% of the included patients did not even have clearance of the 
perigastric (N1) lymph nodes. This surgical undertreatment was held responsible for poor 
survival and was quantifi ed by the introduction of the concept of MI.11 The prognostic value 
of MI and its use as guidance for “tailored” lymphadenectomy was investigated in the Dutch 
D1D2 study population.
One major issue of modern cancer treatment is the individualization of therapy. Rather 
than relying on general risk groups of patient populations who share similar characteristics, 
there is growing need for prediction tools that provide individual-based specifi c information. 
In this manner patient counselling and adjuvant therapy decision-making may be optimised. 
For gastric cancer, colleagues at Memorial Sloan-Kettering Cancer Center, New York, U.S., 
developed a nomogram predicting individual patient risk of tumour-related death after cura-
tive resection for gastric cancer.47 The nomogram, requiring input from basic patient-related 
variables, provided a higher predictive ability than the current staging by the International 
Union Against Cancer. However, the validity of the nomogram was not yet shown in patients 
from other institutions. Chapter 5 investigated whether the nomogram was a predictive tool 
for patients treated in other institutions as well. Four hundred fi fty-nine patients from the 
Dutch Gastric Cancer trial were under investigation: the discrimination ability of the nomo-
gram with respect to 5 and 9-year disease-specifi c survival was studied and compared to that 
of the American Joint Committee on Cancer (AJCC) staging system.
As mentioned before, TME for rectal cancer has had signifi cant eff ects in terms of improved 
local control and survival. Although these benefi ts are beyond dispute, there is much con-
cern about the increased risk of symptomatic anastomotic leakage in TME treated patients. 
The rise in sphincter saving procedures and the subsequent higher proportion of patients 
with distal bowel anastomoses might contribute to an increase of anastomotic failure. Also, 
removing the mesorectum may compromise blood supply to the remaining rectum and may 
thus endanger anastomotic healing. Finally, TME leaves a presacral space for accumulation of 
haematoma, which can involve into the vulnerable anastomosis leading to a dehiscence. In 
order to establish an optimal quality of care, all attempt should be made in order to prevent 
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anastomotic failure. Patients included in TME trial were studied in order to identify risk factors 
for symptomatic anastomotic leakage in rectal cancer patients who undergo TME surgery. 
By performing this risk analysis in a large group of patients treated in as much as 84 Dutch 
hospitals with detailed information on the surgical procedure, guidelines were proposed in 
order to minimise the risk of anastomotic leakage. The results of this analysis are described 
in chapter 6.
As outlined earlier, the early results of the TME trial has shown that preoperative short term 
radiotherapy improves local control in rectal cancer patients treated with total mesorectal 
excision (TME). Moreover, this radiotherapy regimen turned out to be a safe procedure; there 
was only a slight increase in acute complications when compared with TME alone: Marijnen 
et al. showed that irradiated patients had 100 ml more blood loss during the operation 
(P <.001) and suff ered more often from perineal complications (P =.008) in case of abdomi-
noperineal resection.48 Apart from “hard endpoints” such as local control and survival, there 
is a growing awareness that functional outcome and quality of life after combined modality 
treatment is of interest as well. There are some early reports indicating that radiotherapy, 
applying two-portal techniques possibly aff ects urinary bladder and bowel function. In the 
mean time however, radiotherapy and surgical techniques have been optimised, possibly 
leading to reduced long term morbidity. To investigate the long term sequela of both TME 
and radiotherapy, a questionnaire was sent to Dutch patients of the TME trial. Chapter 7 
reports on the results of this study.
Early results of the TME trial at a median follow-up of 2 years revealed signifi cant lower 
recurrence rates in irradiated patients. Although local failure had always been responsible for 
poor survival, there was no detectable diff erence in overall survival between the randomisa-
tion arms.36 It was concluded that an eff ect of radiotherapy was not detected because of the 
small number of local recurrences and the short follow-up. Chapter 8 deals with results of 
the TME trial at a median follow-up of 6 years and investigated whether there was still an ef-
fect of radiotherapy on local control and the impact of this eff ect on survival. In an attempt to 
tailor radiotherapy to those patients who are most likely to benefi t from it, subgroup analyses 
of the radiotherapy eff ect in patients with proximal and distal lesions may be of use, as well 
as for patients with or without nodal involvement. Although subgroup analyses are not to 
be encouraged from methodological point of view, they may be of use in understanding the 
biological eff ect of radiotherapy and in the development of future trials.
In rectal cancer, it is pivotal to perform a radical, curative resection. A positive circumfer-
ential resection margin (CRM) is an important predictor for local failure. When free circum-
ferential margins are not likely to be obtained, neoadjuvant multimodality treatments may 
be valuable with preoperative downsizing as main goal. The Catharina Hospital in Eindhoven 
is a national referral centre for rectal cancer patients in whom radical resection is deemed 
unlikely. To assess the effi  cacy of multimodality neoadjuvant (chemo)radiotherapy in locally 
advanced rectal cancer, treatment outcome in Eindhoven was benchmarked using a subset 
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of patients from the TME trial with mobile pT3/pT4 rectal cancer. The results of these analyses 
are described in chapter 9.
In patients with solid malignancies involvement of lymph nodes is an important prognos-
tic factor. Lymph node clearance may serve staging purposes by investigating the removed 
lymph nodes and thus determining the need for adjuvant treatment. On the other hand, 
lymphadenectomy may be therapeutic as well by reducing tumour burden and infl uencing 
the likelihood of metastatic spread. Lymph node dissection may be associated with postop-
erative morbidity especially in patients with breast cancer or malignant melanoma. To limit 
the side eff ects of lymphadenectomy sentinel node biopsy (SNB) has been introduced: the 
histopathological state of the sentinel node is presumed to refl ect that of all regional lymph 
nodes. Tumour negative sentinel nodes obviates regional lympadenectomy. Moreover, 
sentinel node biopsy off ers the opportunity to examine the sentinel node thoroughly apply-
ing laborious and focused techniques like immunohistochemistry and reverse transcriptase 
polymerase chain reaction. In this manner, the presence of so-called minimal residual disease 
(MRD) can be determined, identifying a subset of patients with a hypothetically worse prog-
nosis. Although this seems a promising strategy, there is a considerable variety in applied 
SNB techniques and pathological examination which obscures the benefi ts of SNB and the 
prognostic value of MRD. Chapter 10 reviews SNB and MRD in (sentinel) lymph nodes in 
breast, gastric and colorectal carcinoma, and focuses on the variety of the applied techniques. 
Chapter 11 provides a summary of this thesis as well as a discussion on future prospects of 
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Abstract
Multimodality and quality controlled treatment result in improved treatment outcome in 
patients with solid tumours. Quality assurance focuses on identifying and reducing variations 
in treatment strategy. Treatment outcome is subsequently improved through the introduc-
tion of programs that reduce treatment variations to an acceptable level and implement 
standardised treatment. In chemotherapy and radiotherapy, such programmes have been 
introduced successfully. In surgery however, there has been little attention for quality assur-
ance so far.
Surgery is the mainstay in the treatment of patients with gastric and rectal cancer. In gastric 
cancer, the extent of surgery is continuously being debated. In Japan, extended lymph node 
dissection is favoured whereas in the West this type of surgery is not routinely performed 
with two large European trials concluding that there is no survival benefi t from regional 
lymph node clearance. Postoperative chemoradiation is part of the standard treatment in 
the United States, although its role in combination with adequate surgery has not been 
established yet. These global diff erences in treatment policy clearly relate to the extent and 
quality of surgical treatment.
As for gastric cancer, surgical treatment of rectal cancer patients determines patient’s prog-
nosis to a large extent. With the introduction of total mesorectal excision, local control and 
survival have improved substantially. Most rectal cancer patients receive adjuvant treatment, 
either pre- or postoperatively. The effi  cacy of many adjuvant treatment regimens has been 
investigated in combination with conventional suboptimal surgery. Traditional indications 
of adjuvant treatment might have to be re-examined, considering the substantial changes 
in surgical practise.
Quality assurance programs enable the introduction of standardised and quality controlled 
surgery. Promising adjuvant regimens should be investigated in combination with optimal 
surgery.
Keywords: gastric cancer, rectal cancer, surgery, quality assurance
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1 INTRODUCTION
In recent years, quality of care is increasingly acknowledged as a crucial factor in the treat-
ment of cancer patients[1]. Keys to improved treatment outcome are multidisciplinary 
treatment and standardised, quality controlled therapy. These are, at least for a substantial 
part, integrated into most of the clinical trials. This may partly explain why trial patients often 
experience a survival advantage over non-participating patients[2]. The goal of (randomised) 
clinical trials is primarily to prove the advantage of one treatment over the other. Ultimate goal 
of all research eff orts should be however, to improve cancer care for all cancer patients and to 
expand the knowledge obtained from clinical research to a broader patient population. This 
means that the level of quality control carried out in a trial, should ideally be maintained in 
daily clinical practise and integrated into oncological care in a standardised manner. Quality 
assurance is an area of research that is engaged in evaluating and interpreting variations in 
treatment and linking them with treatment outcome. To improve outcome, quality assur-
ance focuses on the complete set of systematic actions that is required to achieve a certain 
standard of care, that is considered possible and feasible to achieve and to maintain. This 
implies that there is need to formulate a minimum standard of care, to defi ne an acceptable 
level of variation in treatment outcome, and consequently, to identify factors that are crucial 
to achieve this standard. Considering the ongoing advances in oncological care, especially in 
the surgical area, it is key to appreciate these advances for cancer patients and to make every 
eff ort to put them into practise.
Although quality assurance is still in childhood, several quality assurance programmes 
have been employed successfully in chemotherapy[3-6] and radiotherapy[7-14]. In surgery 
however, that is generally considered the cornerstone of treatment of patients with solid 
tumours, there has been remarkable little attention for quality control and standardization 
so far. Of course, surgery is often still looked upon as merely a craft, which may hinder stan-
dardization: quantifi able parameters are assumed hard to defi ne and to measure, and each 
surgical performance is considered a unique event with irreproducible and unpredictable 
events. However, recent large scale surgical initiatives have undoubtly shown that surgeons 
are willing to refl ect upon their performance and are eager to improve their surgical tech-
nique[15-17]. These initiatives showed clearly that training and audit of surgeons is feasible 
and can result in signifi cant improved local control and survival when compared to historical 
controls[18]. Through surgical training programmes it has become clear that many treatment 
failures, that had often been considered to be a result of aggressive biological tumour be-
haviour, are in fact caused by inadequate local therapy[19]. The changes in surgical practise 
have to be taken stock of by not only surgeons, but also by radiation and medical oncologists. 
With the advent of superior surgical techniques, one may have to re-examine the role of 
(neo-)adjuvant treatment regimens that often have been established in the era of suboptimal 
surgery. This review deals with the recent developments in the treatment of gastric and rectal 
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cancer with an emphasis on quality control. Gastric and rectal cancer will be discussed here 
as surgical treatment of these malignancies is subjected to ongoing debate and has changed 
substantially in recent decades respectively.
2 GASTRIC CANCER
2.1 Introduction
Although its incidence is declining in Western Europe[20], gastric cancer remains the second 
most common cause of cancer death worldwide[21]. The decreasing mortality in the West 
due to gastric cancer is almost solely related to a decreased incidence. This is in contrast 
to Japan, where apart from the decreasing incidence, overall cure rates are a contributing 
factor as well. Fuchs and Mayer[22] compared in 1995 stage specifi c survival between the 
United States and Japan and noticed remarkable diff erences in both stage of disease and 
stage specifi c 5 year survival rates in favour of Japan. There is some evidence that diff erences 
in biological behaviour are responsible for these diff erences: Japanese patients are younger 
at the time of diagnosis, have less often proximal lesions, and more often gastric cancer of the 
“intestinal” type whereas in the West, the diff use type is more often seen[23]. Bonenkamp et 
al.[24] compared patient characteristics from Dutch, Japanese en German centers: Japanese 
patients were on average 3 years younger than German and 8 years younger than Dutch 
patients, while they had more T4 tumours. Five year survival rates were superior for Japanese 
patients without an diff erence in sex distribution, histology and lymph node involvement. In 
another report from Bollschweiler et al.[25], two patient populations from Germany and Japan 
were compared. Univariate analysis of 5 year survival rates were 44% and 77% respectively. 
However, German patients had fewer T1 stage, fewer N0 stage and more M1 stage tumours. 
Also, they were on average 6 years older and had twice as many proximal tumours. Finally, 
mass screening as employed in Japan, provides an opportunity to detect gastric cancer in 
an early stage, and is associated with improved survival rates compared to patients who are 
not subjected to screening examination[26]. Although the biological diff erences may at least 
partly explain the diff erences in outcome between Japan and the West, the global discussion 
focuses predominantly on the extent of surgery.
2.2 Surgery
Surgery is the only possible treatment that can lead to cure. On January 22nd 1881, Theodor 
Billroth was the fi rst to perform a successful operation on a gastric cancer patient, a subtotal 
gastric resection with a gastro-duodenal anastomosis. The 43 years old woman had a favour-
able postoperative course, was discharged 26 days after surgery, but died of recurrence 14 
months later[27]. For Billroth, the operation was a triumph, and 14 years later, his series com-
prised 257 cases. Since then, surgical techniques have evolved and improved substantially 
Quality assurance of surgery in gastric and rectal cancer 27
with lower rates of postoperative morbidity and mortality and better survival. When looking 
at a review of articles published in English since 1970, it becomes clear that in recent decades, 
the number of patients that underwent surgery increased as well as rates of complete resec-
tion. These fi gures are accompanied by mean 5 year survival rates ranging from 21% before 
the 1970s to 55% in the 1980s[28]. Despite this progress in gastric cancer treatments the 
global debate on the most appropriate surgical technique is still heated[29].
2.2.1. Extent of gastrectomy
In earlier years, the extent of gastrectomy was still a matter of controversy, especially for can-
cer in the distal/middle stomach. An en principle total gastrectomy, i.e. a total gastrectomy, 
even when adequate clearance of margins can be obtained by subtotal resection was initially 
promoted in the United States[30] and France[31] as the preferred surgical treatment. How-
ever, several non-randomised series showed that total and subtotal gastrectomy resulted in 
comparable oncological outcome[32-34]. Moreover, in a Norwegian study, there was a sig-
nifi cant lower morbidity rate for subtotal resections in comparison to total gastrectomy(28% 
versus 38%)[35], which was in line with results from a German study (23% versus 48%)[36]. 
Also, two convincing prospective randomised trials showed no signifi cant diff erences 5 year 
survival rates between subtotal and total gastrectomy[37,38]. The more conservative opera-
tion is to be favoured in patients with cancer of the lower or middle stomach, as total gastrec-
tomy is often accompanied by splenectomy which has an adverse eff ect on postoperative 
complications and the susceptibility to infections[39-42]. So, one could argue that the extent 
of gastrectomy is no longer a controversial issue: subtotal gastrectomy is the treatment of 
choice unless the tumour is localised proximally in the stomach, there is a diff use tumour 
growth pattern or a safe proximal margin cannot be obtained. The importance of complete 
tumour removal was investigated by Songun et al.[43] who showed that margin involvement, 
which was seen in 5.9% of the evaluable patients in the Dutch Gastric Cancer Trial, was associ-
ated with signifi cantly worse survival. It was concluded from this study that frozen section 
examination should be routinely performed, especially in patients with poorly diff erentiated, 
signet ring cell or anaplastic tumours.
2.2.2. Extent of lymph node dissection
Unlike the extent of gastrectomy, the extent of lymph node dissection remains among sur-
geons subject to heated debate. It was as early as 1889 that Mikulicz propagated lymph node 
dissection in addition to gastrectomy with removal of the pancreatic tail if necessary[44]. 
Cunéo showed in 1900 that locoregional lymph nodes played an important role in the me-
tastasis of gastric cancer[45]. Gastric cancer is a disease in which local regional control is 
diffi  cult to obtain[46]. In order prevent failure and to improve survival, all eff orts should be 
directed toward adequate local therapy. The main discussion centres on the question; what is 
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adequate local therapy? Is this the territory of the surgeon alone or may have (neo-)adjuvant 
treatment any value as well?
As mentioned before, reported survival rates have always been consistently better in Japan 
than in the West. Extended and standardised lymph node dissection as employed in Japan, 
is according to the Japanese investigators the main explanation for their superior treatment 
outcome. In the East, it is believed that lymph nodes are governors of metastatic disease. 
According to this philosophy, it is considered crucial to remove these lymph nodes to prevent 
metastasis and to improve survival. This extended (prophylactic) lymph node dissection is as-
sociated with accurate staging, as understaging due to failure to detect tumour involvement 
of undissected lymph nodes is very unlikely. This approach is contrast to Western believe 
that states that lymph nodes are merely indicators of disease: lymphadenectomy is solely 
performed in order to stage patients and subsequently to plan adjuvant treatment and not 
necessary to cure them. Lymph node involvement in gastric cancer is thus thought to be a 
sign of widespread disease and poor prognosis. These two opposite movements determine 
the extent of lymph node dissection.
The Japanese Research Society for the Study of Gastric Cancer (JRSGC) has provided strict 
guidelines for standardization of surgical treatment and pathological examination[47]. Ac-
cording to these guidelines, 16 diff erent lymph node compartments are identifi ed around 
the stomach (fi gure 1). Basically, along the lesser curvature stations 1, 3 and 5 are discerned 
and along the greater curvature stations 2, 4 and 6. these perigastric nodes are grouped N1, 
whereas nodes along the left gastric (7), common hepatic (8), celiac (9) and splenic (10,11) 
arteries are grouped N2. Further lymph nodes of stations 13 to 16 have been described. A D1 
lymph node dissection entails removal of the greater and lesser omentum and all its perigas-
tric nodes. The extended D2 dissection involves dissecting not only the perigastric nodes, but 
also the regional N2 nodes. Convinced of the benefi ts of extended lymph node dissection, 
Japanese investigators have always been reluctant to perform a randomised trial comparing 
limited and extended lymph node dissection. In Japan, it is generally considered unethical 
towards patients and deemed unfeasible among surgeons to run a such trial. Considering the 
superior outcome in Japan, attempts have been made to introduce extended surgery into 
the West. Four randomised trials tested D2 against D1 dissection.
Dent et al[48]. were the fi rst to perform a prospective randomised study of gastrectomy 
with or without D2 dissection. From 1982 to 1986 608 cases were evaluated, and 403 were 
deemed surgical candidates; as few as 43 patients turned out to be eligible for the trial. The 
age diff erence between the two patient populations was remarkable: D2 patients were older 
(55.8 vs. 45.1 years), and were more often male (15 male patients in the D2 group, 12 in the R1 
group). No survival diff erence was noticed, but the number of patients was very low, which 
makes it very hard to detect diff erences that may be small, but clinically relevant to both 
patients and their doctors. Moreover, there was no explicit quality control and this was a 
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single institution trial, conducted by only 3 surgeons. Finally, there was a very low eligibility 
rate, which makes the trial not representative for all patients with gastric cancer.
From 1987 to 1991, 55 patients with antral tumours in Hong Kong underwent subtotal gas-
trectomy and were randomised to either D1 or D3 dissection[49]. Only 3 surgeons accounted 
for 75% of the cases. Distal pancreatectomy and splenectomy were part of the D3 dissection. 
The two patient groups had similar baseline characteristics. Actually, the D1 group had bet-
ter median survival (1511 vs. 922 days, p < 0.05) with a shorter operative time (140 vs. 160 
minutes, p < 0.05), less blood transfusions (p < 0.05), and shorter hospital stay (8 vs. 16 days, 
p < 0.05). One patient died in the D1 group and none in the D3 group (n.s.). Postoperative 
complications rates (mainly subphrenic abscess and esophagojejunal anastomotic failure) 
were around 10% and did not diff er between the two randomised arms.
From 1986 through 1995 the British Medical research Council set up a prospective ran-
domised trial investigating the possible benefi ts from D2 dissection over D1 dissection. D1 
dissection was defi ned as a dissection of lymph nodes that were located within 3 centimetres 
Figure 1. Lymph node stations surrounding the stomach. 1 = right cardial nodes; 2 = left cardial nodes; 
3 = nodes along the lesser curvature; 4 = nodes along the greater curvature; 5 = suprapyloric nodes; 6 = 
infrapyloric nodes; 7 = nodes along the left gastric artery; 8 = nodes along the common hepatic artery; 9 
= nodes around the coeliac axis; 10 = nodes at the splenic hilus; 11 = nodes along the splenic artery; 12 
= nodes in the hepatodoudenal ligament; 13 = nodes at the posterior aspect of the pancreas head; 14 = 
nodes at the root of the mesenterium; 15 = nodes in the mesocolon of the tranverse colon.
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of the tumour, according to the 1987 TNM classifi cation. D2 dissection concerned dissection 
of the so called TNM N2 nodes (celiac, hepatodoudenal, retroduodenal, splenic and pancreatic 
nodes, depending on the location of the tumour) with removal of the nodes located at more 
than 3 centimetres of the tumour. Surgical quality was guaranteed through pre-trial educa-
tion which consisted of an operative booklet and videotapes of the requested operating 
procedures. Using a staging laparotomy and intraoperative frozen sectioning, randomisation 
of ineligible patients (i.e. patients with advanced disease or margin involvement) was limited 
to only 3 out of 400 randomised cases. The pancreatic tail was removed almost exclusively 
in the D2 group, the spleen was taken away frequently in both groups, but more often in 
patients assigned to D2 dissection. With a median follow-up of 6.5 years, 5 year survival rates 
were 35% for the D1 group and 33% for the D2 group(n.s.)[50]. Splenectomy and resection of 
the pancreatic tail seriously impacted on survival and proved to be independent predictors 
of poor survival. Moreover, there was notably increased postoperative morbidity (28% for 
D1 and 46% for D2) and mortality (6.5% for D1 and 13% for D2) in patients that underwent 
extended lymph node dissection[51].
Finally, from 1989 to 1993, Dutch gastric cancer patients were randomised between D1 and 
“Japanese D2 lymphadenectomy”. Before the start of the trial, surgeons from 80 centres and 
eight expert consulting surgeons were extensively instructed to perform surgery according 
to the protocol of the Japanese Research Society for the Study of Gastric Cancer (JRSGC)[52]. 
1078 patients were randomised prior to surgery of whom 82 were excluded for unavailability 
of a consultant surgeon, poor physical condition or lack of histological confi rmation of the di-
agnosis. Of the remaining 996 patients, 711 underwent the allocated treatment with curative 
intent. At a median follow-up of 72 months, 5 year survival was 45% for the D1 group and 47% 
for the D2 group[53]. Morbidity and mortality were 25% and 4% in the D1 group and 43% and 
10% in the D2 group respectively[54]. In conclusion, the results of all mentioned randomised 
trials do not favour the routine use of extended lymph node dissection for gastric cancer, at 
least not in Western patients.
The matter is however a bit more complicated. The trials that were initiated in South Africa 
and Hongkong had very few patients randomised and have to be considered underpowered 
to detect a clinical relevant diff erence. The British and Dutch trials included a large number 
of patients and had a good trial design, yet did not detect any signifi cant survival diff erence. 
There is however some criticism raised against the two European trials.
First, despite elaborate quality control in the Dutch trial, there were surgical protocol devia-
tions that blurred the intended distinction between D1 and d2 dissection. If lymph node sta-
tions were removed that were not to be harvested, this was called “contamination”, whereas 
“noncompliance” was defi ned as the absence of lymph nodes that had to be harvested accord-
ing to the protocol. Contamination occurred in 6% of D1 cases and noncompliance in 51% of 
D2 patients[55]. It became clear that, although detailed treatment guidelines were available, 
variability among surgeons was considerable. The protocol deviations were detected during 
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the early phase of the trial, which prompted the investigators to take additional to ensure 
protocol adherence: expert consultants paid more attention to protocol compliance, lymph 
node retrieval from the resected specimen was standardised and consistently performed by 
a specially trained surgical coordinator, immediately after each operation. Notwithstanding 
these unique eff orts, the initiators of the trial concluded themselves that contamination in 
D1 resections and noncompliance in D2 resections lead to a partial homogenisation of the 
groups, undermining the likelihood of detecting any potential therapeutic advantage to D2 
dissection. The MRC trial did not report on similar problems, simply because they did not 
investigate the level of surgical non-compliance.
Another important confounding factor in the Dutch and the British trial was the high post-
operative mortality caused by splenectomy and pancreatectomy. Both procedures were con-
sidered compulsory during the course of the trials to ensure adequate clearance of especially 
stations 10 and 11. There is ample evidence that pancreaticosplenectomy is associated with 
increased postoperative morbidity and mortality[56,57], with a signifi cant adverse eff ect on 
survival as well[37]. In the Dutch trial, the spleen and pancreatic tail were removed in as many 
as 38% and 30% of the D2 patients and were responsible for postoperative complications. 
Preservation of the spleen is important considering the high rates of anastomotic failure in 
patients that underwent a subtotal D2 gastrectomy. A most likely explanation is that in a D2 
dissection, the left gastric artery is divided at its origin, which leads to only a marginal blood 
supply of the remaining short gastric arteries to the rest of the stomach, thus complicating 
anastomotic healing. In the meanwhile, organ preservation techniques have become avail-
able and are employed successfully with adequate clearance of the regional N2 tier, not only 
in Japanese but also in Western patients. Dedicated centres in Western Europe have reported 
mortality rates of less than 5% for extended lympadenectomy with organ preservation[58-
60]. In contrary to earlier belief, it has become clear that preservation of the spleen does 
not compromise survival due to inadequate lymph node removal: a randomised trial from 
Chile found no survival benefi t from splenectomy whereas morbidity was again signifi cantly 
increased[61]. Another trial in Japan, studying the same matter is on its way[62].
A third and fi nal reason why D2 lymph node dissection did not prove to be superior might 
relate to the fact that the surgical case load was rather low in both large randomised trials. 
As many as eighty hospitals participated in the Dutch trial; therefore, a mean of only two 
patients in any one hospital underwent extended lymph-node dissection in any one year. 
For this reason, quality control was mandatory, but apparently could not prevent the high 
postoperative complication rates. Publications on the relation between volume and outcome 
are numerous, also in gastric cancer, but far from unanimous. A retrospective study by Mc-
Culloch[63] and the results of the German Gastric Cancer Study[36] showed clear diff erences 
in outcome based on surgical experience whereas no such pattern was discovered among 
surgeons participating in the Dutch trial[64,65]. Recent reports from experienced centres 
do suggest however, that outcome improves with higher case-load[66]. This might relate to 
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low complication rates due to organ preservation that has become part of the standardised 
D2 dissection in specialized centres. Other factors may include superior surgical skill itself, 
optimal perioperative care, patient selection bias, or a combination of either these. Fact is 
however, that surgical gastric cancer treatment is increasingly centralised.
One important issue has been underexposed so far. There is one possible explanation why 
patients that undergo extended lymph node removal perform better. D2 dissection generally 
yields more lymph nodes for pathological examination than D1 dissection. The more lymph 
nodes are examined, the more accurate the staging will be. A so called stage migration[67] 
may occur when as a result of extended lymph node dissection, a proportion of the patients 
is assigned to a more advanced stage than would otherwise be the case. Of course, the prog-
nosis is the same in both cases. If this phenomenon takes place, overall results in each stage 
improve, and the proportion of patients staged as having advanced disease increases. This 
stage migration has been held responsible for survival diff erences between Japanese and 
Western patients. In the Dutch trial, the stage migration eff ect was estimated by comparing 
stage specifi c 5 year survival rates between D1 and D2 patients. Prognosis of TNM stage II 
patients was 38% for D1 and 43% for D2 patients, for stage IIIA patients these rates were 10% 
and 29% respectively[68]. Upstaging occurred in as many as 30% of the D2 patients[55]. To 
limit the blurring eff ect of stage migration when comparing D1 to D2 dissection, standard-
ization of surgery and pathological examination, as both the surgeon and the pathologist 
infl uence the number of lymph nodes that are examined.
So, there is no defi nite answer as to whether the gastric cancer patient should be treated 
with extended lymph node dissection or not. Removal of regional lymph nodes that may carry 
(micro)metastases makes sense either to prevent local failure, and perhaps also to improve 
survival. In the West, the main drawback from extended surgery has been until recently, the 
high rates of postoperative complications due to organ removal and/or low case load. The 
future looks promising with results from experienced centres in the West that have shown 
low rates of in hospital morbidity and mortality in combination with organ preservation. 
From quality assurance point of view, interinstitution and intersurgeon variability should be 
tackled by centralised treatment and strict protocol guidelines with adequate audit to ensure 
protocol adherence. This includes certainly standardization of pathological examination. 
There are still some important questions to be answered: is retrieval and investigation of 
each of the separate 12 or 16 lymph node stations really necessary and feasible in the West? 
Or is retrieval of at least 15 lymph nodes according to the present TNM classifi cation without 
any specifi cation on its location suffi  cient to perform an adequate staging? These questions 
have to be answered not only for staging purposes, but also to assess the effi  cacy of adjuvant 
treatment.
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2.3 Adjuvant treatment
Although it is beyond the scope of this review, few words must be said on the role of ad-
juvant treatment. The discussion centers around the question whether adjuvant therapy is 
capable of increasing local and distant control and thus improving survival in addition to 
adequate surgery. This question has remained unresolved so far. The use of chemotherapy 
in gastric cancer is based on experience in the use of a wide variety of combinations of this 
modality in therapy for palliative management[69-73]. The chemotherapy regimen FAMTX 
(high dose methotrexate, high-dose 5 FU, doxorubicine and leucovorin) has been tested in 
a randomised fashion against 5-FU, doxorubicin and mitomycin (FAM regimen), showing a 
superior response rate (41% versus 9%, p < 0.0001), survival (10.5 months vs. 7.2 months, p = 
0.004) for patients receiving FAMTX[74]. In concordance with the results of this trial, this regi-
men was considered a standard therapy in the mid 1990s, at least for patients with advanced 
disease. A few years later Webb et al.[75] compared FAMT with epirubicin, cisplatin and 5 
FU (ECF) in patients with oesofagogastric cancer. ECF proved to be superior with regard to 
overall response rate (45% vs. 21%, p = 0.002) and median survival (8.9 vs. 5.7 months, p = 
0.0009).
Adjuvant cytotoxic chemotherapy alone has been tested widely during the past three de-
cades, and proven to be of limited value according to an early meta-analysis of Hermans[76]. 
Recent meta-analyses however, including trials studying novel agents, showed however, a 
marginal but signifi cant benefi t of postoperative chemotherapy[77-79]. The combination of 
radiation therapy and a fl uorinated pyrimidine as a radiation sensitizer may possibly eradicate 
small amounts of residual or recurrent disease, in both gastric[80] and oesofageal cancer[81]. 
The US Intergroup study tested whether the combination of 5 FU/LV plus radiation therapy 
had any value to patients with resected gastric cancer. The study included 556 eligible patients 
and showed a signifi cant overall survival benefi t after postoperative chemoradiation (36 
versus 27 months median overall survival in the surgery alone-group, p = 0.005). Moreover, 
there was increased local control after combined treatment with a relapse free survival of 19 
months in the surgery alone arm, compared to 30 months in the chemoradiation arm[82]. 
The results of trial have lead to standardisation of this regimen in the United States. It is 
remarkable that this decision is based on a study in which 54% of the patients did not have a 
complete clearance of even the perigastric nodes. Although comparison of patient popula-
tions of two separate trials must be made carefully, the diff erences in outcome with the Dutch 
trial are striking: 6 year survival rates of Dutch patients undergoing D2 dissection were 47% 
compared to a 3 year survival percentage of 50% in the superior arm of the US trial. It seems 
that chemoradiation is capable of at least partly compensating suboptimal surgery. Its role 
however, in combination with good surgery remains questionable. The American initiators 
of the trial claim that their patients had more advanced disease than the Dutch patients, 
which precludes any reliable comparison. Indeed, almost 70% of the US patients had at least 
a T3 lesion, and 85% had nodal involvement, whereas these fi gures in the Dutch trial were 
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27% and 55% respectively. Nevertheless, the level of surgical quality control was remarkable 
low: patients were randomised after surgery, thus leaving no room for any surgical quality 
assurance: the only surgical requirements were a “resection with curative intent”, and a “en 
bloc resection”. This is in sharp contrast to the level of quality control of the radiotherapy part, 
refl ected by as much as 35% of the radiotherapy plans that were adjusted to avoid toxic eff ects 
on critical organs. The marginal attention for the surgical part lead to a shocking 54% of cases 
that did not even have clearance of the N1 tier. Initiators of the trial showed themselves that 
the level of surgical undertreatment clearly aff ected survival[83]. This statement was made 
using a novel measure of adequacy of lymphadenectomy, termed the “Maruyama Index of 
Unresected Disease”. This index refl ects the adequacy of lymphadenectomy in relation to the 
extent of nodal disease. The basis of the index is a computer program, created by Maruyama 
and colleagues at the National Cancer Center Hospital in Tokyo, that off ers a computerized 
search of Japanese gastric cancer cases. The program requires a number of individualized 
demographic and tumour-related input variables, after which similar Japanese cases are col-
lected. The output consists of the percentage likelihood of positive lymph nodes at each of 
the 16 lymph node stations. The program has proven to provide a valid and accurate predic-
tion of nodal involvement in a large German patient population[84]. The index, as defi ned by 
Hundahl et al.[83], represents the sum of predictions of nodal disease for the regional stations 
that have been left unresected by the surgeon. A high Maruyama Index refl ects therefore a 
high level of residual nodal disease. The index was shown to be an independent predictor 
of survival in the SWOG trial (median 70, range 0 – 429), which forced the investigators to 
conclude that surgical undertreatment, as observed in this trial, clearly undermined survival. 
Presently, the Maruyama Index of Disease is being calculated in the Dutch trial, thus assessing 
the quality of surgery in this patient population that has less advanced disease compared to 
the US trial patients.
In conclusion for gastric cancer, substantial progress has been made in the treatment of 
gastric cancer patients, especially in the surgical area. Adjuvant treatment may have a role 
either preoperative by increasing resectability and thus local control, or postoperatively by 
eradicating residual (micro)metastatic disease. To our belief, its effi  cacy must however be 
tested in relationship with adequate surgery before it may be considered standard therapy. 
Surgical and pathological quality assurance is key in future prospective randomised trails 
that will investigate the role of promising novel chemotherapeutics.
3 RECTAL CANCER
3.1 Surgery
Like for gastric cancer, surgery is the key to cure for patients with rectal cancer. The surgi-
cal principles in the treatment of colorectal cancer were formulated for the fi rst time at the 
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beginning of the twentieth century. Until then local recurrences after surgery for rectal 
cancer occurred in almost 100% of the cases and postoperative morbidity and mortality were 
substantial. Miles introduced in 1908 a combined abdominal and perineal approach that was 
initially associated with high operative mortality (42%)[85]. However, in 1923 Miles reported 
a large series with postoperative mortality dropping to 10% and local recurrences occurring 
in 30% of the cases[86]. In the same year Hartmann proposed an alternative technique, a two 
step procedure for cancers located proximally in the rectum: a colostomy was established 
at the fi rst operation, after which resection of the tumour took place via the abdomen with 
the distal part of the rectum left behind at the second operation[87]. Sphincter preserving 
techniques with restoration of bowel continuity were introduced in recent decades. The obvi-
ous advantage of anterior resection is the avoidance of permanent colostomy, which may 
infl uence patient’s quality of life. The introduction of mechanical stapling devices[88] and the 
observation that a distal resection margin of 2 centimetres can be considered a oncological 
safe margin[89,90], led to an increased rate of sphincter saving procedures. The downfall in 
often mutilating abdominal perineal resections and the accompanying defi nite colostomies 
can be considered a major advance in the surgical treatment of rectal cancer patients. 
Despite these advances, it still remains diffi  cult to obtain local control after surgical treat-
ment, considering the often high rates of local recurrences that vary considerably between 
institutions[91-95]. It is important to prevent local recurrences as they cause in disabling 
symptoms like bleeding, pain and faecal incontinence[96] and often lead to death[97]. The 
narrow anastomotic boarders of the rectum pose the challenge to the surgeons to remove 
rectal tumours completely from the pelvic area. In an attempt to improve local control and 
survival, many surgeons have changed their surgical technique in an essential way. The basic 
conventional surgical technique involving blunt digital dissection, often resulted in incom-
plete removal of the mesorectal tissue. Resection of the mesorectum is important as this fatty 
tissue surrounding the rectum often contains non-nodal foci of metastatic disease that are 
responsible for local failure[98]. Table 1 shows local recurrence after so called curative surgery 
in conventional surgery series. Rates from 12% up to 38% have been reported. In addition to 
this lack of local control, damage to the autonomous pelvic nerve plexus is common leading 
to sexual [98,99] and bladder dysfunction after surgical treatment [100] .
A major breakthrough was achieved with the introduction of Total Mesorectal Excision 
by Heald at the North Hampshire Hospital in Basingstoke in 1979[101]. It was postulated 
that local failure was more a result of leaving behind mesorectal tissue than of the inherent 
nature of rectal cancer. Meticulous dissection under direct vision to envelope and remove the 
lymphovascular tissue entirely was hypothesized as crucial to avoid local failure. Few years 
later Quirke et al.[102] showed that local recurrences were more often seen in patients with 
involved lateral margins, thus unraveling the major mechanism of local recurrence. In a series 
of 115 consecutive curative anterior resections by Heald, a cumulative risk of local recurrence 
at 5 years was as low as 3.7%, with an overall survival rate of 87.5%. No patient received 
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adjuvant therapy. Surprised by these excellent results, independent audit was required to 
convince colleagues of the validity of the data[103]. In the 1980s, Enker in the United States 
changed his practise to TME and produced similar results to Heald for local control and sur-
vival[104-106]. Aitken documented a series of 64 curatively resected TME cases of which only 
one had a local recurrence[107]. The acknowledgment of the importance of mesorectal exci-
sion led to nationwide programs in Europe to introduce TME. The Norwegian Rectal Cancer 
Project-initiated in 1993- encouraged and taught surgeons to employ TME surgery[17]. Out-
come of total mesorectal excision was compared with conventional surgery. The proportion 
of patients undergoing total mesorectal excision was 78% in 1994, increasing up to 92% in 
1997. The observed local recurrence rate for patients undergoing a curative resection was 6% 
in the group treated by total mesorectal excision and 12% in the conventional surgery group. 
Table 1. Local recurrence after “curative”conventional surgery; adapted from Kapiteijn et al.[15]





Rao ’81[148] 204 44 21.6
Rich ’83[149] 142 43 30.3
Pahlman ’84[150] 197 74 37.6
Phillips ’84[92] 848 124 14.6
Pilipshen ’84[151] 382 105 27.5 27% received preop RT
McDermott ’85[152] 934 193 20.7
Pescatori ’87[153] 162 19 11.7
Athlin ’88[154] 99 37 37.4 unknown no. of patients 
received postop RT/CT
Rinnert-Gongora ’89[155] 258 53 20.5
Zirngibl ’90[156] 1153 265 23.0
Akyol ’91[157] 294 49 16.7
Stipa ’91[158] 235 42 17.9
Adam ’94[159] 141 32 22.7 6% received postop RT
Nymann ’95[160] 175 37 21.1
Damhuis ’97[161] 902 162 18.0 8% received postop RT
Mollen ’97[162] 232 42 18.1 27% received postop RT
Kapiteijn ’98[91] 668 150 22.5 36% received postop RT
Kapiteijn ’02[18] 269 43 16
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Four-year survival rates were 73% after TME and 60% after conventional surgery. In Sweden a 
similar project was launched[16]. As part of a surgical quality assurance program, workshops 
were organized that included 11 television-based demonstrations. Pathology quality control 
consisted of histopathology sessions in order to teach pathologists to identify possible lateral 
tumour spread. The study population consisted of all patients who underwent TME surgery in 
the Stockholm County during 1995 and 1996 (n=447). Outcomes at 2 years were compared 
with those from the Stockholm I (n=790) and II (n=542) trials as historical controls. Local 
recurrence occurred in signifi cantly fewer of the TME group than of the Stockholm I and II 
groups (6% vs. 15% and 14%, p<0.001) as did cancer-related death (9% vs. 15% and 16%, 
p<0.002). In the Netherlands, TME was introduced within the framework of the “Dutch TME 
trial” that investigated the effi  cacy of preoperative short term radiotherapy in TME treated 
patients. Patients that underwent curative TME surgery without any adjuvant treatment, 
were compared with patients from an older trial (cancer recurrence and blood transfusion 
(CRAB)) in which conventional surgery was performed without any quality control[108]. The 
local recurrence rate decreased from 16% in the CRAB trial after 2 years to 9% in the TME trial 
(p = 0.002) with a higher overall survival after TME (86% vs. 77%, p = 0.002)[18].
TME does not only result in improved oncological outcome. By performing surgery under 
direct vision of the pelvic area, autonomic nerves that are crucial for bladder and sexual 
functioning, can be identifi ed and spared. Nesbakken et al.[109] reported a series of 39 TME 
patients that had a remarkable low frequency of serious bladder and sexual dysfunction. 
Maurer et al.[110] showed that TME off ers a signifi cant advantage with regard to preservation 
of postoperative sexual function in men. Operative procedures for primary rectal cancer from 
Japan combine pelvic nerve-preserving techniques with radical tumour resection to ensure 
optimal local tumour control with minimal bladder and sexual dysfunction. In the Nether-
lands, a prospective study was undertaken to evaluate functional outcome of TME surgery. 
Forty-seven patients were operated on by a Japanese surgeon who was familiar with nerve 
preserving TME surgery. Voiding and sexual function were analysed using questionnaire. 
Three of 11 women and 19 of 30 men were sexually active. Two men were impotent after 
operation. Impotence was related to sacrifi ce of the inferior hypogastric plexus (p = 0.037). 
Preservation of the superior hypogastric plexus was crucial for ejaculation (p = 0.003). 
So TME results in better local control and survival, increased sphincter preservation[111] 
and improved functional outcome. However, there is some concern about the increased 
risk of symptomatic anastomotic dehiscence after TME surgery[107,112,113], which may 
infl uence local control in negative way according to a recent publication[114]. The increased 
rates of anastomotic failure probably relate to the rise in sphincter preservation procedures 
and the consequent higher proportion of patients with distal bowel anastomoses. Also, TME 
potentially endangers the blood supply to the remaining rectum, thus jeopardizing anasto-
motic healing. Finally, removing the mesorectum leaves a large pelvic space for accumulation 
of an infected haematoma, which bears the risk of sepsis. To avoid severe complications 
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of anastomotic failure like peritonitis, septic shock and even death, it is crucial to take all 
possible measures to prevent symptomatic anastomotic dehiscence. The most important 
measures advocated so far is stoma formation[113,115], especially for the low lying rectal 
tumours[116,117] Again, there is considerable inter-institution and intersurgeon variation 
with respect to postoperative morbidity and mortality[118-121]. It is remarkable that there 
is no unanimous policy among surgeons to minimise the risk for the most important surgical 
complication after rectal cancer surgery, responsible for signifi cant morbidity and mortal-
ity[115,122-125]. In our Dutch TME population, anastomotic leakage occurred in 11.8% of the 
Dutch patients who underwent an anterior resection (n = 924). A protective stoma formation 
was done in only 57% of the cases. Patients with a stoma had signifi cant less often a anasto-
motic leakage than patients that did not have a stoma (16.0 vs. 8.2%, p<0.001). Surprisingly, 
lack of pelvic drains proved to be the most signifi cant risk factor in the multivariate analysis: 
23.8% of patients that did not have pelvic drainage developed a leakage compared to 9.6% 
of the patients with drainage. Considering the wide variation in rates of postoperative com-
plications and surgical procedures, it is necessary to standardise surgical treatment in order 
to reduce surgical morbidity of TME.
3.2 Adjuvant treatment
Although not practiced yet worldwide, the impact of total mesorectal excision is beyond 
dispute. Apart from this signifi cant progress in the surgical area, various adjuvant treatment 
regimens have shown to improve both local control and survival as well. Radiotherapy, either 
before or after surgery, has been tested in several major trials[126-133]. The rationale of 
combining surgery with radiotherapy is that surgery is capable of removing tumour bulk 
whereas radiotherapy kills peripheral malignant cells in well vascularized tissues surrounding 
the tumour.
It is being heavily debated whether radiotherapy should be given pre- or postoperatively. 
Postoperative treatment has the advantage of accurate selection of high risk patients, based 
on histopathological examination and avoids therefore possible under- and overtreatment in 
contrast to neoadjuvant treatment. However, the only available randomised trial comparing 
pre- and postoperative treatment clearly showed the superiority of preoperative radiotherapy 
regarding side eff ects and local control (local recurrence rates of 12 and 21% respectively, p = 
0.02)[134]. In terms of tumour biology, preoperative radiotherapy is to be preferred to post-
operative irradiation as tumour cells before surgery have higher oxygen saturation and are 
therefore more sensitive to irradiation. Furthermore, preoperative radiotherapy devitalises 
tumour cells that maybe dispersed during the operation, and reduces therefore the risk of 
metastasis. In the Swedish Rectal Cancer trial it was shown that a short-term regimen of high-
dose preoperative radiotherapy (5x5 Gy) administered in one week was capable of reducing 
local recurrence rates (27 vs. 11%, p<0.001) and improving 5 year overall survival (48% vs. 
58%, p = 0.004) compared to surgery alone. The results are in line with a large meta-analysis, 
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including 8507 patients from 22 randomised trials that concluded that preoperative is superior 
to postoperative radiotherapy in terms of cancer specifi c death (45% and 50% respectively, 
p=0.0003) and reduction of local recurrence risk (46% and 37%, p=0.002)[135]. Moreover, 
preoperative treatment has clear advantages in terms of compliance, morbidity and fi nancial 
costs. Despite these clear benefi ts, the National Institutes of Health guidelines in the USA 
still recommends combined postoperative chemoradiation in T3, T4 or N+ patients[136]. To 
guarantee its eff ectiveness, postoperative irradiation should start not later than 4 tot 6 weeks 
after surgery to prevent tumour cell proliferation in the postoperative, fi brous and hypoxic 
tissues. However, many patients turn out not to be fully recovered from the operation at this 
point in time, which causes a delay in receiving adjuvant radiotherapy. This lack of compli-
ance jeopardises therefore the possible benefi ts of postoperative radiotherapy.
Another important indication of preoperative radiotherapy is to achieve downstaging and 
downsizing in order to facilitate complete resection of locally advanced tumours. The level 
of downstaging correlates with the fraction size and total dose of radiotherapy applied. To 
allow enough time to for tumours to reduce in size, the interval between the fi rst day of 
radiotherapy and surgery needs to be at least 4 weeks. The short term regimen of 5 daily 
fractions of 5 Gy is not suitable for this purpose, since surgery must be performed as soon as 
possible after completion of this therapy to avoid surgical complications. So irresectable large 
tumours should be treated with a conventional radiotherapy scheme of 46 to 60 fractions of 
2.0 or 1.8 Gy. After a time interval of 4 to 6 weeks the downsized and downstaged rectal 
tumours can be resected. It is obvious that complete resection of these tumours without 
neoadjuvant treatment is not feasible.
Concern has been raised on the toxic eff ects from adjuvant radiotherapy. In the Stockholm I 
trial there was 8% mortality in the 5x5 Gy arm compared to 2% in the surgery alone arm[126]. 
In the Imperial Cancer Research Fund trial these rates were 12% and 7% respectivelty[127]. 
These unacceptable high proportion of treatment related deaths were clearly due to subop-
timal treatment techniques: radiotherapy in these trial was delivered by two opposed fi elds, 
which increases the volume treated with the prescribed dose considerably. Results of later 
trials[134,137], employing adequate treatment techniques, demonstrated that daily 5 Gy 
fractions can be given safely. In the Dutch TME trial, testing 5x5 Gy in TME treated patients, 
hardly any acute toxicity from radiotherapy occurred.
Late toxicity of radiotherapy has been described by Frykholm et al.[134] who in showed 
increased rates of bowel obstruction requiring surgery in irradiated patients. Dahlberg et 
al.[138] showed that short term preoperative radiotherapy in the Swedish Rectal Cancer trial 
infl uenced long-term bowel function, considering the high bowel frequency (p<0.01), ur-
gency (p<0.01), and emptying diffi  culties (p<0.05) in irradiated patients. Finally, Kollmorgen 
et al.[139] studied the long term eff ects of postoperative chemoradiation and concluded 
that this adjuvant regimen had a major long-term detrimental eff ect on bowel function. 
With improved radiation techniques, late toxic eff ects will be less pronounced. Currently, late 
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morbidity is being analysed in the Dutch TME trial, using questionnaires to be sent to every 
patient who is disease-free. The possible late toxic eff ects have to be counterbalanced against 
the benefi ts of radiotherapy on both local control and survival. One of the goals should be 
to give radiotherapy to those patients only who will benefi t the most from it. This of course 
implies accurate pre-treatment staging.
The benefi ts of (neo-)adjuvant chemotherapy and/or radiotherapy have all been estab-
lished in the era of suboptimal conventional surgery. With the advent of TME surgery local 
control and survival have been improved dramatically. Results from experienced centers 
have been excellent without the application of any adjuvant therapy at all. So, the ques-
tion had to be answered whether adjuvant treatment has any value in combination with 
TME surgery. This issue was addressed by the Dutch Colorectal Cancer Group together with 
the Nordic Gastrointestinal Tumour Adjuvant Therapy Group and the EORTC that initiated 
a large prospective randomised multicenter trial to investigate the effi  cacy of preoperative 
radiotherapy (5x5 Gy) in combination with TME. Standardization and quality control of sur-
gery, radiotherapy, and pathology were achieved by means of a monitoring committee of 
specially trained instructor surgeons, a panel of supervising pathologists and study coordina-
tors for surgery, radiotherapy and pathology. Surgical techniques were standardised and the 
participating surgeons attended workshops and symposiums, saw instructional videotapes 
and were monitored by specially trained surgeons[140]. Pathologists were taught to identify 
lateral spread of the tumour according to the protocol of Quirke et al.[102]. A total of 1861 
patients were randomly assigned to one of the two treatment groups. Before the start of the 
TME trial, there were doubts whether the excellent results obtained by specialized surgeons 
could be matched in a large multicenter trial. There was a low rate of local recurrence after 
2 years (8.2%) in the group assigned to surgery alone.[141] This fi gure indicates that general 
surgeons, who are adequately trained in the TME surgery, can achieve similar excellent 
results.
In the Dutch TME trial, preoperatively irradiated patients had an even lower risk of local 
failure (2.4%) after a median follow-up of 2 years than patients who underwent surgery alone, 
thus proving that radiotherapy has a value for local control, even when combined with TME 
surgery. There was no signifi cant diff erence in survival (82.0% vs. 81.8%, p=0.84). Complete 
tumour removal proved to be crucial in attempt to prevent local failure. Circumferential 
margin (CRM) involvement was a strong predictor, independent from TNM classifi cation, for 
local recurrence: a resection margin of 2 millimetres or less was associated with a local recur-
rence risk of 16% compared with 6% in patients with more mesorectal tissue surrounding 
the resected specimen (p < 0.0001)[142]. Apart from margin involvement, determination and 
reportage of the completeness of the mesorectum have proved to be a strong instrument 
to predict recurrent disease: patients with an incomplete mesorectum had an increased 
risk for overall recurrence: 36.1% versus 20.3% in the group with a complete mesorectum 
(p = 0.02).[143] This macroscopic direct evaluation of surgery is very informative to the 
Quality assurance of surgery in gastric and rectal cancer 41
individual surgeon and can serve as a good tool to audit and subsequently improve surgical 
performance.
Despite surgical and pathological quality assurance, 18% of the TME treated patients 
had a positive margin (i.e. 1 millimeter or less), which clearly increased the risk of both lo-
cal and distant recurrence. So, there is still room for further improvement. Involvement of 
radiologists may aid in avoiding non-curative resections. MRI provides clear imaging of the 
surgical plain of dissection and the adjacent tumour deposits. Beets et al.[144] showed that 
the circumferential resection margin can be predicted with high accuracy and consistency, 
allowing preoperative identifi cation of patients at risk for unsuccessful tumour clearance. The 
Pelican Mercury study[145] that compares pretreatment MRI staging with pathological stag-
ing in underway and will most likely stress the importance multidisciplinary teams planning 
multimodality treatment. Establishing a complete resection is crucial as, in the Dutch TME 
trial, preoperative irradiation had only limited eff ect in reducing the local recurrence risk in 
patients with positive margins (9.3% vs. 16.4%, p = 0.08). Neither could postoperative radio-
therapy prevent local failure in these patients (17.3% vs. 15.7%, p = 0.98).[146] In other words, 
adjuvant radiotherapy can only partly compensate for suboptimal surgery. This underlines 
once more the importance of “good” surgery.
So based on the results from the Dutch TME trial one may conclude that the problem of 
local failure has been adequately tackled by both TME surgery and preoperative short term 
radiotherapy. Survival however, needs to be further improved with an increased proportion 
of patients dying from distant/liver metastases. Systemic therapy may be of use in an attempt 
to improve survival, like it is the case in stage III colon cancer. In earlier years, postoperative 
chemotherapy has been tested in a prospective trial by Taal et al.[147]: there was no sig-
nifi cant and disease-free survival benefi t from adjuvant 5 FU plus levamisole in rectal cancer 
patients, possibly due to the fact that there were relatively few rectal cancer patients (n=299), 
but most likely also due to the 23% of patients with local recurrences, being an important 
cause of death. One may hypothesize that this high rate of local failure blurred the benefi cial 
eff ect of chemotherapy on survival. The successor of the Dutch TME-trial, the PROCTOR 
(Preoperative Radiotherapy and/Or adjuvant Chemotherapy combined with Tme-surgery in 
Operable Rectal cancer) trial is currently investigating the additional value of postoperative 
chemotherapy (5-FU/Leucovorin according to Mayo or Nordic regime) in stage II and III rectal 
cancer patients. The overall survival in the arm treated without chemotherapy is expected 
to be 60%. Assuming that postoperative chemotherapy leads to an improvement in overall 
survival from 60 to 70%, 500 patients are needed per arm.
As adjuvant treatment improves with the introduction of superior radiotherapy techniques 
and novel chemotherapeutic agents, surgical technique has changed dramatically. The data 
for the superiority of mesorectal excision over conventional surgery are overwhelming. 
However, adoption of surgical and pathological concepts arising from TME surgery has been 
remarkably slow so far. Blunt digital dissection is still reported in a 2002 United States surgical 
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textbook, describing the “sucking noise” when removing the rectum bluntly. When costly and 
only marginally eff ective chemotherapy regimens are swiftly introduced into clinical practise, 
it is astonishing that TME surgery, that has been shown to improve local control, survival, 
nerve and sphincter preservation dramatically, is not implemented systematically by health 
care providers. From quality assurance point of view, it is crucial to expand TME surgery 
beyond the boarders of clinical trials, like it has been done in Norway[17]. Considering its 
impressive superiority, we believe TME cannot longer withheld from rectal cancer patients. 
Adjuvant treatment is generally accepted as valuable, but should be tested in combination 
with TME surgery. Initiators and participants of future trials should embrace the challenge of 
involving radiologists and pathologists to design new studies with adequate quality control. 
Only in this way, factors can be identifi ed that may determine patients’ prognosis signifi cantly, 
like inadequate surgery and/or pathological examination. This approach will not only result 
in improved surgical treatment, but will provide a more reliable assessment of the benefi ts of 
adjuvant treatment as well.
4 CONCLUSION
Quality assurance comprises all systematic measures leading to quality controlled diagnosis, 
pre-treatment staging and multimodality treatment of cancer patients. Large scale surgical 
quality assurance programs have proven to be feasible and result in signifi cant improved 
treatment outcome compared to historical controls. Surgery is the main discipline respon-
sible for cure in both gastric and rectal cancer. Therefore, investing in the quality of surgery 
will yield a substantial profi t. This is not only important for cancer patients, but also for all 
medical professionals who are willing to optimise multidisciplinary treatment and to test 
new promising treatment regimens in combination with optimal surgery.
Quality assurance of surgery in gastric and rectal cancer 43
REFERENCES
 1. Rougier P, Neoptolemos JP: The need for a multidisciplinary approach in the treatment of ad-
vanced colorectal cancer: a critical review from a medical oncologist and surgeon. Eur J Surg 
Oncol 1997: 23:385-396.
 2. Stiller CA: Centralised treatment, entry to trials and survival. Br J Cancer 1994: 70:352-362.
 3. Favalli G, Vermorken JB, Vantongelen K et al.: Quality control in multicentric clinical trials. An 
experience of the EORTC Gynecological Cancer Cooperative Group. Eur J Cancer 2000: 36:1125-
1133.
 4. Vantongelen K, Steward W, Blackledge G et al.: EORTC joint ventures in quality control: treatment-
related variables and data acquisition in chemotherapy trials. Eur J Cancer 1991: 27:201-207.
 5. Steward WP, Vantongelen K, Verweij J et al.: Chemotherapy administration and data collection in 
an EORTC collaborative group--can we trust the results? Eur J Cancer 1993: 29A:943-947.
 6. Verweij J, Nielsen OS, Therasse P, Van Oosterom AT: The use of a systemic therapy checklist im-
proves the quality of data acquisition and recording in multicentre trials. A study of the EORTC 
Soft Tissue and Bone Sarcoma Group. Eur J Cancer 1997: 33:1045-1049.
 7. Horiot JC, van der Schueren E., Johansson KA et al.: The programme of quality assurance of the 
EORTC radiotherapy group. A historical overview. Radiother Oncol 1993: 29:81-84.
 8. Bentzen SM, Bernier J, Davis JB et al.: Clinical impact of dosimetry quality assurance programmes 
assessed by radiobiological modelling of data from the thermoluminescent dosimetry study of 
the European Organization for Research and Treatment of Cancer. Eur J Cancer 2000: 36:615-
620.
 9. Belletti S, Dutreix A, Garavaglia G et al.: Quality assurance in radiotherapy: the importance of 
medical physics staffi  ng levels. Recommendations from an ESTRO/EFOMP joint task group. 
Radiother Oncol 1996: 41:89-94.
 10. Izewska J, Andreo P: The IAEA/WHO TLD postal programme for radiotherapy hospitals. Radiother 
Oncol 2000: 54:65-72.
 11. Kehoe T, Rugg LJ: From technical quality assurance of radiotherapy to a comprehensive quality of 
service management system. Radiother Oncol 1999: 51:281-290.
 12. Lanson JH, Essers M, Meijer GJ et al.: In vivo dosimetry during conformal radiotherapy: require-
ments for and fi ndings of a routine procedure. Radiother Oncol 1999: 52:51-59.
 13. Leer JW, Corver R, Kraus JJ et al.: A quality assurance system based on ISO standards: experience 
in a radiotherapy department. Radiother Oncol 1995: 35:75-81.
 14. Thwaites D, Scalliet P, Leer JW, Overgaard J: Quality assurance in radiotherapy. European Society 
for Therapeutic Radiology and Oncology Advisory Report to the Commission of the European 
Union for the ‘Europe Against Cancer Programme’. Radiother Oncol 1995: 35:61-73.
 15. Kapiteijn E, van de Velde CJ: Developments and quality assurance in rectal cancer surgery. Eur J 
Cancer 2002: 38:919-936.
 16. Martling AL, Holm T, Rutqvist LE et al.: Eff ect of a surgical training programme on outcome of 
rectal cancer in the County of Stockholm. Stockholm Colorectal Cancer Study Group, Basingstoke 
Bowel Cancer Research Project. Lancet 2000: 356:93-96.
 17. Wibe A, Moller B, Norstein J et al.: A national strategic change in treatment policy for rectal 
cancer-- implementation of total mesorectal excision as routine treatment in Norway. A national 
audit. Dis Colon Rectum 2002: 45:857-866.
 18. Kapiteijn E, Putter H, van de Velde CJ: Impact of the introduction and training of total mesorectal 
excision on recurrence and survival in rectal cancer in The Netherlands. Br J Surg 2002: 89:1142-
1149.
 19. MacFarlane JK: Nodal metastases in rectal cancer: the role of surgery in outcome. Surg Oncol Clin 
N Am 1996: 5:191-202.
 20. Ekstrom AM, Hansson LE, Signorello LB et al.: Decreasing incidence of both major histologic 
subtypes of gastric adenocarcinoma--a population-based study in Sweden. Br J Cancer 2000: 
83:391-396.
 21. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int 
J Cancer 1999: 80:827-841.
 22. Fuchs CS, Mayer RJ: Gastric carcinoma. N Engl J Med 1995: 333:32-41.
44 Chapter 2
 23. Fielding JW: Gastric cancer: diff erent diseases. Br J Surg 1989: 76:1227.
 24. Bonenkamp JJ, van de Velde CJ, Kampschoer GH et al.: Comparison of factors infl uencing the 
prognosis of Japanese, German, and Dutch gastric cancer patients. World J Surg 1993: 17:410-
414.
 25. Bollschweiler E, Boettcher K, Hoelscher AH et al.: Is the prognosis for Japanese and German 
patients with gastric cancer really diff erent? Cancer 1993: 71:2918-2925.
 26. Kampschoer GH, Fujii A, Masuda Y: Gastric cancer detected by mass survey. Comparison between 
mass survey and outpatient detection. Scand J Gastroenterol 1989: 24:813-817.
 27. Billroth T. Off enes schreiben an Herrn Dr. Wittelshofer. Wien Med Wochenschr [31], 162-165. 
1881. 
 28. Akoh JA, Macintyre IM: Improving survival in gastric cancer: review of 5-year survival rates in 
English language publications from 1970. Br J Surg 1992: 79:293-299.
 29. van de Velde CJ, Peeters KC: The gastric cancer treatment controversy. J Clin Oncol 2003: 21:2234-
2236.
 30. McNeer G, Bowden L, Booner RJ, McPeak CJ: Elective total gastrectomy for cancer of the stomach: 
end results. Ann Surg 1974: 180:252-256.
 31. Lortat-Jacob J, Giuli R, Estenne B, Clot P: [Value of total gastrectomy for treatment of cancers of 
the stomach. Study of 482 radical operations]. Chirurgie 1975: 101:59-67.
 32. Launois B, Cardin JL, Bardaxoglou E et al.: Management of cancer of the stomach: total gastrec-
tomy versus sub-total gastrectomy. Hepatogastroenterology 1991: 38:45-52.
 33. Le Treut YP, Echimane A, Hans D et al.: [Cancer of the gastric antrum. What can be expected from 
the systematic enlargement of the excision? Retrospective study of 73 cases]. Presse Med 1985: 
14:1319-22, 1327.
 34. Gennari L, Bozzetti F, Bonfanti G et al.: Subtotal versus total gastrectomy for cancer of the lower 
two-thirds of the stomach: a new approach to an old problem. Br J Surg 1986: 73:534-538.
 35. Viste A, Svanes K, Janssen CW, Jr. et al.: Prognostic importance of radical lymphadenectomy in 
curative resections for gastric cancer. Eur J Surg 1994: 160:497-502.
 36. Bottcher K, Siewert JR, Roder JD et al.: [Risk of surgical therapy of stomach cancer in Germany. 
Results of the German 1992 Stomach Cancer Study. German Stomach Cancer Study Group (‘92)]. 
Chirurg 1994: 65:298-306.
 37. Bozzetti F, Marubini E, Bonfanti G et al.: Subtotal versus total gastrectomy for gastric cancer: fi ve-
year survival rates in a multicenter randomized Italian trial. Italian Gastrointestinal Tumor Study 
Group. Ann Surg 1999: 230:170-178.
 38. Gouzi JL, Huguier M, Fagniez PL et al.: Total versus subtotal gastrectomy for adenocarcinoma of 
the gastric antrum. A French prospective controlled study. Ann Surg 1989: 209:162-166.
 39. Cuschieri A, Fayers P, Fielding J et al.: Postoperative morbidity and mortality after D1 and D2 
resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial.
The Surgical Cooperative Group. Lancet 1996: 347:995-999.
 40. Bozzetti F, Marubini E, Bonfanti G et al.: Total versus subtotal gastrectomy: surgical morbidity and 
mortality rates in a multicenter Italian randomized trial. The Italian Gastrointestinal Tumor Study 
Group. Ann Surg 1997: 226:613-620.
 41. Brady MS, Rogatko A, Dent LL, Shiu MH: Eff ect of splenectomy on morbidity and survival follow-
ing curative gastrectomy for carcinoma. Arch Surg 1991: 126:359-364.
 42. Otsuji E, Yamaguchi T, Sawai K et al.: End results of simultaneous splenectomy in patients under-
going total gastrectomy for gastric carcinoma. Surgery 1996: 120:40-44.
 43. Songun I, Bonenkamp JJ, Hermans J et al.: Prognostic value of resection-line involvement in 
patients undergoing curative resections for gastric cancer. Eur J Cancer 1996: 32A:433-437.
 44. Mikulicz J: Beitrage zur Technik der Operationen des Magencarcinoms. Archiv für Klinische 
Chirurgie (Berlin) 1898: 1:524-532.
 45. Cunéo D: De l’ennvahissement du systeme lymphatique dans le cancer de l’estomac et de ses 
consequences chirurgicales. Paris, Steinheil 1900.
 46. Gunderson LL, Sosin H: Adenocarcinoma of the stomach: areas of failure in a re-operation se-
ries (second or symptomatic look) clinicopathologic correlation and implications for adjuvant 
therapy. Int J Radiat Oncol Biol Phys 1982: 8:1-11.
Quality assurance of surgery in gastric and rectal cancer 45
 47. Kajitani T: The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical 
classifi cation. Jpn J Surg 1981: 11:127-139.
 48. Dent DM, Madden MV, Price SK: Randomized comparison of R1 and R2 gastrectomy for gastric 
carcinoma. Br J Surg 1988: 75:110-112.
 49. Robertson CS, Chung SC, Woods SD et al.: A prospective randomized trial comparing R1 subtotal 
gastrectomy with R3 total gastrectomy for antral cancer. Ann Surg 1994: 220:176-182.
 50. Cuschieri A, Weeden S, Fielding J et al.: Patient survival after D1 and D2 resections for gastric 
cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group. Br J 
Cancer 1999: 79:1522-1530.
 51. Cuschieri A, Fayers P, Fielding J et al.: Postoperative morbidity and mortality after D1 and D2 
resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial.
The Surgical Cooperative Group. Lancet 1996: 347:995-999.
 52. Sasako M, Maruyama K, Kinoshita T et al.: Quality control of surgical technique in a multicenter, 
prospective, randomized, controlled study on the surgical treatment of gastric cancer. Jpn J Clin 
Oncol 1992: 22:41-48.
 53. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ: Extended lymph-node dissection for gastric 
cancer. Dutch Gastric Cancer Group. N Engl J Med 1999: 340:908-914.
 54. Bonenkamp JJ, Songun I, Hermans J et al.: Randomised comparison of morbidity after D1 and D2 
dissection for gastric cancer in 996 Dutch patients. Lancet 1995: 345:745-748.
 55. Bunt TM, Bonenkamp HJ, Hermans J et al.: Factors infl uencing noncompliance and contamination 
in a randomized trial of “Western” (r1) versus “Japanese” (r2) type surgery in gastric cancer. Cancer 
1994: 73:1544-1551.
 56. Griffi  th JP, Sue-Ling HM, Martin I et al.: Preservation of the spleen improves survival after radical 
surgery for gastric cancer. Gut 1995: 36:684-690.
 57. Roukos DH, Lorenz M, Encke A: Evidence of survival benefi t of extended (D2) lymphadenectomy 
in western patients with gastric cancer based on a new concept: a prospective long-term follow-
up study. Surgery 1998: 123:573-578.
 58. Siewert JR, Bottcher K, Stein HJ, Roder JD: Relevant prognostic factors in gastric cancer: ten-year 
results of the German Gastric Cancer Study. Ann Surg 1998: 228:449-461.
 59. Marubini E, Bozzetti F, Miceli R et al.: Lymphadenectomy in gastric cancer: prognostic role and 
therapeutic implications. Eur J Surg Oncol 2002: 28:406-412.
 60. Sue-Ling HM, Johnston D, Martin IG et al.: Gastric cancer: a curable disease in Britain. BMJ 1993: 
307:591-596.
 61. Csendes A, Burdiles P, Rojas J et al.: A prospective randomized study comparing D2 total gas-
trectomy versus D2 total gastrectomy plus splenectomy in 187 patients with gastric carcinoma. 
Surgery 2002: 131:401-407.
 62. Sano T, Yamamoto S, Sasako M: Randomized controlled trial to evaluate splenectomy in total 
gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF. 
Jpn J Clin Oncol 2002: 32:363-364.
 63. McCulloch P: Should general surgeons treat gastric carcinoma? An audit of practice and results, 
1980-1985. Br J Surg 1994: 81:417-420.
 64. Bonenkamp JJ, Songun I, Hermans J et al.: Randomised comparison of morbidity after D1 and D2 
dissection for gastric cancer in 996 Dutch patients. Lancet 1995: 345:745-748.
 65. Bonenkamp JJ, van de Velde CJ, Sasako M, Hermans J: R2 compared with R1 resection for gastric 
cancer: morbidity and mortality in a prospective, randomised trial. Eur J Surg 1992: 158:413-418.
 66. Degiuli M, Sasako M, Ponti A et al.: Morbidity and mortality after D2 gastrectomy for gastric 
cancer: results of the Italian Gastric Cancer Study Group prospective multicenter surgical study. J 
Clin Oncol 1998: 16:1490-1493.
 67. Feinstein AR, Sosin DM, Wells CK: The Will Rogers phenomenon. Stage migration and new diag-
nostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985: 
312:1604-1608.
 68. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ: Extended lymph-node dissection for gastric 
cancer. Dutch Gastric Cancer Group. N Engl J Med 1999: 340:908-914.
 69. Cascinu S, Labianca R, Alessandroni P et al.: Intensive weekly chemotherapy for advanced gastric 
cancer using fl uorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and fi lgrastim: a 
46 Chapter 2
report from the Italian Group for the Study of Digestive Tract Cancer. J Clin Oncol 1997: 15:3313-
3319.
 70. Crookes P, Leichman CG, Leichman L et al.: Systemic chemotherapy for gastric carcinoma followed 
by postoperative intraperitoneal therapy: a fi nal report. Cancer 1997: 79:1767-1775.
 71. Kelsen D, Atiq OT, Saltz L et al.: FAMTX versus etoposide, doxorubicin, and cisplatin: a random 
assignment trial in gastric cancer. J Clin Oncol 1992: 10:541-548.
 72. Preusser P, Wilke H, Achterrath W et al.: Phase II study with the combination etoposide, doxorubi-
cin, and cisplatin in advanced measurable gastric cancer. J Clin Oncol 1989: 7:1310-1317.
 73. Wils J, Bleiberg H, Dalesio O et al.: An EORTC Gastrointestinal Group evaluation of the combi-
nation of sequential methotrexate and 5-fl uorouracil, combined with adriamycin in advanced 
measurable gastric cancer. J Clin Oncol 1986: 4:1799-1803.
 74. Wils JA, Klein HO, Wagener DJ et al.: Sequential high-dose methotrexate and fl uorouracil com-
bined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the 
European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative 
Group. J Clin Oncol 1991: 9:827-831.
 75. Webb A, Cunningham D, Scarff e JH et al.: Randomized trial comparing epirubicin, cisplatin, and 
fl uorouracil versus fl uorouracil, doxorubicin, and methotrexate in advanced esophagogastric 
cancer. J Clin Oncol 1997: 15:261-267.
 76. Hermans J, Bonenkamp JJ, Boon MC et al.: Adjuvant therapy after curative resection for gastric 
cancer: meta-analysis of randomized trials. J Clin Oncol 1993: 11:1441-1447.
 77. Earle CC, Maroun JA: Adjuvant chemotherapy after curative resection for gastric cancer in non-
Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999: 35:1059-1064.
 78. Mari E, Floriani I, Tinazzi A et al.: Effi  cacy of adjuvant chemotherapy after curative resection for 
gastric cancer: a meta-analysis of published randomised trials. A study of the GISCAD (Gruppo 
Italiano per lo Studio dei Carcinomi dell’Apparato Digerente). Ann Oncol 2000: 11:837-843.
 79. Panzini I, Gianni L, Fattori PP et al.: Adjuvant chemotherapy in gastric cancer: a meta-analysis of 
randomized trials and a comparison with previous meta-analyses. Tumori 2002: 88:21-27.
 80. A comparison of combination chemotherapy and combined modality therapy for locally ad-
vanced gastric carcinoma. Gastrointestinal Tumor Study Group. Cancer 1982: 49:1771-1777.
 81. Herskovic A, Martz K, al Sarraf M et al.: Combined chemotherapy and radiotherapy compared with 
radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992: 326:1593-1598.
 82. Macdonald JS, Smalley SR, Benedetti J et al.: Chemoradiotherapy after surgery compared with 
surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 
2001: 345:725-730.
 83. Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T: Surgical treatment variation in a prospec-
tive, randomized trial of chemoradiotherapy in gastric cancer: the eff ect of undertreatment. Ann 
Surg Oncol 2002: 9:278-286.
 84. Bollschweiler E, Boettcher K, Hoelscher AH et al.: Preoperative assessment of lymph node metas-
tases in patients with gastric cancer: evaluation of the Maruyama computer program. Br J Surg 
1992: 79:156-160.
 85. Miles W.E.: A method of performing abdomino-perineal excision for carcinoma of the rectum and 
of the terminal portion of the pelvic colon. Lancet 1908: 2:1812-1813.
 86. Miles W.E.: Cancer of the Rectum. Lettsomiam Lectures 1923:63.
 87. Hartmann H.: Chirurgie du Rectum. Congres francais de Chirurgie 1923: 30:411.
 88. Kyzer S, Gordon PH: Experience with the use of the circular stapler in rectal surgery. Dis Colon 
Rectum 1992: 35:696-706.
 89. Pollett WG, Nicholls RJ: The relationship between the extent of distal clearance and survival and 
local recurrence rates after curative anterior resection for carcinoma of the rectum. Ann Surg 
1983: 198:159-163.
 90. Parks AG, Percy JP: Resection and sutured colo-anal anastomosis for rectal carcinoma. Br J Surg 
1982: 69:301-304.
 91. Kapiteijn E, Marijnen CA, Colenbrander AC et al.: Local recurrence in patients with rectal cancer 
diagnosed between 1988 and 1992: a population-based study in the west Netherlands. Eur J Surg 
Oncol 1998: 24:528-535.
Quality assurance of surgery in gastric and rectal cancer 47
 92. Phillips RK, Hittinger R, Blesovsky L et al.: Local recurrence following ‘curative’ surgery for large 
bowel cancer: I. The overall picture. Br J Surg 1984: 71:12-16.
 93. Simons AJ, Ker R, Groshen S et al.: Variations in treatment of rectal cancer: the infl uence of hospital 
type and caseload. Dis Colon Rectum 1997: 40:641-646.
 94. Hermanek P, Hermanek PJ: Role of the surgeon as a variable in the treatment of rectal cancer. 
Semin Surg Oncol 2000: 19:329-335.
 95. Porter GA, Soskolne CL, Yakimets WW, Newman SC: Surgeon-related factors and outcome in rectal 
cancer. Ann Surg 1998: 227:157-167.
 96. Holm T, Cedermark B, Rutqvist LE: Local recurrence of rectal adenocarcinoma after ‘curative’ 
surgery with and without preoperative radiotherapy. Br J Surg 1994: 81:452-455.
 97. Wiggers T, de Vries MR, Veeze-Kuypers B: Surgery for local recurrence of rectal carcinoma. Dis 
Colon Rectum 1996: 39:323-328.
 98. Havenga K, Enker WE, McDermott K et al.: Male and female sexual and urinary function after total 
mesorectal excision with autonomic nerve preservation for carcinoma of the rectum. J Am Coll 
Surg 1996: 182:495-502.
 99. van Driel MF, Weymar Schultz WC, van de Wiel HB et al.: Female sexual functioning after radical 
surgical treatment of rectal and bladder cancer. Eur J Surg Oncol 1993: 19:183-187.
 100. Petrelli NJ, Nagel S, Rodriguez-Bigas M et al.: Morbidity and mortality following abdominoperineal 
resection for rectal adenocarcinoma. Am Surg 1993: 59:400-404.
 101. Heald RJ: A new approach to rectal cancer. Br J Hosp Med 1979: 22:277-281.
 102. Quirke P, Durdey P, Dixon MF, Williams NS: Local recurrence of rectal adenocarcinoma due to inad-
equate surgical resection. Histopathological study of lateral tumour spread and surgical excision. 
Lancet 1986: 2:996-999.
 103. MacFarlane JK, Ryall RD, Heald RJ: Mesorectal excision for rectal cancer. Lancet 1993: 341:457-
460.
 104. Enker WE: Total mesorectal excision--the new golden standard of surgery for rectal cancer. Ann 
Med 1997: 29:127-133.
 105. Arbman G, Nilsson E, Hallbook O, Sjodahl R: Local recurrence following total mesorectal excision 
for rectal cancer. Br J Surg 1996: 83:375-379.
 106. Enker WE, Thaler HT, Cranor ML, Polyak T: Total mesorectal excision in the operative treatment of 
carcinoma of the rectum. J Am Coll Surg 1995: 181:335-346.
 107. Aitken RJ: Mesorectal excision for rectal cancer. Br J Surg 1996: 83:214-216.
 108. Houbiers JG, Brand A, van de Watering LM et al.: Randomised controlled trial comparing transfu-
sion of leucocyte-depleted or buff y-coat-depleted blood in surgery for colorectal cancer. Lancet 
1994: 344:573-578.
 109. Nesbakken A, Nygaard K, Bull-Njaa T et al.: Bladder and sexual dysfunction after mesorectal exci-
sion for rectal cancer. Br J Surg 2000: 87:206-210.
 110. Maurer CA, Z’Graggen K, Renzulli P et al.: Total mesorectal excision preserves male genital func-
tion compared with conventional rectal cancer surgery. Br J Surg 2001: 88:1501-1505.
 111. Engel AF, Oomen JL, Eijsbouts QA et al.: Nationwide decline in annual numbers of abdomino-
perineal resections: eff ect of a successful national trial? Colorectal Dis 2003: 5:180-184.
 112. Carlsen E, Schlichting E, Guldvog I et al.: Eff ect of the introduction of total mesorectal excision for 
the treatment of rectal cancer. Br J Surg 1998: 85:526-529.
 113. Poon RT, Chu KW, Ho JW et al.: Prospective evaluation of selective defunctioning stoma for low 
anterior resection with total mesorectal excision. World J Surg 1999: 23:463-467.
 114. Bell SW, Walker KG, Rickard MJ et al.: Anastomotic leakage after curative anterior resection results 
in a higher prevalence of local recurrence. Br J Surg 2003: 90:1261-1266.
 115. Rullier E, Laurent C, Garrelon JL et al.: Risk factors for anastomotic leakage after resection of rectal 
cancer. Br J Surg 1998: 85:355-358.
 116. Karanjia ND, Corder AP, Bearn P, Heald RJ: Leakage from stapled low anastomosis after total 
mesorectal excision for carcinoma of the rectum. Br J Surg 1994: 81:1224-1226.
 117. Heald RJ, Leicester RJ: The low stapled anastomosis. Br J Surg 1981: 68:333-337.
 118. McArdle CS, Hole D: Impact of variability among surgeons on postoperative morbidity and mor-
tality and ultimate survival. BMJ 1991: 302:1501-1505.
48 Chapter 2
 119. Kessler H, Hermanek P, Jr., Wiebelt H: Operative mortality in carcinoma of the rectum. Results of 
the German Multicentre Study. Int J Colorectal Dis 1993: 8:158-166.
 120. Fielding LP, Stewart-Brown S, Blesovsky L, Kearney G: Anastomotic integrity after operations for 
large-bowel cancer: a multicentre study. Br Med J 1980: 281:411-414.
 121. Hannan EL, O’Donnell JF, Kilburn H, Jr. et al.: Investigation of the relationship between volume and 
mortality for surgical procedures performed in New York State hospitals. JAMA 1989: 262:503-
510.
 122. Averbach AM, Chang D, Koslowe P, Sugarbaker PH: Anastomotic leak after double-stapled low 
colorectal resection. Dis Colon Rectum 1996: 39:780-787.
 123. Antonsen HK, Kronborg O: Early complications after low anterior resection for rectal cancer using 
the EEA stapling device. A prospective trial. Dis Colon Rectum 1987: 30:579-583.
 124. Pakkastie TE, Luukkonen PE, Jarvinen HJ: Anastomotic leakage after anterior resection of the 
rectum. Eur J Surg 1994: 160:293-297.
 125. Graf W, Glimelius B, Bergstrom R, Pahlman L: Complications after double and single stapling in 
rectal surgery. Eur J Surg 1991: 157:543-547.
 126. Cedermark B, Johansson H, Rutqvist LE, Wilking N: The Stockholm I trial of preoperative short term 
radiotherapy in operable rectal carcinoma. A prospective randomized trial. Stockholm Colorectal 
Cancer Study Group. Cancer 1995: 75:2269-2275.
 127. Goldberg PA, Nicholls RJ, Porter NH et al.: Long-term results of a randomised trial of short-course 
low-dose adjuvant pre-operative radiotherapy for rectal cancer: reduction in local treatment 
failure. Eur J Cancer 1994: 30A:1602-1606.
 128. Randomised trial of surgery alone versus surgery followed by radiotherapy for mobile cancer of 
the rectum. Medical Research Council Rectal Cancer Working Party. Lancet 1996: 348:1610-1614.
 129. Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal 
Cancer Trial. N Engl J Med 1997: 336:980-987.
 130. Gerard A, Buyse M, Nordlinger B et al.: Preoperative radiotherapy as adjuvant treatment in rectal 
cancer. Final results of a randomized study of the European Organization for Research and Treat-
ment of Cancer (EORTC). Ann Surg 1988: 208:606-614.
 131. Krook JE, Moertel CG, Gunderson LL et al.: Eff ective surgical adjuvant therapy for high-risk rectal 
carcinoma. N Engl J Med 1991: 324:709-715.
 132. O’Connell MJ, Martenson JA, Wieand HS et al.: Improving adjuvant therapy for rectal cancer by 
combining protracted-infusion fl uorouracil with radiation therapy after curative surgery. N Engl J 
Med 1994: 331:502-507.
 133. Chan AK, Wong AO, Langevin JM et al.: “Sandwich” preoperative and postoperative combined 
chemotherapy and radiation in tethered and fi xed rectal cancer: impact of treatment intensity on 
local control and survival. Int J Radiat Oncol Biol Phys 1997: 37:629-637.
 134. Frykholm GJ, Glimelius B, Pahlman L: Preoperative or postoperative irradiation in adenocarcinoma 
of the rectum: fi nal treatment results of a randomized trial and an evaluation of late secondary 
eff ects. Dis Colon Rectum 1993: 36:564-572.
 135. Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 ran-
domised trials. Lancet 2001: 358:1291-1304.
 136. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 
1990: 264:1444-1450.
 137. Frykholm GJ, Isacsson U, Nygard K et al.: Preoperative radiotherapy in rectal carcinoma--aspects of 
acute adverse eff ects and radiation technique. Int J Radiat Oncol Biol Phys 1996: 35:1039-1048.
 138. Dahlberg M, Glimelius B, Graf W, Pahlman L: Preoperative irradiation aff ects functional results 
after surgery for rectal cancer: results from a randomized study. Dis Colon Rectum 1998: 41:543-
549.
 139. Kollmorgen CF, Meagher AP, Wolff  BG et al.: The long-term eff ect of adjuvant postoperative 
chemoradiotherapy for rectal carcinoma on bowel function. Ann Surg 1994: 220:676-682.
 140. Kapiteijn E, Kranenbarg EK, Steup WH et al.: Total mesorectal excision (TME) with or without 
preoperative radiotherapy in the treatment of primary rectal cancer. Prospective randomised trial 
with standard operative and histopathological techniques. Dutch ColoRectal Cancer Group. Eur J 
Surg 1999: 165:410-420.
Quality assurance of surgery in gastric and rectal cancer 49
 141. Kapiteijn E, Marijnen CA, Nagtegaal ID et al.: Preoperative radiotherapy combined with total 
mesorectal excision for resectable rectal cancer. N Engl J Med 2001: 345:638-646.
 142. Nagtegaal ID, Marijnen CA, Kranenbarg EK et al.: Circumferential margin involvement is still an 
important predictor of local recurrence in rectal carcinoma: not one millimeter but two millime-
ters is the limit. Am J Surg Pathol 2002: 26:350-357.
 143. Nagtegaal ID, van de Velde CJ, van der WE et al.: Macroscopic evaluation of rectal cancer resection 
specimen: clinical signifi cance of the pathologist in quality control. J Clin Oncol 2002: 20:1729-
1734.
 144. Beets-Tan RG, Beets GL, Vliegen RF et al.: Accuracy of magnetic resonance imaging in prediction 
of tumour-free resection margin in rectal cancer surgery. Lancet 2001: 357:497-504.
 145. http://www.pelicancentre.com/researchprojects/researchprojects.html. 
 146. Marijnen CA, Nagtegaal ID, Kapiteijn E et al.: Radiotherapy does not compensate for positive 
resection margins in rectal cancer patients: report of a multicenter randomized trial. Int J Radiat 
Oncol Biol Phys 2003: 55:1311-1320.
 147. Taal BG, Van Tinteren H, Zoetmulder FA: Adjuvant 5FU plus levamisole in colonic or rectal cancer: 
improved survival in stage II and III. Br J Cancer 2001: 85:1437-1443.
 148. Rao AR, Kagan AR, Chan PM et al.: Patterns of recurrence following curative resection alone for 
adenocarcinoma of the rectum and sigmoid colon. Cancer 1981: 48:1492-1495.
 149. Rich T, Gunderson LL, Lew R et al.: Patterns of recurrence of rectal cancer after potentially curative 
surgery. Cancer 1983: 52:1317-1329.
 150. Pahlman L, Glimelius B: Local recurrences after surgical treatment for rectal carcinoma. Acta Chir 
Scand 1984: 150:331-335.
 151. Pilipshen SJ, Heilweil M, Quan SH et al.: Patterns of pelvic recurrence following defi nitive resec-
tions of rectal cancer. Cancer 1984: 53:1354-1362.
 152. McDermott FT, Hughes ES, Pihl E et al.: Local recurrence after potentially curative resection for 
rectal cancer in a series of 1008 patients. Br J Surg 1985: 72:34-37.
 153. Pescatori M, Mattana C, Maria G et al.: Outcome of colorectal cancer. Br J Surg 1987: 74:370-372.
 154. Athlin L, Bengtsson NO, Stenling R: Local recurrence and survival after radical resection of rectal 
carcinoma. Acta Chir Scand 1988: 154:225-229.
 155. Rinnert-Gongora S, Tartter PI: Multivariate analysis of recurrence after anterior resection for 
colorectal carcinoma. Am J Surg 1989: 157:573-576.
 156. Zirngibl H, Husemann B, Hermanek P: Intraoperative spillage of tumor cells in surgery for rectal 
cancer. Dis Colon Rectum 1990: 33:610-614.
 157. Akyol AM, McGregor JR, Galloway DJ et al.: Recurrence of colorectal cancer after sutured and 
stapled large bowel anastomoses. Br J Surg 1991: 78:1297-1300.
 158. Stipa S, Nicolanti V, Botti C et al.: Local recurrence after curative resection for colorectal cancer: 
frequency, risk factors and treatment. J Surg Oncol Suppl 1991: 2:155-160.
 159. Adam IJ, Mohamdee MO, Martin IG et al.: Role of circumferential margin involvement in the local 
recurrence of rectal cancer. Lancet 1994: 344:707-711.
 160. Nymann T, Jess P, Christiansen J: Rate and treatment of pelvic recurrence after abdominoperineal 
resection and low anterior resection for rectal cancer. Dis Colon Rectum 1995: 38:799-802.
 161. Damhuis RA, Wiggers T, Wereldsma JC: Association between age and local recurrence of rectal 
cancer: results from a retrospective study of 902 patients. Int J Colorectal Dis 1997: 12:235-239.
 162. Mollen RM, Damhuis RA, Coebergh JW: Local recurrence and survival in patients with rectal 
cancer, diagnosed 1981-86: a community hospital-based study in the south-east Netherlands. 
Eur J Surg Oncol 1997: 23:20-23.

3The gastric cancer 
treatment controversy
CJH van de Velde, KCMJ Peeters
J Clin Oncol. 2003 Jun 15;21(12):2234-6
This editorial was released referring to the following report of Nashimoto et al. 
Randomized trial of adjuvant chemotherapy with mitomycin, Fluorouracil, and Cytosine 
arabinoside followed by oral Fluorouracil in serosa-negative gastric cancer: Japan Clinical 
Oncology Group 9206-1. J Clin Oncol. 2003 Jun 15;21(12):2282-7
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ABSTRACT of the report by Nashimoto et al.
PURPOSE: To evaluate the survival benefi t of adjuvant chemotherapy after curative resection 
in serosa-negative gastric cancer patients (excluding patients who were T1N0), we conducted 
a multicenter phase III clinical trial in which 13 cancer centers in Japan participated. PATIENTS 
AND METHODS: From January 1993 to December 1994, 252 patients were enrolled into the 
study and allocated randomly to adjuvant chemotherapy or surgery alone. The chemotherapy 
comprised intravenous mitomycin 1.33 mg/m2, fl uorouracil (FU) 166.7 mg/m2, and cytara-
bine 13.3 mg/m2 twice weekly for the fi rst 3 weeks after surgery, and oral FU 134 mg/m2 daily 
for the next 18 months for a total dose of 67 g/m2. The primary end point was relapse-free 
survival. Overall survival and the site of recurrence were secondary end points. RESULTS: 
Ninety-eight percent of patients underwent gastrectomy with D2 or greater lymph node 
dissection. There were no treatment-related deaths and few serious adverse events. There 
was no signifi cant diff erence in relapse-free and overall survival between the arms (5-year 
relapse-free survival 88.8% chemotherapy v 83.7% surgery alone; P =.14 and 5-year survival 
91.2% chemotherapy v 86.1% surgery alone; P =.13, respectively). Nine patients (7.1%) in the 
chemotherapy arm and 17 patients (13.8%) in the surgery-alone arm had cancer recurrence. 
CONCLUSION: There was no statistically signifi cant relapse-free or overall survival benefi t 
with this adjuvant chemotherapy for patients with macroscopically serosa-negative gastric 
cancer after curative resection, and there was no statistical diff erence between the two arms 
relating to the types of cancer recurrence. We do not recommend adjuvant chemotherapy 
with this regimen for this population in clinical practice
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Gastric cancer is still a major problem being the most frequent cause of cancer-related deaths, 
although its incidence steadily declined during the last decades in Western countries. Outside 
Japan, where a screening program is active, gastric cancer is often diagnosed in an advanced 
stage. In operable gastric cancer, both the extent of surgery as well as the value of adjuvant 
treatment remains subject to considerable international controversy. Surgery is the corner-
stone in the treatment for gastric cancer. In Japan, a D2 lymph node dissection is the standard 
surgical procedure, known to have an acceptable safety profi le and to result in superior treat-
ment outcome. This extended lymph node dissection was also performed in the randomised 
trial, reported in this issue of the Journal of Clinical Oncology that investigated the role of 
postoperative adjuvant therapy with Mitomycin C, 5-Fluorouracil and Cytosine arabinoside 
followed by oral Fluorouracil in serosa negative gastric cancer in combination with surgery 
versus surgery alone. In fact, 98% of the patients underwent a D2 or greater lymph node 
dissection. There was one postoperative death in the surgery only arm. Total recurrence rate 
was almost double in the surgery alone group (13.8 versus 7.1%), indicating a possible role 
for chemotherapy in the prevention of recurrence. This diff erence was however not statisti-
cally signifi cant. Remarkably was the local control: only 2 patients in the surgery alone arm 
versus none in the combined treatment arm developed a local recurrence. This excellent local 
control is probably due to extended surgery. The administered chemotherapy did not lead to 
a signifi cant diff erence in relapse free and overall survival when compared to surgery alone. 
Two hundred fi fty-two patients were enrolled in the study and 5-year relapse-free survival 
was 88.8% in the chemotherapy and 83.7% in the surgery alone arm. The study was designed 
to detect a 15% diff erence in 5-year survival. When comparing this percentage for instance 
with breast cancer, polychemotherapy is administered to early breast cancer patients in the 
age group over 50 years, based on a meta-analysis of 18,000 patients that showed a 10-year 
survival benefi t of 2 to 3%.(1) To accomplish an increase in 5-year survival rate from 70 to 85% 
in gastric cancer patients seems rather optimistic, even if they are diagnosed in a relatively 
early stage (serosa negative, T2). Reaching no signifi cant diff erence in an underpowered trial 
is therefore not surprising.
Although a D2 dissection is the generally accepted surgical procedure in Japan, the debate 
on the benefi ts of D1 versus D2 lymph node dissection is still ongoing. Convinced of the ben-
efi ts of a D2 resection, Japanese investigators have always been reluctant to conduct a trial 
comparing D2 with D1 dissection. In Europe however, two large randomised controlled trials 
were performed that addressed this issue. The British Medical Research Council Trial(2) could 
not detect a diff erence in survival, the 5-year survival rates being 35% for D1 and 33% for D2. 
Moreover, postoperative morbidity (28% for D1 and 46% for D2) and mortality (6.5% for D1 
and 13% for D2) were increased in the D2 arm. Another large-scale randomised trail, set up 
by the Dutch Gastric Cancer Group(3), proved neither any benefi t from D2 lymphadenec-
tomy with regard to survival and local relapse rates. This latter trial included surgical quality 
control requiring instructing surgeons to be trained in the technique of node dissection by 
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a Japanese surgeon.(4) Additional quality measures were taken to guarantee the intended 
diff erence between D1 and D2 resection. Nevertheless ‘contamination’ (dissection of lymph 
nodes outside the indicated area) and ‘non-compliance’ (incomplete lymph node dissection) 
were defi ned and acknowledged as possible confounders of treatment outcome.(5) After ex-
cluding postoperative deaths, patients that underwent a curative resection (i.e. R0 resection) 
had a cumulative risk of relapse of 43% after a D1 dissection and 37% after a D2 dissection 
(95% confi dence interval –2.4% to +14.4%). However, morbidity and mortality were 25% 
and 4% in the D1 group and 43% and 10% in the D2 group, respectively.(6) Splenectomy 
was performed in 11% of the D1 patients and in 37% of the D2 patients. Resection of the 
spleen carried a major risk for hospital death (hazard ratio 2.16) and overall complications 
(hazard ratio 2.13), while pancreatosplenectomy (30% in the D2 group, 2.6% in the D1 group) 
increased the risk for surgical complications (hazard ratio 3.34). The operative mortality 
due to splenectomy in both European trials could have masked a marginal benefi t from D2 
resection that might have existed. In conclusion however, both randomised trials failed to 
demonstrate an advantage for the extended D2 procedure. Bozetti et al. clearly showed by 
multivariate analysis that splenectomy had a deleterious eff ect on fi ve year survival prob-
ability.(7) Deguili et al.(8) showed however in a randomised surgical trial of 153 patients with 
gastric cancer comparing D1 to D2 dissection that extended lymph node dissection could be 
performed with low morbidity (9.4% and 16.3% respectively, p<0.1) and mortality (1.3% and 
0% respectively) in experienced centers. A prospective randomised trial by Wu et al. of 220 
eligible patients, comparing D1 with D2/D3 dissection showed equal morbidity (7%) and no 
mortality in both treatment groups.(9) Taking all these fi ndings into account, a so called ‘over 
D1’ lymphadenectomy (i.e. a D1 dissection and retrieval of at least 20 to 25 nodes) might be 
recommended, based on the fi nding that the probability of staging a lymph node as tumour 
positive increases with the number of nodes resected with a plateau reached at 20 to 25 
nodes.(10) This recommendation adheres to the principle that lymph nodes are regarded as 
indicators rather than governors of disease.(11) The controversy between D1 and D2 lymph 
node dissection seems to be settled by the introduction of the ‘over D1’ dissection with om-
mitment of splenectomy and distal pancreatectomy.
The role of (neo-)adjuvant therapy has been debated for a long time as well. Although a 
meta-analysis(12) of randomised trials to evaluate the eff ect of adjuvant treatment concluded 
that postoperative chemotherapy could not be considered as standard adjuvant treatment, 
both in Japan as well as in Southern Europe many patients routinely receive postoperative 
chemotherapy. The results of the US Intergroup study by the South West Oncology Group, 
that indicated a signifi cant overall survival benefi t (36 versus 27 months in the surgery alone 
group) after postoperative chemoradiation, lead to standardisation of this regimen in the 
United States.(13) During the trial, much attention was paid to quality assurance for radio-
therapy, refl ected by 35% of the treatment plans that were found to contain major or minor 
deviations from the protocol and could be corrected before the start of radiotherapy. There 
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was however criticism on the adequacy of the surgical procedure: although a D2 lymph node 
dissection was recommended in the protocol, this procedure was only performed in 10% 
of the cases. 54% of the patients not even had a formal clearance of the N1 tier of regional 
lymph nodes. This non-compliance clearly undermined survival(14) and led to a high relapse 
rate of 64% after a median follow-up of 5 years in the surgery only arm compared to 44% 
after a median follow-up of 6 years in the D1 arm of the Dutch trial. It is clear that the extent 
and quality of surgery dictates the value of adjuvant treatment. In a considerable part of 
Europe however, surgery only is the standard of care with increasing emphasis on quality 
assurance. In Japan, seven early trials, conducted before 1975 used various adjuvant che-
motherapy regimes with a comparison to a surgery alone arm. After 1975 the surgery alone 
arm suddenly disappeared in Japanese multi institutional trials without a defi nite reason. 
Therefore 14 trials between 1975 and 1988 were conducted without a surgery alone arm. 
Four were done to compare diff erent regimes of chemotherapy, two were for dose intensity 
comparison of a chemotherapy regimen and eight were designed to test the eff ect of adding 
an immunotherapeutic agent to the chemotherapy. Mitomycin C (MMC), also investigated in 
the present study, was almost always used as an inductive agent in combination regiments. 
Another meta-analysis by Earle and Maroun(15) of 13 trials showed a small but signifi cant 
survival benefi t for patients receiving postoperative chemotherapy. There was an absolute 
risk reduction from 65% to 61% in relapse-free survival after postoperative chemotherapy, 
implying 25 patients that are needed to treat to prevent one death. Gastric cancer is a disease 
in which loco-regional control is diffi  cult to obtain. Gunderson and Sosin showed that relapse 
in gastric cancer patients after initial ‘curative’ surgery consisted of local recurrence and/or 
regional lymph node metastasis in 87.8% of the patients.(16) The high risk of local recurrence 
prompted some investigators to study the combination of radiotherapy and chemotherapy. 
In the present study recurrence occurred in 2 patients in the surgery only arm, which means 
that loco-regional control was very well established by extensive surgery. In the SWOG trial 
local relapse occurred in 29% and regional relapse in as much as 72% of the patients after 
surgery alone. Chemoradiaton improved loco-regional control to 19% and 65% respectively, 
indicating a role for adjuvant treatment in compensating partly for inadequate surgery. 
However, in the presented Japanese study, the investigated chemotherapy regimen was not 
capable of further improving treatment outcome. The question remains however whether 
novel and eff ective chemotherapeutical agents have a role in combination with optimal 
surgery to further increase loco-regional control and survival. Large randomised trials with 
enough power to detect clinically relevant diff erences are necessary to answer this question. 
Neoadjuvant treatment seems an attractive option in patients with gastric cancer. It has a 
potential of down staging enabling curative resection and increased compliance of systemic 
therapy in patients who often have prolonged morbidity after surgery. Ongoing randomised 
trials will answer the question whether neoadjuvant chemotherapy has a role in gastric 
cancer. The MAGIC trial, initiated by the Royal Marsden Hospital and the Institute of Cancer 
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Research, is investigating the role of pre- and postoperative Epirubicin, Cisplatin and 5-FU 
(ECF-regimen) chemotherapy in combination with surgery versus surgery alone, and their 
fi rst results will be anxiously awaited with at the forthcoming ASCO meeting. New treatment 
regimes based on novel cytotoxic agents like paclitaxel and CPT-11 and biological agents like 
antiangiogenics and EGFR-mAB might gain a place in the treatment for gastric cancer in the 
future. The limited role of adjuvant therapy in many trials so far might be due to a residual tu-
mor burden after surgery that is too high, a delayed initiation of chemotherapy, a sample size 
in trials that is too small, an insuffi  cient acting mechanism of current chemotherapeutics or 
combination of these. Within Europe, the need for a well-designed prospective randomized 
trial is acknowledged by the European Organisation for Research and Treatment of Cancer 
(EORTC) to study the role of eff ective chemotherapeutic agents (CPT-11, high infusional 5-FU 
plus leucovorin) in combination with radiotherapy after surgery for resectable gastric cancer. 
Patients will be treated in specialist centers to ensure optimal surgery which implicates an 
‘over D1 resection’ without splenectomy and preservation of the pancreatic tail, thus mini-
mising postoperative morbidity and mortality. Mandatory will be extensive quality assurance 
of surgery and radiotherapy and close cooperation with pathology. In this way, the role of 
adjuvant treatment in combination with optimal surgery will be established. Presently, tools 
are being developed to identify patients with a high risk of lymph node metastases, which 
could infl uence the extent of surgery. Genomic profi ling of gastric adenocarcinomas using 
microarray analysis of chromosomal copy number changes, seems a promising development, 
enabling a more tailor made treatment.(17) Until then, we can solely rely on the evidence 
originating from quality-controlled trials. Setting up these kind of trials seems worthwhile to 
improve treatment outcome in gastric cancer patients.
The gastric cancer treatment controversy 57
REFERENCE LIST
 1. Polychemotherapy for early breast cancer: an overview of the randomized trials. Early Breast 
Cancer Trialists’ Collaborative Group. Lancet 1998; 352(9132):930-942.
 2. Cuschieri A, Weeden S, Fielding J, Bancewicz J, Craven J, Joypaul V et al. Patient survival after 
D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. 
Surgical Co-operative Group. Br J Cancer 1999; 79(9-10):1522-1530.
 3. Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ. Extended lymph-node dissection for gastric 
cancer. Dutch Gastric Cancer Group. N Engl J Med 1999; 340(12):908-914.
 4. Sasako M, Maruyama K, Kinoshita T, Bonenkamp JJ, van de Velde CJ, Hermans J. Quality control 
of surgical technique in a multicenter, prospective, randomized, controlled study on the surgical 
treatment of gastric cancer. Jpn J Clin Oncol 1992; 22(1):41-48.
 5. Bunt TM, Bonenkamp HJ, Hermans J, van de Velde CJ, Arends JW, Fleuren G et al. Factors infl uenc-
ing noncompliance and contamination in a randomized trial of “Western” (r1) versus “Japanese” 
(r2) type surgery in gastric cancer. Cancer 1994; 73(6):1544-1551.
 6. Bonenkamp JJ, Songun I, Hermans J, Sasako M, Welvaart K, Plukker JT et al. Randomised compari-
son of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet 1995; 
345(8952):745-748.
 7. Bozzetti F, Marubini E, Bonfanti G, Miceli R, Piano C, Gennari L. Subtotal versus total gastrectomy 
for gastric cancer: fi ve-year survival rates in a multicenter randomized Italian trial. Italian Gastro-
intestinal Tumor Study Group. Ann Surg 1999; 230(2):170-178.
 8. Deguili M, Sasako M, Garino M et al. Outcome of D1 and D2 gastrectomy for gastric cancer. Pre-
liminary results of the Italian Gastric Cancer Study Group (IGCSG) randomized controlled surgical 
trial. XXXIII World Congress of the International College of Surgeons. October 27-November 1, 
2002, Taipei, Taiwan.
 9. Wu CW. Preliminary results of gastric cancer surgery trials in a single institute. XXXIII World Con-
gress of the International College of Surgeons. October 27-November 1, 2002, Taipei, Taiwan.
 10. Bozzetti F. Principles of surgical radicality in the treatment of gastric cancer. Surg Oncol Clin N Am 
2001; 10(4):833-54, ix.
 11. Cady B. Lymph node metastases. Indicators, but not governors of survival. Arch Surg 1984; 
119(9):1067-1072.
 12. Hermans J, Bonenkamp JJ, Boon MC, Bunt AM, Ohyama S, Sasako M et al. Adjuvant therapy 
after curative resection for gastric cancer: meta-analysis of randomized trials. J Clin Oncol 1993; 
11(8):1441-1447.
 13. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN et al. Chemo-
radiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or 
gastroesophageal junction. N Engl J Med 2001; 345(10):725-730.
 14. Hundahl SA, Macdonald JS, Benedetti J, Fitzsimmons T. Surgical treatment variation in a prospec-
tive, randomized trial of chemoradiotherapy in gastric cancer: the eff ect of undertreatment. Ann 
Surg Oncol 2002; 9(3):278-286.
 15. Earle CC, Maroun JA. Adjuvant chemotherapy after curative resection for gastric cancer in 
non-Asian patients: revisiting a meta-analysis of randomised trials. Eur J Cancer 1999; 35(7):1059-
1064.
 16. Gunderson LL, Sosin H. Adenocarcinoma of the stomach: areas of failure in a re-operation se-
ries (second or symptomatic look) clinicopathologic correlation and implications for adjuvant 
therapy. Int J Radiat Oncol Biol Phys 1982; 8(1):1-11.
 17. Weiss MM, Kuipers EJ, Postma C et al. Genomic profi ling of gastric cancer predicts lymph node 




A Blinded Re-analysis of 
the Dutch D1-D2 Trial
K.C.M.J. Peeters, S.A. Hundahl, E. Klein Kranenbarg, H. Hartgrink, 
and C.J.H. van de Velde
World J Surg. 2005 Dec;29(12):1576-84
60 Chapter 4
ABSTRACT 
A quantitative estimate of residual nodal disease after gastric cancer surgery, the “Maruyama 
Index of Unresected Disease” (MI), proved a strong independent predictor of survival in a 
large U.S. adjuvant chemo-radiation study in which surgical under-treatment was frequent. 
Data from the Dutch D1-D2 Lymphadenectomy Trial permits an opportunity to assess the 
prognostic value of this variable in a cohort with lower-stage disease treated with minimum 
D-1 lymphadenectomy and no adjuvant chemoradiation. Methods: Blinded to survival, and 
excluding those cases with missing information, MI could be calculated for 648 of the original 
711 patients treated with curative intent. Survival was assessed by log rank and multivariate 
Cox regression analysis. All cases have been followed for a minimum of 11 years. Results: 
Overall Dutch Trial fi ndings were not impacted by the absence of 63 cases with incomplete 
data. As expected, median MI was 26, much lower than in the previous U.S. study. In contrast 
to D level, MI < 5 proved a strong predictor of survival by both univariate and multivariate 
analysis. MI was an independent predictor of both overall survival (p= 0.016, HR=1.45, 95% CI 
1.07-1.95) and relapse risk (p= 0.010, HR=1.72, 95% CI 1.14-2.60). Strong “dose-response” with 
respect to MI and survival was also observed. Conclusions: We conclude that in this trial, “low- 
Maruyama-index” surgery is associated with enhanced survival, whereas, outside of certain 
sub-groups, routine D-2 lymphadenectomy is not. This observation suggests that surgeons 
might better impact on patient survival by achieving a “low-Maruyama-index” operation 
rather than a particular d-level.
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INTRODUCTION
Intergroup 0116 (SWOG 9008) , a two-armed prospective, randomized multi-center North 
American trial, established the value of postoperative, 5-FU-based, adjuvant chemo-radio-
therapy for gastric cancer patients with suffi  cient caloric intake, good performance status, 
and adequate organ function.[1] While this conclusion has been questioned for certain sub-
groups, such as UICC Stage I-B cases, [2] and, more recently, cases with diff use histology,[3] 
such adjuvant chemo-radiotherapy is now considered standard in North America.
Data elements capturing the extent of surgery and the extent of lymphadenectomy for 
Intergroup 0116 patients were meticulously collected and analyzed prior to any survival 
analysis. Although printed trial materials recommended D2 lymphadenectomy and included 
appropriate instructions, the extent of surgery was not mandated beyond the requirement 
that all margins of resection be negative and there be no identifi able residual disease. The 
nature of postoperative registration largely thwarted eff ective communication of such 
surgical recommendations, and the trial captured existing patterns of surgical care in North 
America during the accrual period, 8/’91 - 7/’98. Disappointingly, 54% of cases had less-than-
D-1 lymphadenectomy (“D-0 lympghadenectomy”), and only 10% underwent D-2-or-greater 
lymphadenectomy.[1, 4] Critics of the trial emphasize it might have been positive because of 
high average burden of unresected regional nodal disease.[2] 
Anticipating this possibility while the trial was still accruing, and funding a separate 
study to assess potential survival impact, one of the authors (S.H.) attempted to quantify 
the likelihood of unresected nodal disease for each INT 0116 patient by defi ning a so-called 
“Maruayama Index of Unresected Disease” or “Maruyama Index” (MI).[4] To calculate MI, the 
“Maruyama Computer Program” [5] was used to estimate the percentage likelihood of nodal 
involvement for each “regional” lymph node station left in situ by a given patient’s surgeon. For 
the purpose of this analysis, “regional” was defi ned as in JRSGC [6] node stations #1 through 
#12 (see Figure 1). For the benefi t of those unfamiliar with this tool, the “Maruyama Computer 
Figure 1. Defi ned lymph node stations. Stations #1-#16 are defi ned by the Maruyama Program. Stations 
#1-#12 are deemed “regional” and used for “Maruyama Index of Unresected Disease” (MI) calculations.
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Program” [5] simply matches a given case with very similar cases previously treated at the 
National Cancer Center Hospital in Tokyo. The large number of cases in the N.C.C. Tokyo data 
base (3,843 cases, and recently expanded [7] ) serves to make the nodal predictions of this 
computer program very accurate, not only for Japanese cases, but for cases from Germany 
and Italy as well.[5, 8, 9]. The “Maruyama Index of Unresected Disease” or “Maruyama Index” 
(MI) is defi ned as simply the sum of regional nodal disease percentages for “regional” node 
stations (#1-#12) not removed by the surgeon. Prior to any survival analysis, it was predicted 
that those with MI<5 would enjoy higher survival.
Despite diff erences in median survival (i.e. 27 months for D-0, 29 months for D-1, and 48 
months for D-2), d-level failed to prove a signifi cant predictor of survival in Intergroup 0116. 


































Figure 2. Updated overall survival curves for Intergroup 0116 chemoradiation cases. Overall survival (a) 
and relapse-free survival (b). Data kindly provided by the Southwest Oncology Group (see references 4 
and 10)
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univariate analysis (see updated survival curves in Figure 2a and 2b) and multivariate analysis 
to be a signifi cant predictor, with a dose-response eff ect also noted. For cases with MI < 5 vs. 
MI ≥ 5, median overall survival was 87 months vs. 27 months (p=0.005). Median relapse free 
survival was 87 vs. 20 months (p=0.001). With T, N, and treatment group as covariates, hazard 
ratio was 1.9 for overall survival (95% CI 1.3-2.8) and was 2.0 for disease-free survival (95% CI 
1.4-2.9).[4, 10] 
Each case in the Dutch D1-D2 Trial has now been followed for a minimum of 11 years. 
Outside certain subgroups, (e.g. the subgroup with N-2 disease) the trial remains negative 
overall.[11] Compared to cases in the Intergroup Trial, cases in the Dutch Trial had generally 
lower-stage disease and also received more adequate surgical treatment. For example, 69% 
of Dutch cases were node-negative, versus only 15% in the Intergroup cases. Additionally, all 
but 137 (non-compliant) cases of the 711 treated for cure in the Dutch Trial received at least 
a D1 lymphadenectomy. Finally, none of the cases received adjuvant postoperative therapy. 
These facts, combined with the detailed lymphadenectomy data collected for each Dutch 
D1-D2 Trial participant, made Maruyama Index analysis attractive. We now report a blinded 
post hoc analysis of the impact of MI on survival and recurrence in this trial.
METHODS
Entry criteria, informed consent, randomization, surgical treatment, and quality control for 
the Dutch D1-D2 trial have been reported previously.[12, 13] 
In the late 80’s, Dr. K. Maruyama and colleagues at the National Cancer Center Hospital 
in Tokyo created a computer program (known as the “Maruyama Program”) which searched 
their meticulously-maintained 3,843-patient database of gastric cancer cases treated by ex-
tensive lymphadenectomy, matching cases with similar characteristics to a given case. With 
seven demographic and clinical inputs (all identifi able pre-operatively or intra-operatively), 
the program predicts the statistical likelihood of nodal disease for 16 (JRSGC-defi ned [6]) 
nodal stations around the stomach (see Figure 1). Maruyama Program predictions have been 
assessed in Japan, Germany, and Italy, and found to be highly accurate.[5,8,9] The original 
version of the Maruyama Program was used for the Intergroup-0116 analysis. A CD-ROM with 
expanded case volume has recently been released,[7] and this was used for all but 19 of the 
MI calculations in the current study. 
As noted in the introduction, the “Maruyama Index of Unresected Disease” (MI) has been 
defi ned (by author SH) as the sum of Maruyama Program predictions for those regional node 
stations (stations #1-#12) left in situ by the surgeon.[4] An identical defi nition was used for this 
study.
Data suffi  cient for MI calculation was available for 648 of the original 711 cases resected for 
cure in the Dutch D1-D2 Trial, and these constitute the basis for this study. 
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Paralleling the previous Intergroup analysis, an MI cutoff  of 5 was used for the initial uni-
variate survival analysis.
For statistical analysis the SPSS programme was used. A p-value of 0.05 was considered 
statistically signifi cant. Overall survival was calculated from the day of randomisation until ei-
ther day of death (event) or day of last follow-up (censored). Relapse was also calculated from 
the day of randomisation. Data for a patient was censored when at last follow-up contact the 
patient was alive with no evidence of disease or had died of non-neoplastic cause without 
evidence of recurrence. Distribution by D-level was assessed by Pearson Chi-square. Distribu-
tion by MI was assessed by the non-parametric Kruskal-Wallis test. Survival and relapse risk 
was assessed by log rank and multivariate Cox regression analysis. 
All cases were followed for 11 years or more.
Table 1. Surgical and pathological characteristics by D-level of 648 Dutch Trial cases after excluding 
those cases with missing information for the calculation of “Maruyama Index of Unresected Disease” (MI). 






































N stratum (UICC 1997)
 N0
 N1 (1-6 nodes positive)
 N2 (7-15 nodes positive)
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RESULTS
Median age of the 648 cases was 66 years. Fifty-six percent were male. Distribution according 
to D-level by tumor site, T-stage, nodal stratum, type of gastrectomy, and UICC stage largely 
paralleled that of the originally reported 711 patients (Table I).[12] 
As shown in Table 2, overall median MI for the 648 cases was 26. Median MI generally 
increased with advancing UICC stage, number of nodes positive, T-stage, D-level, and tumor 
involvement of overlapping sites, in that order. Tumors involving overlapping gastric sub-
Table 2. Maruyama Indices according to surgical and pathological characteristics. Percentages in 
parentheses. Statistics: Non-parametric testing according to Kruskal-Wallis
Variable N Median MI Range Interquartile 
range
P-value





































































Number of positive nodes
 N0
 N1 (1-6 nodes positive)
 N2 (7-15 nodes positive)
























































sites (i.e. “diff use” site) had a median MI of 63, signifi cantly higher than for more localized 
tumors (P=0.03). Median MI was also higher for D1 cases (MI= 50 vs. 10, P=0.01). 
Unsurprisingly, D1 and D2 survival curves for the 648 case cohort are similar (Figure 3).
Only 154 cases had MI < 5. Overall survival (Figure 4) appears higher and relapse risk lower 














































































Figure 4. Overall survival for 648 Dutch Trial cases, according to MI <5 vs. MI >=5 status
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Mutivariate Cox regression analysis reveals hazard ratios for overall survival as depicted 
in Table 3 and for disease-free period as depicted in Table 4. In contrast to D-level, MI was a 
signifi cant independent predictor of overall survival and disease-free interval. 
Overall survival (Figure 5) and relapse risk (not shown) by MI quartiles indicate what may 
be termed a “dose-response” eff ect with respect to likelihood of residual nodal disease as esti-
mated by MI. Survival is highest for the low MI quartile and poorest for the high-MI quartile.
DISCUSSION
Median MI for the 648 cases in this study is 26. For cases in the previous Intergroup Trial, it was 
70. This is not surprising given the 54% D0 rate in the latter study.[1, 4]
Nodal staging in this study is more accurate than for Intergroup Trial cases. More nodes 
were resected and pathological assessment of these nodes was more detailed.[12, 13] 
The relationship between MI, T-stage, nodal stratum, and UICC stage is complicated. If one 
hypothetically holds the extent of lymphadenectomy constant, higher-stage, more advanced 
tumors will tend to have a higher likelihood of disease in un-dissected regional node stations 
and, therefore, a higher MI. Such linkage with T-stage and nodes positive potentially biases 
the analysis against signifi cance for MI in a multivariate analysis. Nevertheless, in multivariate 
Table 3. Multivariate Cox regression analysis of overall survival for 648 cases
Variable Hazard ratio 95% CI P-value














































2.14 1.54 – 2.97 <0.001
Age 1.04 1.04 – 1.03 <0.001
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Cox regression analysis, correcting for T and N, MI remains a strong independent predictor 
of survival and relapse-free survival. When MI is divided in quartiles, as depicted in Figures 
5, there is clear and signifi cant “dose-response” with respect to survival and relapse risk. This 
further supports the prognostic value of MI.
D-level derives from the detailed and somewhat complicated Japanese Research Society 
for Gastric Cancer (JRSGC) defi nitions of nodal levels.[6] This scheme assigns, based on tumor 
location, a nodal level (N-1 through N-4) for each defi ned nodal station around the stomach, 
upper abdomen, and pera-aortic areas. In a D1 lymphadenectomy, all N-1 level node sta-
tions are removed, but not all N-2 level node stations. In a D2 dissection, all N-1 and N-2 
nodal stations are removed, but not all N-3 nodal stations. D3 and D4 dissections are similarly 
defi ned. In general, all JRSGC N1 and most N2 nodal stations are considered “regional” by 
North American surgeons, and N3 and N4 nodes are generally considered “extra-regional.” MI 
is calculated according to: a) the status (dissected or undissected) of “regional” node stations 
#1-#12; b) the Maruyama Program prediction of disease in any of the nodes of that station (i.e. 
percent likelihood of disease); and c) whether or not the surgeon has dissected the station. 
Worldwide, because gastric cancer is now staged according to UICC/AJCC TNM defi nitions, 
surgeons - particularly Western surgeons - not thoroughly familiar with the complicated 
JRSGC system have diffi  culty precisely defi ning which node stations need to be dissected 
for a “D1” or “D2” lymphadenectomy. In contrast, running the Maruyama Program either pre-
Table 4. Multivariate Cox regression analysis of disease free period for 648 cases
Variable Hazard ratio 95% CI P-value














































2.44 1.72 – 3.47 <0.001
Age 1.01 1.00 – 1.02 0.041
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operatively or intra-operatively, and seeing visual and tabular output for quantifi ed risk of 
disease in all defi ned regional nodal stations[7] is probably easier in the era when laptop 
computers and PC computers are available in most operating room suites.
Moveover, three separate prospective, randomized trials of D-1 versus D-2 lymphadenec-
tomy have failed to show consistent value for routine use of more-extensive D2 lymphad-
enectomy.[12, 14, 15] Three additional trials of routine total gastrectomy, with or without 
extensive lymphadenectomy, have failed to show improved survival.[16-18] Scant data 
concerning results with D-0 lymphadenectomy are available because most experts consider 
this inadequate surgical treatment.
Despite the enormous expertise and experience involved in their derivation, the JRSGC 
defi nitions for N-level and D-level are arbitrary. In contrast, Maruyama Program output 
refl ects actual experience with actual tumors of precisely matched characteristics, drawn 
from a staggeringly large data base. As noted, previous work has shown Maruyama Program 
predictions to be quite accurate.[5, 8, 9]. Surgeons adhering to the time-honored concept of 
trying to match the extent of surgical resection with the extent of regional disease should 
fi nd the Maruyama Program a useful tool. In any case, the arbitrary and complicated, “D-level,” 
JRSGC approach has not proven helpful.[11, 12, 14-18]
Both the MRC and Dutch Trials document that in European patients, JRSGC-defi ned D2 
dissections (i.e. more extensive - but arbitrarily-defi ned – node dissections) are associated 
with signifi cantly higher 30-day and in-hospital postoperative mortality (13% vs. 6.5% for 
the MRC Trial and 10% vs. 4% for the Dutch Trial), with much of (but not all of ) the excess 























































Figure 5. Overall survival for 648 Dutch Trial cases, by MI quartile. A “dose response” for estimated 
unresected disease, as quantifi ed by MI, is evident
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mortality deriving from associated pancreatic-splenic resection in the D2 groups.[12, 15, 
19, 20] Pancreas/spleen-preserving lymph node dissections are now advocated. Particularly 
since gastric cancer patients tend to be older, with frequent co-morbid conditions, limiting 
lymphadenectomy to only nodal stations at risk may decrease postoperative mortality by 
decreasing tissue trauma and decreasing operative time. The Maruyama Program represents 
a tool to facilitate this. 
Only 154 cases had MI < 5, despite the protocol mandate that half the cases be treated 
with D2 dissection. Median MI for the D2 cases was 10. Fifty-one percent of the D2 cases 
in the trial had less-than-D2 dissection because of pathology-determined non-compliance 
with the protocol (i.e. no nodes found in 2 or more node stations which should have been 
dissected). [11, 12, 21] This may explain why so few of the cases had MI < 5. It must also be 
emphasized, however, that some “compliant” D2 cases still did not achieve MI < 5; D2 guided 
surgery “missed” some node stations at risk. Additionally, some D1 cases had MI < 5 either 
because of favorable characteristics of a particular tumor (e.g. favorable location, depth, size, 
histology) or because of documented “contamination,” with tendency toward “D1.5” dissec-
tion.[11, 12, 21] 
The management of splenic hilar nodes at station #10 represents a continued challenge 
for those desiring to plan and execute a “low Maruyama Index” operation. While pancreas-
preserving dissection of #11 splenic artery nodes is feasible and recommended, [22, 23] 
especially when such nodes are at high risk per Maruyama Program, splenic preservation 
while dissecting splenic hilar nodes is problematic. Splenic resection appears to increase peri-
operative mortality and may compromise long-term survival.[11, 15, 20, 24, 25] particularly in 
the elderly.[26] For this reason, neither splenectomy nor pancreatectomy are recommended, 
unless required to remove evident actual disease.
This blinded, retrospective analysis of Dutch Trial data suggests that “low Maruyama Index” 
surgery is associated with signifi cantly increased survival. “Dose-response” with respect to 
Maruyama Index and survival is also apparent. We advocate using the Maruyama Program, 
a computerized tool based on actual patient experience, to identify nodal stations at risk, 
either preoperatively or intra-operatively, in order to customize surgical lymphadenectomy 
and routinely generate a “low Maruyama Index” operation. Our observations strongly suggest 
“dumping D “ in favor of “low Maruyama Index surgery.” Level I, prospective, randomized vali-
dation is the next step, and an international trial of this concept is currently being planned.
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ABSTRACT
A statistical model for predicting disease-specifi c survival in gastric cancer patients, based on 
a single US institution experience, was tested for validity in a diff erent set of patients treated 
at diff erent institutions. Four hundred and fi fty-nine patients from the Dutch Gastric Cancer 
trial comparing D1 to D2 lymph node dissection, were analysed. Discrimination ability of 
nomogram with respect to 5 and 9 year disease-specifi c survival probabilities was superior to 
that of the AJCC stage. There was considerable heterogeneity of risk within many of the AJCC 
stages. Calibration plots suggested that predicted probabilities from the nomogram corre-
sponded closely to actual disease-specifi c survival. The gastric cancer nomogram performed 
well when applied to patients treated in a large number of institutions. The nomogram pro-
vided predictions that discriminated better than AJCC stage, regardless the extent of lymph 
node dissection. Patient counselling and adjuvant therapy decision making should benefi t 
from use of the nomogram.
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INTRODUCTION
Although the incidence is declining in Western Europe(1), gastric cancer remains the second 
most common cause of cancer death worldwide.(2) Surgery is the only curative treatment. 
The infl uence of extent of gastric and lymph node resection is debated.(3-5) Adjuvant chemo-
radiation has been proposed as well and tested in an attempt to improve local control and 
survival. The US Intergroup study by the Southwest Oncology Group showed a signifi cant 
overall survival benefi t after postoperative chemoradiation (36 versus 27 months median 
overall survival in the surgery alone-group), which lead to standardisation of this regimen in 
the United States.(6) The trial was criticized however for the suboptimal surgery employed 
and the level of unresected nodal disease. Surgical undertreatment, as observed in this trial, 
clearly undermined survival.(7)
Although treatment delivered determines patient’s prognosis to a large extent, other factors 
such as patient characteristics, age and sex, the stage of disease at presentation, and tumour 
location and morphology play a substantial role. Current staging modalities, that solely focus 
on depth of tumour invasion and the presence of nodal disease, do not take these factors 
into account. Nomograms have been developed to address this problem: they are predictive 
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Prob. of 9-Year DSS
0.010.10.30.50.70.80.90.940.97
Figure 1. Nomogram for disease-specifi c survival
Instructions for Physician: 
Locate the patient’s sex on the Sex axis. Draw a line straight upwards to the Points axis to determine how many 
points towards gastric cancer-specifi c death the patient receives for his or her sex. Repeat this process for the 
other axes, each time drawing straight upward to the Points axis. Sum the points achieved for each predictor 
and locate this sum on the Total Points axis. Draw a line straight down to the disease-specifi c survival axes to 
fi nd the patient’s probability of surviving gastric cancer assuming he or she does not die of another cause fi rst.
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tools for the individual patient based on known prognostic variables including the extent of 
surgical treatment. Nomograms aid in patient counselling, follow-up scheduling and clinical 
trial determination and have been developed in soft tissue sarcoma(8), prostate(9-12), renal 
cell(13), pancreatic(14), and breast cancer.(15) The statistical model developed for gastric 
cancer (see fi gure 1) was able to predict the individual patient’s probability for disease-spe-
cifi c 5 and 9 year survival after an R0 resection for gastric cancer in a single institution US 
patient population involving 1039 patients treated from 1985 to 2002.(16)
The purpose of this study was to assess the validity of this prediction tool when applied 
to patients with a diff erent stage of disease at presentation, diff ering (surgical) treatment at 
diff erent institutions. We also compared the discriminating value of the nomogram to the 
AJCC staging system.
PATIENTS AND METHODS
Patients were enrolled in the Dutch Gastric Cancer trial. This trial was undertaken between 
August 1989 and July 1993 and randomized gastric cancer patients, coming from 80 Dutch 
hospitals, between a limited (D1) and an extended (D2) lymph node dissection as recom-
mended by the Japanese Research Society for the Study of Gastric Cancer.(17;18) The results 
of this trial have been published.(19-21) For the present analysis, patients were considered 
eligible if they had underwent an R0 resection, i.e. a resection with negative margins without 
any evidence of tumour spillage (n = 633). In agreement with our previous report, the fol-
lowing prognostic variables were assembled for use in validating the nomogram: age, sex, 
primary site (distal one third, middle one third, proximal one third, and gastroesophageal 
junction), Lauren histotype (diff use, intestinal, mixed), number of positive lymph nodes re-
sected, number of negative lymph nodes resected, and depth of invasion as defi ned by 
the standard nomenclature.(22) Patients with suspected vs. defi nite serosal invasion are 
distinguished in the nomogram. However, pathologic analysis from the Dutch trial did not 
distinguish between these depths. For purposes of nomogram validation, we calculated the 
nomogram prediction assuming a point half way between these two points on the nomo-
gram. Patients with one or more missing values were excluded (Lauren histotype, n = 126; 
size, n = 19; primary site, n = 41), leaving 459 patients that had values for all nomogram 
predictor variables, AJCC stage, and follow-up. For each of these patients, the nomogram 
5 and 9 year disease-specifi c survival probabilities were computed and compared with the 
AJCC stage on the basis of discrimination ability, as measured by the concordance index. 
Disease-specifi c survival was estimated using the Kaplan-Meier method.
Nomogram validation comprised two activities. First, discrimination was quantifi ed with 
the concordance index.(23) Similar to the area under the receiver operating characteristic 
curve, but appropriate for censored data, the concordance index provides the probability 
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that, in a randomly selected pair of patients in which one patient dies before the other, the 
patient who died fi rst had the worse predicted outcome from the nomogram.
Second, calibration was assessed. This was done by grouping patients with respect to 
their nomogram-predicted probabilities and then comparing the mean of the group with 
the observed Kaplan-Meier estimate of disease-specifi c survival. All analyses were performed 
using S-plus 2000 Professional software (Statistical Sciences, Seattle, WA) with the Design and 
Hmisc libraries added.(24)
RESULTS
Table 1 depicts the patient and tumor characteristics of the 459 eligible patients with all the 
information available for the nomogram calculation. With a median follow-up of 10 years, 
194 of the 459 patients had died of disease. Disease specifi c survival by AJCC stage grouping 
is shown in fi gure 2, suggesting a reasonable number of patients alive at both 5 and 9 years 
for nomogram validation. The concordance index for the nomogram was 0.77. Calibration 
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Figure 2. Disease specifi c survival by AJCC stage grouping 
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We compared predictions from the nomogram with those obtained by using the AJCC 
stage groupings. Individual AJCC stage groups and nomogram predictions were compared 
for their ability to rank the patients (e.g. concordance index). Nomogram discrimination was 
superior to that of AJCC stage grouping (concordance index 0.77 vs. 0.75 P < .001, Z-test). This 
diff erence is diffi  cult to appreciate clinically, and therefore, fi gure 4 illustrates the discrepan-
cies between the two prediction methods. Within each AJCC stage grouping is a histogram of 
nomogram-predicted probabilities, illustrating heterogeneity within many of the stages.
DISCUSSION
Patient prognosis is currently estimated on the basis of AJCC staging, and not on other factors 
like age, sex or morphology that may have an impact on disease-specifi c survival. Integrating 
these variables in a nomogram has yielded a model that is a more accurate predictor for 
disease specifi c survival than is AJCC stage. This study validates the predictive value of the 
nomogram, previously tested in a single US institution.(16) The diff erence in concordance 




























Figure 3. Calibration curves for the nomogram. X-axis is nomogram predicted probability. Patients were 
grouped by quartiles of predicted risk. Y-axis is actual disease-specifi c survival as estimated by the Kaplan-
Meier method. Solid line is performance of the 5-year prediction; dotted line represents 9-year prediction. 
Vertical bars represent 95% confi dence intervals. For each quartile of both nomogram predictions, the 
95% confi dence intervals overlap the diagonal “ideal” line, where predicted would exactly match actual 
disease-specifi c survival
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clinically irrelevant. However, fi gure 4 shows the clinical meaningfullness and benefi ts of no-
mogram predictions: patients within diff erent AJCC stages with heterogeneous prognosis are 
successfully discerned, using the nomogram. Apparently, the present AJCC staging system is 
unable to identify subsets of patients with homogeneous prognoses. Accurate prediction 
can aid in individual patient counselling and in follow-up scheduling. It may also play a role 
in designing future trials, identifying subsets of patients within known AJCC stages that have 
a diff erent prognosis, and likewise a potential for diff erent response to novel adjuvant treat-
ment regimens. It is important that this model, shown to be valuable in a single institution US 
patient population, is valid in a multicenter European gastric cancer patient population. The 
type of gastric cancer management depends largely on where the patient is being treated: 
many US gastric cancer patients receive postoperative chemoradiation(6), whereas adjuvant 
treatment is not the norm in Europe. In the current patient population as well as the original 
group of patients used to develop the nomogram, no adjuvant treatment was given, and 
the surgical treatment consisted of D1 and D2 dissection in all validation patients. This is 
more extensive surgery than undertaken in the general US patient population. The American 
College of Surgeons evaluated surgical treatment of over 18,000 gastric cancer patients be-
tween 1982 and 1987 and concluded that dissection of the celiac nodes occurred in only 14% 
of the cases.(25) Among the 3,804 patients having a curative resection, only 695 (18%) had 
dissection of the nodes along the celiac axis, hepatic artery, or splenic artery (N2 nodes).(26) 
Stage of disease diff ers between the current patient population and the US patients that 


















































Figure 4. Nomogram predicted probabilities within each of the AJCC stages. Numbers in parentheses for 
each stage indicate number of patients within that stage. Note the large variation in nomogram predicted 
probability present within many of the stages
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patient population because we included R0 patients only. Despite these major discrepancies 
between the series, the nomogram predicted accurately, superior to AJCC stage, for disease 
specifi c survival in a patient population treated in as many as 80 hospitals, consistent with 
common surgery in the Netherlands.
Patients in the present analysis were derived from the Dutch Gastric Cancer trial, com-
paring D1 to D2 dissection. The nomogram predicted well in this series despite the fact 
that type of dissection was not a variable, per se, in the nomogram. The likely reason for 
this favourable outcome is that the numbers of positive and negative nodes are predictor 
variables in the model. Thus far, there is still no overall diff erence in survival rates between 
the arms of the Dutch trial.(21) Consequently, considering the type of resection as an input 
variable for nomogram construction does not seem to have additional value. Defi ning the 
extent of lymph node dissection (i.e. D1 or D2) requires intra-operative identifi cation of all 
16 lymph node stations as defi ned by the Japanese Research Society for the Study of Gastric 
Cancer (JRSGC).(17;18) Identifi cation and subsequent resection of all these separate stations 
may contribute to improving clinical outcome, even in Western patients considering recent 
publications that focus on adequate lymph node removal with critical organ resection, thus 
minimising postoperative morbidity and mortality.(27-29) Notwithstanding the eff orts of 
improving locoregional control through extended nodal dissection, the surgical eff ort of me-
ticulous dissection is not routinely performed in Western gastric cancer patients, especially 
not outside the framework of clinical trials. Including the type of resection as a mandatory 
input variable in the predictive nomogram would therefore make the nomogram less ap-
plicable in daily practise. However, the basis of the initial nomogram was an institution where 
extended lymph node dissection is performed in the majority, but not all, of patients. By 
requiring only the numbers of negative and positive lymph nodes resected for the nomogram 
computation without specifying their location, we believe that the extent of lymph node 
dissection is suffi  ciently addressed.
In conclusion, the gastric cancer nomogram performed well when applied to a validation 
dataset of patients, coming from a large number of institutions with diff erent stage of dis-
ease, treated with a focus on lymph node clearance. The nomogram provided predictions 
that discriminated better than AJCC stages, regardless of the extent of lymph node dissec-
tion, and illustrated the heterogeneity of risk within many stages. With the availability of this 
external validation, individual patient counselling and tailored adjuvant therapy decision 
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ABSTRACT
Background: Anastomotic leakage is a major complication after rectal cancer surgery. We 
investigated risk factors that were associated with symptomatic anastomotic leakage after 
total mesorectal excision.
Method: Between 1996 and 1999 patients with operable rectal cancer were randomised 
between short-term radiotherapy followed by TME and TME alone. Eligible Dutch patients 
who underwent an anterior resection (n = 924) were retrospectivally studied.
Results: Leakage occurred in 107 patients (11.8%). Pelvic drainage and the use of a protec-
tive stoma were signifi cantly associated with decreased anastomotic failure rates. A signifi -
cant correlation between the absence of a stoma and anastomotic dehiscence was present in 
both male and female patients, and not only for distal, but also for proximal rectal tumours. 
In case of anastomotic failure, the presence of pelvic drains and a covering stoma were both 
related to a reduction in leaks requiring surgical reintervention. 
Conclusion: It is recommendable to place one or more pelvic drains after TME to limit 
the consequences of anastomotic failure. A covering stoma is signifi cantly associated with 
decreased anastomotic dehiscence and re-intervention rates in patients with both low and 
high rectal tumours, regardless their gender. The decision to construct a temporary stoma 
may be supported by this study.
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INTRODUCTION
Symptomatic anastomotic leakage is the most important surgical complication following 
rectal cancer surgery. Leakage after low anterior resection can result in signifi cant morbidity 
and mortality1-5 and may be associated with a higher incidence of local recurrence6-8. Since the 
introduction of total mesorectal excision (TME) by Heald et al.9, TME has become the accepted 
standard for rectal cancer surgery. The low recurrence rates and improved survival rates in TME 
series support the idea of removing the fatty tissue around the rectum, also known as the me-
sorectum10-12. However, concern has been expressed about the increased risk of symptomatic 
anastomotic leakage associated with the introduction of TME13,14. The rise in sphincter saving 
procedures and the subsequent higher proportion of patients with distal bowel anastomoses 
might contribute to an increase of anastomotic failure. Also, TME potentially endangers the 
blood supply to the remaining rectum, thus jeopardizing anastomotic healing. Finally, remov-
ing the mesorectum leaves a large pelvic space for accumulation of a haematoma, which 
bears the risk of infection and sepsis. To avoid severe complications of anastomotic failure like 
peritonitis, septic shock and even death, it is crucial to take all possible measures to prevent 
symptomatic anastomotic dehiscence. The aim of this study was to identify risk factors for 
symptomatic anastomotic leakage in rectal cancer patients who undergo TME surgery.
PATIENTS AND METHODS
Study population
In the current study we used the database of the “Dutch TME trial”, a large international mul-
ticenter trial that investigated the effi  cacy of short term preoperative radiotherapy (5x5 Gy) 
in TME treated rectal cancer patients. From January 1996 until December 1999 1861 patients 
with histologically proven adenocarcinoma of the rectum without evidence of distant metas-
tases were included in the study and randomised between preoperative irradiation followed 
by TME surgery or TME alone. Patients were eligible for randomisation when the tumour 
was located below the level of S1/2 and 15 centimetres or less from the anal verge, being 
measured during withdrawal of a fl exible coloscope. Also, the tumour had to be clinically 
resectable which meant that the tumour, on examination by the surgeon, was considered to 
be mobile and resectable without leaving behind any residual tumour (i.e. a R0 resection). 
Results of this trial have been published previously15.
In the present retrospective analysis, only data that had been collected prospectively dur-
ing the course of the TME trial were used. Only Dutch patients (n = 1530) were considered as 
data of only these patients regarding patient and treatment characteristics, as well as surgical 
complications and mortality, are complete and were checked extensively during trial accrual 
by the study coordinators16.
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Surgery
Within the context of the trial an extensive structure of workshops, symposia and instruction 
videos was set up to warrant optimal surgical quality and standardisation of TME technique17. 
In the protocol, the construction of a defunctioning stoma was recommended according to 
the surgeon’s discretion, as well as the decision to drain the remaining pelvic cavity. In addi-
tion, a side to end or pouch anastomosis was advised, in an attempt to minimise the risk for 
anastomotic dehiscence. All surgical characteristics as well as operative and postoperative 
complications were recorded and completed on forms by the operating surgeon. These 
forms were compared with the operating report and discharge letters by the surgical trial 
coordinator and checked for inconsistencies. In case of unclear or incomplete data, additional 
information was requested.
Regarding the endpoint of this analysis, symptomatic anastomotic leakage was defi ned as 
clinically apparent leakage (i.e. gas, pus or faecal discharge from the pelvic drain, or peritoni-
tis) or extravasation of endoluminal administered water soluble contrast on X-ray or CT-scan. 
An abscess around the anastomosis was also recorded as a leakage. Radiological examination 
was performed only in case of suspicion of anastomotic leakage.
Data Collection and Statistics
All case reports forms were sent to the central data centre in Leiden. After elaborate checking, 
data were entered in a database and analysed with SPSS statistical software (version 11.5 for 
Windows, SPSS, Chicago). Chi-square tests were used to compare proportions. A two-sided 
P-value of 0.05 was considered signifi cant. The infl uence of independent variables on the risk 
of clinical anastomotic leakage was calculated using single variable regression analysis. All 
variables associated with leakage with P < 0.1 were entered in a multiple regression analysis. 
A P-value of 0.05 or less was considered signifi cant.
RESULTS
Of all 1530 randomised Dutch patients, 1480 patients were eligible for enrolment into the clini-
cal trial. Reasons for ineligibility were no adenocarcinoma (n=7), other/previous malignancy 
(n=26), previous treatment (n=3), transanal resection (n=1), double tumour (n=6), sigmoid 
carcinoma (n=5) and tumour not considered resectable at randomisation (n=2). Of all eligible 
patients 441 underwent an abdominoperineal resection, 78 patients a Hartmann procedure 
and in 37 patients no tumour resection was performed. The remaining 924 patients, who 
were evaluated in the present analysis, underwent an anterior resection according to the TME 
principle. 
Five hundred seventy patients (61.7%) were male and 354 (38.3%) were female. Median 
age was 64.0 years (range 23-92). The average distance of the tumour from the anal verge 
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was 8.4 cm (range 0-18 cm). Four hundred and fi fty nine patients (49.7%) were assigned to 
preoperative radiotherapy, the remaining patients to surgery alone. In 107 patients (11.8%) a 
clinical symptomatic anastomotic leakage was detected.
Patients who received pre-operative irradiation did not have an increased risk of anasto-
motic leakage compared to non-irradiated patients (10.9% versus 12.3%, P = 0.517). However, 
in irradiated patients the operating surgeon decided more often to construct a defunction-
ing stoma (59.9% versus 53.3%, P = 0.044). 
A protective ileo- or colostoma was constructed in 56.6% of the patients. Eight point two 
percent of the patients with a stoma had a leakage compared to 16.0% of the patients without 
a stoma (P < 0.001). Leaving behind one or more pelvic drains after surgery was strongly as-
sociated with decreased leakage rates: in patients with pelvic drainage, anastomotic leakage 
was diagnosed in 9.6% of the patients, compared to 23.5% of the patients without a drain 
(P < 0.001). Male patients suff ered more often from leakage (13.2% versus 9.0%) although 
this diff erence was not statistically signifi cant (P = 0.057). The construction of a pouch was 
done in 261 patients. Patients with a pouch had a leakage rate of 8.4% compared to 12.4% in 
patients with an side-end anastomosis and 15.9% in patients with an end-end anastomosis 
(P = 0.092).
The correlation between tumour location and leakage rate was not signifi cant: leakage rates 
for tumours 5 cm or less located from the anal verge, between 5.1 and 10 cm, and for tumours 
at more than 10.1 cm were 13.4%, 11.3% and 11.6% respectively (P = 0.872). However, if the 
tumour was located more proximally, a protective stoma was less often was constructed: 
faecal diversion was performed in 73.1%, 62.3% and 47.1% respectively (P < 0.001).
In the single variable regression analysis, a number of other continuous and dichotomous 
parameters were analysed that were possibly associated with clinical anastomotic leakage. 
The absence of a diverting stoma, the lack of one or more of pelvic drains left behind after 
surgery, male gender and the formation of an end-end or end-side anastomosis appeared to 
be signifi cantly associated with the occurrence of anastomotic failure (table 1).
Multiple regression analysis was performed to exclude confounding due to interaction 
between the covariates. The absence of a defunctioning stoma and the lack of pelvic drain-
age remained the only two signifi cant risk factors. Male gender was a non-signifi cant risk 
factor with a P-value of 0.055 (table 2). The absence of a protective stoma was signifi cantly 
associated with increased anastomotic dehiscence rates in both male and female patients 
(table 3). Moreover, this association is also present in patients with both low and high rectal 
tumours (table 3).
Management of symptomatic anastomotic leakage
Fifteen of the 107 patients (14.0%) with anastomotic leakage died within 30 days after 
surgery. Mortality related to anastomotic leakage did not diff er signifi cantly between pa-
tients with and without diversion (14.0% vs. 14.1%, P = 0.987), nor between patients with 
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Table 1. Single variable regression analysis of symptomatic anastomotic leakage. Values in parentheses 
are percentages. * n = 1 is missing. ** n = 6 missing. *** n = 7 missing. ETE: end-to end anastomosis. STE: 
side-to-end anastomosis
Number of patients 
(%)








Age 0.99 0.97-1.01 0.417
Distance tumour from anal verge
 ≥10.1 cm
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or without pelvic drainage (11.8% vs. 19.4%, P = 0.310). Seventy nine patients underwent a 
surgical reintervention due to a (suspected) anastomotic failure: in 44 patients a diversion 
was constructed after all, in 8 patients an end-colostomy, 13 patients underwent a Hartmann 
procedure and in 14 patients the reintervention consisted of abscess drainage only. Fifteen 
out of 79 patients that had a surgical reintervention died as none died in the patient group 
without reintervention.
The need for surgical reintervention after detecting anastomotic failure was signifi cantly 
lower for patients with pelvic drainage (56 out of 76 patients (73.7%) than for patients with-
out drain (30/31, 96.8%, P = 0.006). A diverting stoma was also associated with lower rates of 
surgical reintervention as only 26 out of 43 patients (60.5%) with a stoma underwent surgery 
for the second time, compared to 60 out of 64 patients without a stoma (93.8%, P < 0.001).
Table 2. Multiple regression analysis of symptomatic anastomotic leakage. Values in parentheses are 
percentages



























Table 3. Number of patients with symptomatic anastomotic leakage distributed according to gender, 
tumour location and the use of a protective stoma. Values in parentheses are percentages

























In this large study population, symptomatic anastomotic leakage was detected in 11.8%, 
which is comparable with previous reports1,12,13,18. Before the start of the randomised trial, 
some surgeons expected increased surgical morbidity due to irradiation. In an earlier report 
it was shown that preoperative hypofractionated radiotherapy is a safe treatment without 
a rise in surgical complications19. There was no signifi cant association between leakage and 
preoperative short term radiotherapy, which has become part of the standard regime for 
rectal cancer treatment in many European countries.
Data in the current analysis were derived from a prospective randomised trial that inves-
tigated the effi  cacy of short term preoperative radiotherapy in TME treated rectal cancer 
patients. The trial was not set up to answer any question regarding anastomotic leakage. 
Therefore, any statement based on data from the trial must be made most carefully. However, 
the performed analysis is informative and can identify risk factors for anastomotic leakage 
reliably.
In the multiple regression analysis, the lack of pelvic drains left behind after TME surgery, 
as well as the absence of a defunctioning stoma were the only two signifi cant factors associ-
ated with anastomotic dehiscence. The possible acting mechanism of pelvic drainage and 
defunctioning in preventing clinical leakage can be explained biologically. After TME surgery, 
the large presacral space is a signifi cant collector of fl uids that may constitute an excellent 
medium for bacteria20. Infection of this haematoma may extend to, involve and drain into 
the anastomosis and cause dehiscence. The accumulation of these fl uids is likely hindered by 
pelvic drainage. Nonetheless, several trials that investigated the usefulness of placing a drain 
after colorectal surgery do not favour pelvic drainage 21,22,22-25. However, these trials often 
describe a heterogeneous population with either colonic23,24 or colorectal resection22,25 that 
did not undergo TME surgery21,25. Therefore, the results of these trials cannot be extrapolated 
automatically to TME treated rectal cancer patients. Also, the performed trials are often un-
derpowered and hence not able to detect small diff erences that may be clinically relevant to 
both surgeons and their patients22. Furthermore, there are hardly any drawbacks from pelvic 
drainage: drains are easily left behind after rectal surgery and hardly burden the patient. 
Although not prospectively investigated, these data on TME rectal cancer patients suggest 
that it is recommendable to leave behind one or more pelvic drains after rectal surgery.
A covering stoma diverts the faecal stream from a healing anastomosis. In case of an 
anastomotic dehiscence, no faeces can be transported through a defective anastomosis into 
the abdominal cavity. In this way, the consequences of anastomotic failure are mitigated. It 
is generally accepted that low rectal anastomoses after TME are particularly vulnerable to 
anastomotic failure1,26. In the present series however, patients with both low and high rectal 
tumours were at substantial risk for anastomotic leakage and both patient categories may 
benefi t from faecal diversion, as well as both male and female patients do. In this trial, the 
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decision to construct a defunctioning stoma was left to the discretion of the individual sur-
geon. Clearly, this decision is not solely made in an attempt to prevent leakage. Other factors, 
like the possible decreased quality of life after stoma formation27, and the need to close a 
temporary stoma28 play an important role as well. Indeed, temporary protective stomas tend 
to remain longer in situ than initially anticipated. In fact, after a median follow up of 5 years, 
19% of the analysed patients with a so called temporary diversion, still has a stoma.
One possible important risk factor for anastomotic leakage is the performance of the 
individual surgeon29-32. This confounding factor is hard to measure but may be crucial. In this 
study population, it was examined whether each individual surgeon had a common policy of 
creating a protective stoma or placing pelvic drains when performing TME surgery on rectal 
cancer patients. There was a variable surgical strategy, i.e. most patients without pelvic drain-
age or a protective stoma were operated upon by surgeons who choose to place drains and 
divert the faecal steam in other patients, most likely based on intraoperative risk assessment 
of the likelihood of anastomotic dehiscence (data not shown). Thus, one could argue that 
patients with drains and a protective stoma would have a higher a priori risk of anastomotic 
dehiscence. This is however refuted by the present analysis, which strengthens the signifi cant 
correlation between drainage, faecal diversion and lower rates of anastomotic failure.
In conclusion, the construction of a temporary stoma and the placement of one or more 
drains in the pelvic area are signifi cantly associated with decreased anastomotic failure rates 
in rectal cancer patients treated with TME surgery. Moreover, these two measures are as-
sociated with a reduction in the rate of leaks requiring secondary surgery and thus with a 
mild clinical course in case of anastomotic dehiscence. In an attempt to minimise the risk of 
clinical leakage, stoma formation seems advisable, for patients with both proximal and distal 
rectal tumours, regardless their gender. However, individual patient characteristics have to 
be taken into account as well when deciding to construct a stoma. Considering the minimal 
burden to both patients and surgeons, we recommend placement at least one drain after 
TME for rectal cancer.
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Preoperative short term radiotherapy improves local control in patients treated with total 
mesorectal excision (TME). This study was performed in order to assess the presence and 
magnitude of long term side eff ects of preoperative 5x5 Gy and TME. Also, hospital treatment 
was recorded for diseases possibly related to late side eff ects of rectal cancer treatment.
Patients and Methods:
Long term morbidity was assessed in patients from the prospective randomized TME trial, 
investigating the effi  cacy of 5x5 Gy prior to TME surgery for mobile rectal cancer. Dutch 
patients without recurrent disease were sent a questionnaire.
Results:
Results were obtained from 597 patients with a median follow up of 5.1 years. Stoma function, 
urinary function and hospital treatment rates did not diff er signifi cantly between the treat-
ment arms. However, irradiated patients reported increased rates of fecal incontinence (62% 
vs. 38%, P < 0.001), pad wearing due to incontinence (56% vs. 33%, P < 0.001), anal blood 
loss (11% vs. 3%, P = 0.004) and mucus loss (27% vs. 15%, P = 0.005). Satisfaction with bowel 
function was signifi cantly lower in irradiated patients, and the impact of bowel dysfunction 
on daily activities was greater in case of radiotherapy.
Conclusion: 
Although preoperative short term radiotherapy for rectal cancer results in increased local 
control, there is more long term bowel dysfunction in irradiated patients than in patients 
who undergo TME alone. Rectal cancer patients should be informed on late morbidity of 
both radiotherapy and TME. Future strategies should be aimed at selecting patients for 
radiotherapy who are at high risk for local failure.
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INTRODUCTION
Surgery is the key to cure for patients with rectal cancer. In the past, local recurrence rates 
after conventional surgery averaged 30% and varied considerably between institutions from 
15% to 45%.(1-3) The acknowledgement of the importance of circumferential lateral spread 
in the occurrence of local failure(4) has led to the introduction of total mesorectal excision 
(TME).(5) This surgical technique ensures resection of the complete mesorectum in contrast 
to conventional blunt dissection which is known to leave behind fragments of mesorectal 
tissue, that frequently contain non-nodal foci of metastatic disease.(6) TME has proven its su-
periority with regard to local control and survival when compared to historical controls.(7-9) 
Apart from surgery, the benefi t of radiotherapy, either pre- or postoperatively given, has 
been established in several randomized trials as well.(10-15) The only randomized trial com-
paring pre- and postoperative radiotherapy clearly showed the superiority of preoperative 
radiotherapy regarding side eff ects and local control.(16) These results were confi rmed in a 
large meta-analysis, including 8507 patients from 22 randomized trials, that concluded that 
preoperative radiotherapy is superior to postoperative radiotherapy in terms of cancer spe-
cifi c death (45% and 50% respectively, P=0.0003) and reduction of local recurrence risk (46% 
and 37%, P=0.002).(17) Furthermore, in the Swedish Rectal Cancer trial it was shown that a 
short-term regimen of high-dose preoperative radiotherapy (5x5 Gy) administered in one 
week was capable of not only reducing local recurrence rates (27 vs. 11%, P<0.001), but also 
improving 5 year overall survival (48% vs. 58%, p = 0.004) compared to surgery alone.(15) 
The benefi t of this radiotherapy regimen in combination with TME surgery was also sug-
gested in the prospective randomized TME trial: after a median follow-up of 2 years, irradiated 
patients had lower local recurrence rates than patients who underwent radiotherapy alone 
(2.4% vs. 8.2%, P <0.001). No diff erence in overall survival could be detected (81.8% vs. 82%, 
P = 0.84).(18) In a previous report, reporting acute side-eff ects and complications of 5x5 Gy 
followed by TME surgery within one week, we showed that radiotherapy is a safe procedure 
despite a slight increase in complications when compared to TME alone.(19) While acute tox-
icity of short-term radiotherapy has been examined in several other trials as well(12;13;20), 
reports on long term morbidity are remarkably scarce. The aim of this study was to evaluate 
the eff ect of short-term preoperative radiotherapy and TME surgery on long term side eff ects 
in patients with operable rectal cancer.
PATIENTS AND METHODS
Study population
From January 1996 until December 2000, 1861 patients were randomized between preopera-
tive radiotherapy (5x5 Gy) followed by TME and TME alone. Eligibility criteria for trial partici-
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pation included histologically confi rmed adenocarcinoma of the rectum without evidence of 
distant metastases. The inferior margin of the tumor had to be located not further than 15 
centimetres from the anal verge and below the level of S1-2. Patients with fi xed tumors were 
excluded as well as patients with locally treated (transanal resected) tumors.
Most patients (n = 1530) were Dutch. The remaining patients were included by Swedish, 
other European and Canadian centers. Only Dutch patients were considered in the present 
analysis as accurate collection and verifi cation of data on late side eff ects was for logistical 
reasons feasible for these patients only. Secondly, only those patients were included who 
were present in the analysis of acute toxicity as well. In- and exclusion for this analysis has 
been reported previously.(19) Patients had to be free of local or distant recurrent disease 
in order to avoid confounding due to symptoms caused by disease recurrence. Finally, only 
those patients who had responded to the quality of life questionnaires, that were sent 18 and 
24 months after surgery received a questionnaire about toxicity.
Treatment
Radiotherapy consisted of a total dose of 25 Gy given in 5 fractions over 5-7 days. A three 
or four-portal technique was used and the clinical target volume included the primary 
tumor and the mesentery containing the perirectal, presacral and internal iliac nodes up 
to the S1/S2 junction. The anal sphincter was included in the clinical target volume only if 
an abdominoperineal resection was planned. This resulted in an upper border at the level 
of the promontory, and lateral borders 1.5 cm over the pelvic inlet. In the lateral fi elds, the 
entire sacrum had to be included and the anterior border included the posterior part of the 
prostate or the vagina. Treatment was delivered with a three or four portal box technique, 
depending on the institutes’ preference. The protocol prescribed an overall treatment time of 
at most 10 days. It was advised to give the radiotherapy on 5 consecutive days. Other details 
on radiotherapy have been described previously. (19)
All patients underwent surgery according the principles of TME surgery. Workshops, 
symposia and video instructions were organised to ensure quality controlled surgery. More-
over, in each participating center, the fi rst fi ve TME procedures had to be supervised by an 
instructing surgeon. Both radiotherapy and surgical procedures have been reported in detail 
in earlier instance.(18;20)
Measurements
Late morbidity was assessed using a questionnaire that was mailed to all patients in April and 
May 2003. The questionnaire was accompanied with a letter that explained the purpose of the 
study. In a pilot study, the questionnaire was tested for readability and understanding among 
20 eligible patients. Patients that did not respond initially were sent one reminder. Table 1 
shows the items of the questionnaire regarding bowel, stoma and urinary function. Patients 
could indicate the severity of dysfunction on a four-point scale ranging from “no, never” to 
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“sometimes” (less than once a week), to often (more than once a week, but not every day) to 
“yes, always” (every day) for time dependent symptoms, and from “no, not at all” to “a little” to 
“pretty much” to “very seriously” for time independent symptoms. Data from four-point scale 
answers were transformed into binary outcome measures (i.e. signs yes/no present). Only if 
there were no complaints at all, the item was scored as not present. Level of satisfaction with 
bowel and urinary function was assessed using a 3 point verbal scale including “satisfi ed, neu-
tral feelings, or unsatisfi ed”. Because of previously reported neurogenic pain and subacute 
nerve damage using a fraction size of 5 Gy (21), questions regarding neurological function 
were included: patients were asked for the presence of back/buttock ache or pain in one or 
both legs, hip stiff ness or pain, walking diffi  culties and the use of walking aids. In addition, 
patients were asked to rate their overall perceived health during the week prior to receipt of 
the questionnaire by means of a visual analogue scale (a 100 mm horizontal line, anchored at 
the extremes by ‘best imaginable quality of life’ and ‘worst imaginable quality of life’).(22) 
Patients were further asked whether they were treated in the hospital (either on a in- or 
outpatient basis) since rectal cancer surgery for any of the following disorders: bowel obstruc-
Table 1. Questions asked to assess bowel, stoma and urinary function
Bowel function
 mean bowel frequency at day and night
 anal blood and mucus loss
 fecal incontinence at day and night
 pad wearing due to fecal incontinence
Stoma function











 use of pads for urinary incontinence
 need to urinate again within 2 hours
 stream hesitation
 diffi  culty to postpone urination
 weak urinary stream
Impact of bowel and urinary dysfunction on
 work or household activities
 activities outside the house like shopping or paying visits
 social activities like theatre or cinema visiting
 Satisfaction with bowel, stoma and urinary function
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tion, herniae cicatricales, delayed wound healing, anastomotic stenosis, stoma problems like 
parastomal hernia, stenosis and prolaps, chronic cystitis, fracture of hip and/or pelvis, and 
fi nally, myocardial infarction or stroke. Only those groups of diseases that were considered 
possible late side eff ects of treatment were specifi cally mentioned. In addition, patients were 
requested to report any other treatment in the hospital. Data on hospital treatment were 
added with information obtained from the regular follow-up of the TME trial.
Data Collection and Statistics
All questionnaires were sent to the central data centre in Leiden. Data were entered in a da-
tabase and analysed with SPSS statistical software (version 11.5 for Windows, SPSS, Chicago). 
Chi-square tests were used to compare proportions. Student t-testing was applied for test-
ing diff erences between continuous variables. A two-sided P-value of 0.05 was considered 
signifi cant. No correction for multiple testing was applied.
RESULTS
Patients
Of all 1530 randomized Dutch patients, 116 were excluded for the assessment of acute 
radiotherapy toxicity.(19) These patients were also excluded for the present analysis. Other 
reasons for exclusion were death (n = 517), recurrent disease (n = 83) and no compliance 
with the completion of a previous quality of life questionnaire (n = 106). Thus, 708 patients 
remained evaluable. Median follow-up of these patients was 5.09 years since surgery and did 
not diff er signifi cantly between irradiated and non-irradiated patients. Of these patients, 597 
returned the questionnaire, resulting in a response rate of 84%. Distribution of patients and 
clinical characteristics was well balanced between irradiated and non-irradiated patients as 
shown in table 2.
At the time of fi lling out the questionnaires, 362 patients did not have a stoma. Of these 
patients, mean bowel frequency during the day was signifi cantly higher in irradiated patients 
compared to patients who underwent surgery alone (3.69 vs. 3.02, P = 0.011). Mean bowel 
frequency during the night did not diff er statistically between the two randomisation arms 
(0.48 vs. 0.35, P = 0.207). Figure 1 shows signifi cantly increased rates in irradiated patients of 
fecal incontinence at day and night, anal blood and mucus loss, as well as higher rates of pad 
wearing due to fecal incontinence. The severity of fecal incontinence for the two randomisa-
tion arms is shown in fi gure 2. Irradiated patients reported more signs of severe incontinence: 
daily incontinence was 5% in TME alone patients and 14% in irradiated patients. Figure 3 
shows the degree of fecal incontinence depending on tumor distance from the anal verge: 
incontinence at day was signifi cantly more reported after radiotherapy for patients with 
Late side eff ects of short course preoperative radiotherapy combined with total mesorectal excision 103
tumors between 5 and 10 centimeters from the anal verge. The diff erence was not statistically 
signifi cant for proximal lesions up to 15 centimeters.
More irradiated patients reported an impact of bowel dysfunction on daily activities like 
work and/or household (34% vs. 22%, P = 0.01) and activities outside the house (52% vs. 40%, 
P = 0.04). Although statistical signifi cance was not reached, there was an increased impact on 
social activities (46% vs. 37%, P = 0.15) in irradiated patients.
Two hundred and thirty-fi ve patients had a stoma at the time of completing the question-
naire. There were no statistical signifi cant diff erences in stoma related diffi  culties although 
slightly more problems were seen in irradiated patients (table 3). Overall reported stoma 
complaints were 87% in irradiated and 82% in TME alone patients (P = 0.06). The impact of 
stoma (dys)function on work/household activities (31% vs. 33%, P = 0.77), activities outside 
the house (35% vs. 28%, P = 0.27) and social activities (35% vs. 28%, P = 0.29) did not diff er 
signifi cantly between the treatment arms, but was much lower than for patients without a 
stoma. 
Table 2. Clinical and pathological patients characteristics over both treatment arms. Of 1 one irradiated 
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Median follow-up (yrs) 4.98 2.6 – 7.6 5.18 2.7 – 7.5 5.09
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Patients with a stoma were more satisfi ed about their bowel functioning than patients 
without a stoma, whether they had received radiotherapy or not (fi gure 4). In stoma patients 
there was no diff erence in satisfaction between the randomization arms. In patients without 
a stoma, irradiated patients were less satisfi ed than non-irradiated patients (50% vs. 60%, 
p=0.008).
Table 4 summarizes results from urinary function assessment and shows no signifi cant 
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Figure 1 Bowel function 
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P < 0.001
RT + TME (n = 177)










Figure 2. Degree of fecal incontinence at day in patients at risk without a stoma who reported some 
degree of fecal incontinence (n = 362). Sometimes was defi ned as once a week or less; often as more than 
once a week and always as every day
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reported to be incontinent for urine in both groups, and 57% of the patients wore pads due 
to urine incontinence. 
There was no increase in the readmission rates in irradiated patients for the indications as 
displayed in fi gure 5. In particular, the number of cardiovascular accidents was not increased 
RT + TME (n = 86)


















sometimes often always never 
RT + TME (n = 

















P < 0.001 P = 0.196 
A B 
Figure 3. Degree of fecal incontinence at day in patients at risk without a stoma who reported some 
degree of fecal incontinence (n = 362) A. Patients without a stoma with tumors between 5.1 and 
10 centimeters from the anal verge B. Patients without a stoma with tumors between 10.1 and 15 
centimeters from the anal verge. Sometimes was defi ned as once a week or less; often as more than once 
a week and always as every day
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Figure 4. Proportion of patient subgroups that indicated to be satisfi ed with bowel function






n % missing n % missing
Median urinary frequency at day 6.21 21 5.97 11 0.270
Median urinary frequency at night 1.51 6 1.41 4 0.260
Hematuria 5 2 7 2 1 8 0.286
Dysuria 27 9 7 22 8 8 0.585
Urinary incontinence 118 39 6 109 38 3 0.711
Use of pads for incontinence 67 57 5 62 57 5 0.983
Sensation of uncompleted bladder 
emptying 
139 47 13 134 48 9 0.985
Need to urinate again within 2 hours 203 70 16 195 71 18 0.710
Stream hesitation 131 45 15 136 49 13 0.315
Diffi  culty to postpone urination 152 53 17 141 52 17 0.788
Weak urinary stream 158 55 17 144 52 15 0.552
Need to push or stain to urinate 77 26 13 92 33 12 0.079
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in irradiated patients. Moreover, there were not more angina pectoris complaints after radio-
therapy (12% vs. 16%, P = 0.17).
Back/buttock ache or pain in one or both legs was reported by 52% of the irradiated 
patients and 58% of the patients who underwent TME alone (P = 0.20). Hip stiff ness or pain 
occurred in 34% of patients who underwent radiotherapy compared to 37% in case of TME 
alone (P = 0.423). Respective fi gures for walking diffi  culties were 43% and 46%, P = 0.79.
Median score on the visual analogue scale for overall perceived health was 82.0 for irradi-
ated patients (range 13 – 100) and 81.0 for patients without radiotherapy (range 4 – 100) 
(P = 0.38). For patients with fecal incontinence, median VAS score was 79.0 (range 16 – 100) 
compared to 84.0 (range 13 – 100) for patients who were continent (P < 0.001). Of the con-
tinent patients, 68% was satisfi ed with their bowel function. For incontinent patients, this 
fi gure was still 44% (P < 0.001).
DISCUSSION
Short term preoperative radiotherapy has been successfully used to reduce local recurrence 
rates in TME treated rectal cancer patients.(18) This benefi t of radiotherapy has to be balanced 
against the acute and late side eff ects of irradiation. We previously demonstrated that there 
is hardly an increase of acute toxicity after preoperative hypofractionated radiotherapy.(19) 
Concerning late side eff ects, there are only few reports available.(23;24) This study evaluated 
for the fi rst time late sequela of radiotherapy and TME surgery within the framework of a 
randomized prospective trial. There were no signifi cant diff erences in voiding and stoma 
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Figure 5. Rates of hospital treatment in all responding patients
108 Chapter 7
function, nor in symptoms possibly related to pelvic surgery or late side eff ects of radio-
therapy. However, there were clear diff erences in bowel function between irradiated patients 
and patients who underwent TME alone.
In contrast to earlier radiotherapy studies (19;24), we detected no increased rates in ir-
radiated patients of small bowel obstruction, urinary tract disease, femoral neck and pelvic 
fractures and arterial disease. The only randomized trial comparing pre- to postoperative 
radiotherapy, reported an increase in bowel obstruction in patients assigned to postopera-
tive irradiation.(16) We now demonstrate that short-term preoperative radiotherapy does not 
lead to an increase in small bowel obstruction compared to surgery alone. This might be 
explained by the fact that in preoperative radiotherapy the pelvic cavity is still occupied by 
large bowel, thus creating a “natural spacer” for the small bowel, which consequently is not 
exposed to irradiation. This is in contrast to radiotherapy after pelvic surgery, in which case 
the small bowel descends into the small pelvis due to the created open space.
Also, there was no diff erence in the number of femoral head or pelvic fractures. This is in 
contrast with data from the Stockholm trials that showed 5.3% of femoral neck or pelvic frac-
tures after radiotherapy, compared to 2.4% in patients without radiotherapy (P = 0.03)(24). 
In the Stockholm I trial, a two fi eld technique was used that was replaced in the Stockholm II 
trial by a four-fi eld box technique. Concomitant with this change in radiotherapy technique, 
there was a drop in the incidence of femoral neck and pelvic fractures. In our study, a three 
or four fi eld technique was routinely used, which most likely explains the non-signifi cant 
diff erence in fractures in our study population.
Long term urinary function was not deteriorated in irradiated patients compared to TME 
alone patients, which is in agreement with results from the Stockholm I and II trial, in which 
there was no statistical diff erence in urinary function between irradiated and non-irradiated 
patients. A small study (n=42) in male rectal cancer patients undergoing TME with or without 
preoperative radiotherapy demonstrated no signifi cant diff erence in urinary function be-
tween irradiated and non-irradiated patients.(26) Although there is no statistical signifi cant 
diff erence between both treatment arms in urinary incontinence rates, it is noteworthy to 
have incontinence reported in as much as up to 40% in both groups. One has to bare in 
mind however, that for the present study, loosing urine involuntarily once a week or less, was 
scored as urinary incontinence. Yet, there was an impact of urinary incontinence on overall 
perceived health: patients with urinary incontinence had a median VAS score of 77 (range 11 
– 100) compared to 84 (range 4 – 100) for patients without urinary incontinence (P < 0.001).
Despite the undisputable improvements in radiotherapy technique and application in time, 
the adverse eff ect on long term bowel function and its impact on daily activities remains 
an important issue for concern. Dahlberg et al.(23) retrospectivally investigated the eff ect 
of preoperative high-dose radiotherapy in the Swedish Rectal Cancer Trial(15) and showed 
increased bowel frequency, incontinence, urgency and emptying diffi  culties in irradiated 
patients. In a recent report involving 124 patients undergoing anterior rectal resection, Welsh 
Late side eff ects of short course preoperative radiotherapy combined with total mesorectal excision 109
et al.(27) showed higher incontinence scores in patients undergoing 5x5 Gy prior to TME. 
Data of these studies are in line with our results and indicate that there is price to pay for 
increased local control, even with adjusted radiotherapy technique. According to the TME 
radiotherapy protocol, the clinical target volume excluded the anal sphincter in case of an 
anterior resection with the lower border being 3 centimeters above the anal verge. Despite 
sparing of the anal sphincter, fecal incontinence rates were increased in irradiated patients. 
Apart from anal sphincter function, compliance of the rectal remnant is probably important 
for fecal continence as well. The latter might be decreased by radiotherapy due to aspecifi c 
changes in surrounding tissues.
As shown in fi gure 2, the proportion of patients expressing signs of fecal incontinence is 
considerable, especially in case of irradiation. Rates of fecal incontinence up to 62% in irradi-
ated patients might appear unsurpassed when compared to previous studies. It needs to 
be stressed however, that even when the patient reported soiling once a week or less, the 
patient was considered as incontinent for the present study. Thus, comparison with previous 
reports should be made with care. Nevertheless, 14% of the irradiated patients mentioned to 
suff er from fecal incontinence every day compared to 5% of the TME alone patients, making 
the additional toxic eff ect of radiotherapy unnegligible.
Based upon subgroup analyses from the TME trial at a median follow-up of two years, 
radiotherapy is most eff ective for patients with tumors between 5.1 and 10 centimeters with 
local recurrence rates dropping from 10.1% to as low as 1.0% after preoperative radiotherapy 
(P < 0.001).(18) Figure 3 shows that the increase in incontinence rates due to radiotherapy 
is statistically signifi cant in patients with mid-rectal carcinomas. This is not the case for 
patients with proximal lesions 10-15 centimeters from the anal verge. Thus, late term bowel 
dysfunction due to irradiation is more explicit in patients who seem to benefi t most from 
radiotherapy.
It is not clear to what extent patients’ quality of life is aff ected by impaired bowel function. 
In a concomitant study of our group, measuring health related quality of life on diff erent 
time points up to 24 months after surgery, there were only few diff erences in quality of life 
between patients with and without preoperative radiotherapy, despite the presence signifi -
cantly more fecal incontinence and sexual dysfunction in irradiated patients.(28) The current 
analysis of functional outcome was performed later in time and did not include a complete 
quality of life assessment. Nevertheless, overall perceived health was measured in this study: 
the median score of the Visual Analogue Scale was not signifi cantly diff erent between irradi-
ated and nonirradiated patients without a stoma: 83.0 vs. 80.5 (P = 0.374), indicating that 
the increased rate of bowel dysfunction after radiotherapy is not expressed in a signifi cantly 
worse VAS score for the whole population. However, we showed that impairment of bowel 
function had a signifi cant eff ect on daily and social activities and this diff erence is translated 
in the overall perceived health, because the median VAS score was signifi cantly lower for 
incontinent patients compared to continent patients (84.0 vs. 79.0, P = 0.05). In addition, 
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we demonstrated a statistical signifi cant diff erence in satisfaction between irradiated and 
non-irradiated patients without a stoma: 50% vs. 60% respectively (P = 0.008).
We found no signifi cant increase in stoma related problems in irradiated patients. In the 
analysis of acute radiotherapy toxicity, there was no increase of anastomtic dehiscence in 
irradiated patients.(19) Apparently, anastomotic bowel healing is not infl uenced by radio-
therapy. In parallel to this fi nding, in the long run, stoma healing and function is neither 
aff ected adversely by radiotherapy. As shown in fi gure 4, irradiated stoma patients were 
satisfi ed with bowel function in 74% of the cases, versus 75% of non-irradiated patients (P = 
0.753). Apart from the eff ect of radiotherapy, it is remarkable to note the distinction in sat-
isfaction rates between patients with and without a stoma: patients reported to be satisfi ed 
with bowel function in 74% (n = 173) and 55% (n = 199) respectively (P < 0.001). Sphincter 
saving rectal surgery, often accompanied with long term bowel dysfunction, does not seem 
the ultimate goal that should be aimed for in every rectal cancer patient.
In conclusion, late term adverse eff ects of hypofractioned preoperative radiotherapy and 
TME surgery on functional outcome are considerable, using our strict criteria for dysfunction. 
However, an age-matched control group without a history of pelvic disease and treatment 
is lacking in the current study. Studying a control group, would possibly reveal a certain 
degree of dysfunction as well, making the real contribution of radiotherapy and surgery to 
functional outcome more clear. The results of our study, however, enable physicians to inform 
their patients reliably about the side eff ects of both radiotherapy and surgery in rectal cancer. 
Compared to radiotherapy, TME surgery is the main contributor to late bowel dysfunction. 
However, surgery is the only option that can lead to cure in contrast to radiotherapy that 
has merely benefi ts in terms of increased local control. The substantial additional long term 
side eff ect of radiotherapy on bowel dysfunction urges to tailor radiotherapy to those pa-
tients only who are most likely to benefi t from it. In this way, unnecessary exposure to the 
described late side eff ects is avoided. However, pretreatment staging modalities presently 
used are incapable of identifying patients at risk for local failure accurately. Considering the 
signifi cant increase in local control after preoperative radiotherapy for TME treated rectal 
cancer patients, 5x5 Gy remains a valuable treatment regimen.
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ABSTRACT
Objective. To investigate the effi  cacy of preoperative short term radiotherapy in patients with 
mobile rectal cancer undergoing TME surgery.
Summary Background Data. Local recurrence is a major problem in rectal cancer treatment. 
Preoperative short term radiotherapy has shown to improve local control and survival in 
combination with conventional surgery. The TME trial investigated the value of this regimen 
in combination with total mesorectal excision (TME). Long term results are reported after a 
median follow-up of 6 years.
Methods. 1861 patients with resectable rectal cancer were randomized between TME 
preceded by 5x5 Gy or TME alone. No chemotherapy was allowed. There was no age limit. 
Surgery, radiotherapy as well as pathological examination were standardized. Primary end-
point was local control.
Results: Median follow-up of surviving patients was 6·1 years. Five year local recurrence 
risk of patients undergoing a macroscopically complete local resection was 5·6% in case of 
preoperative radiotherapy compared to 10.9% in patients undergoing TME alone (P < 0·001). 
Overall survival at 5 years was 64·2% and 63·5% respectively (P = 0·902). Subgroup analyses 
showed signifi cant eff ect of radiotherapy in reducing local recurrence risk for patients with 
nodal involvement, for patients with lesions between 5 and 10 centimetres from the anal 
verge, and for patients with uninvolved circumferential resection margins.
Conclusions. With increasing follow-up, there is a persisting overall eff ect of preoperative 
short term radiotherapy on local control in patients with clinically resectable rectal cancer. 
However, there is no eff ect on overall survival. Since survival is mainly determined by distant 
metastases, eff orts should be directed towards preventing systemic disease.
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INTRODUCTION
For rectal cancer, surgery is the principal treatment leading to cure. In particular, surgical 
technique determines treatment outcome to a great extent. With the introduction of total 
mesorectal excision (TME) involving resection of the fatty tissue around the rectum, local 
control and survival rates have improved substantially.1-3 In recent years, TME has become the 
standard in many countries and has replaced conventional blunt dissection that is known to 
leave behind mesorectal tissue, exposing patients to high risk of local recurrence and thus, 
poor survival.
Apart from the advances made in surgery, pre-or postoperative treatment has shown to 
be a signifi cant contributor to improved local control and survival as well. The benefi ts of 
(chemo)radiation either given pre- or postoperatively have all been established in combina-
tion with conventional surgery.4-13 The Swedish Rectal Cancer Trial showed that short-term 
high-dose preoperative radiotherapy (5x5 Gy) administered one week prior to surgery was 
capable of reducing 5 years local recurrence rates (27% vs. 11%, P < 0·001) and improving 5 
year overall survival (48% vs. 58%, P = 0·004) compared to surgery alone.14 The Dutch Colorec-
tal Cancer Group initiated a large prospective randomized multicenter trial to investigate the 
effi  cacy of 5x5 Gy prior to TME. The Nordic Gastrointestinal Tumour Adjuvant Therapy Group 
and the European Organisation for Research and Treatment of Cancer (EORTC) participated 
in the trial. Surgical technique was standardized and quality-controlled in order to assess the 
value of radiotherapy in addition to TME reliably. Early results showed a reduced risk of local 
recurrence in irradiated patients at two years (2·4% vs. 8·2%, P < 0.001) without a diff erence in 
overall survival (82·0% vs. 81·8%, P = 0·84).15 In this article, we report on the results of the TME 
trial after a median follow-up of 6 years with a focus on subgroup analyses.
METHODS
Patients with clinically resectable adenocarcinoma of the rectum without any evidence of 
distant disease were randomly assigned to preoperative radiotherapy using 5x5 Gy followed 
by TME or TME alone. Tumours had to be below the level of S1/S2 with the inferior tumour 
margin being 15 centimetres or less from the anal verge as measured during withdrawal 
of a fl exible coloscope. Patients with previous treatment for rectal cancer were excluded 
from trial participation, as well as patients who had previous chemo- or radiotherapy to the 
pelvis. There was no age limit. Other inclusion and exclusion criteria have been reported 
previously.16 Central and local ethics committee approval for the study was obtained as well 
as informed consent from included patients. Randomisation was performed centrally and 
based on permuted blocks of six, with stratifi cation according to centre and the expected 
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type of surgery (i.e. low anterior resection or abdominoperineal resection). Primary endpoint 
was local control. The trial design was based on a local recurrence rate of 5% at 5 years in 
the radiotherapy group for patients who underwent a curative resection (e.g. a resection 
without microscopically involved resection margins) compared to 10% in patients assigned 
to surgery alone. Secondary outcome parameters included distant recurrence, overall and 
cancer specifi c survival. No interim analysis was planned or performed. Trial design, surgery 
and radiotherapy technique as well as pathology procedures have been described in detail 
elsewhere.17-20
The prescribed radiotherapy consisted of 25 Gy in 5 fractions delivered during 5 to 7 days. 
The clinical target volume included the primary tumour and its mesentery with vascular sup-
ply containing the perirectal, presacral and internal iliac nodes, up to the S1/S2 junction. A 
three or four portal “box” technique was recommended. The upper boarder was at the level 
of the promontory. The perineum was included in the treatment fi eld only if the operating 
surgeon anticipated performing an abdominoperineal resection.
Surgery was scheduled to take place in the week after radiotherapy. Surgeons were taught 
to perform proper TME surgery through an extensive structure of workshops, symposia and 
video instruction. Also, a monitoring committee was installed to ensure adherence to the 
strict surgical protocol guidelines. The fi rst fi ve TME procedures in each participating hospital 
were supervised by an experienced instructor surgeon. The administration of concomitant or 
adjuvant chemotherapy was not allowed.
Pathologists were trained to identify lateral tumour spread according to the protocol of 
Quirke and Dixon.19 A panel of supervising pathologists was installed to review the results of 
histopathological examination.21
Patients underwent clinical examination every three months during the fi rst year after 
surgery and annually thereafter for the fi rst two years after surgery. Liver imaging and endos-
copy were mandatory. Local recurrence was defi ned as evidence of tumour within the pelvic 
or perineal area. Criteria for distant recurrence involved tumour growth in any other area, 
including the colostomy site or inguinal region. All recurrences were confi rmed by one of the 
study coordinators by checking all original pathology and radiology reports.
Central data management was done at the Data Center at the Department of Surgery of 
the Leiden Medical University Medical Center, the Netherlands. Information from participat-
ing hospitals was collected on case report forms that were sent to the central offi  ce. Data 
were checked and entered in a database and analysed using the SPSS program (version 11.5 
for Windows SPSS Inc, Chicago, IL). A two-sided P value of 0·05 or less was considered to 
indicate statistical signifi cance. In accordance with our previous report, event-free times were 
recorded from the day of surgery until day of local or distant recurrence, or death, or day of last 
follow-up. Overall survival analyses comprised all eligible patients and were thus performed 
on an intention-to-treat basis. In accordance with our previous report22, only patients who 
underwent a macroscopically complete local resection were included when calculating local 
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recurrence rates. Distant recurrence rates were based on all eligible patients who did not 
have distant metastasis at the time of surgery. Overall recurrence rate was calculated on the 
basis of the number of eligible patients who had a macroscopically complete local resection 
without distant metastasis at the time of surgery. Patient data were censored when at last 
follow-up contact the patient was alive or had no evidence of disease. The χ2 test was applied 
to evaluate diff erences in proportions. Univariate survival analyses were carried out by the 
Kaplan-Meier method. The log-rank test was used for comparison of the Kaplan Meier curves. 
The Cox proportional hazard model was applied to calculate hazard ratios. All variables 
with a P-value of less than 0·10 were entered in a multiple regression analysis. For subgroup 
analyses, no adjustment for multiple testing was applied. Results of subgroup analyses have 
to be judged with care: any signifi cant results must be viewed as generating hypotheses that 
require validation in subsequent studies. In case of subset analyses, a P value of 0·05 may not 
be accurate enough.
RESULTS
Recruitment of patients started in January 1996 and lasted until December 1999 with the 
enrollement of 1861 patients from 84 Dutch and 24 Swedish hospitals, as well as from 1 Cana-
dian and 10 other European centers. Figure 1 shows characteristics for eligible and ineligible 









Incomplete local resection 
with distant metastases N=5 
without distant metastases N=3
No resection
N=16
Complete local resection 
with distant metastases N=47 









Incomplete local resection 
with distant metastases N=0 
without distant metastases N=4 
Complete local resection 
with distant metastases N=48 
without distant metastases N=827
Figure 1. Numbers of eligible patients and extent of resection according to randomisation. (In)complete 
resection implies a macroscopic (in)complete resection.
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Fifty-six patients were considered ineligible after randomisation. Of these ineligible patients, 
27 were randomized to receive radiotherapy prior to surgery, the remaining 29 patients to 
undergo surgery alone. Reasons for ineligibility in the radiotherapy arm were no adenocarci-
noma (n = 5), tumour treated by transanal resection (n = 2), tumour location on more than 15 
centimetres from the anal verge (n = 4), previous cancer (n = 8), coexisiting cancer (n = 4), pre-
vious large-bowel surgery, pelvic radiotherapy and/or chemotherapy (n = 2) and incomplete 
information on eligibility (n = 2). In the surgery alone arm reasons for ineligibility were no 
adenocarcinoma (n = 3), fi xed tumour (n = 2), tumour location on more than 15 centimetres 
from the anal verge (n = 1), previous cancer (n = 13), coexisiting cancer (n = 7), previous large-
bowel surgery, pelvic radiotherapy and/or chemotherapy (n = 1) and incomplete information 
Table 1. Patient and tumour characteristics according to randomisation of 1805 eligible patients*
RT + TME TME alone P-value
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* Characteristics were unknown in some cases because not all case reports were received.
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on eligibility (n = 2). Among the 1805 eligible patients, there were 139 patients with major 
protocol violations including no administration of the intended treatment (n = 54) or delivery 
of postoperative adjuvant treatment against protocol guidelines (n = 85). Minor violations 
included prolonged interval between the end of radiotherapy and surgery (n = 110) and 
non-compliance with the prescribed anatomical borders of the clinical target radiotherapy 
volume (n = 127). Specifi cs on major and minor protocol violations, as well as postoperative 
morbidity and mortality have been described before.23 Patients with major and/or minor 
protocol violations were included in all the analyses. Table 1 shows patient characteristics 
that were well balanced across the treatment groups.
Forty-fi ve eligible patients had no resection at all, 12 patients underwent a local resection 
with macroscopically involved resection margins (i.e. a local R2 resection). In 95 patients, dis-
tant metastases were diagnosed at the time of surgery or after randomisation with additional 
work-up (fi gure 1).
Follow-up was continued until November 2005. Median follow-up of surviving patients was 
6·1 years (range 1·2 to 9·5 years) and did not diff er between the two randomisation arms (6·0 
vs. 6·1 years, P=0·760). Among 1748 patients who underwent a macroscopically complete 
resection, 129 patients had local disease recurrence. Of these patients, 83 (63·4%) patients 
had both local and distant relapse. Figure 2 shows Kaplan-Meier curves for relapse risk with 
Figure 2. Rates of local recurrence among 1748 eligible patients who underwent macroscopically 
complete local resection, according to randomisation
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Table 2. Univariate Cox regression analysis of local recurrence risk among 1748 eligible patients who 
underwent macroscopically complete local resection





2·11 1·46 – 3·04
<0·001
Distance tumour from anal verge
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4·03 2·82 – 5·76
<0·001
Table 3. Multivariate Cox regression analysis of local recurrence risk among 1748 eligible patients who 
underwent macroscopically complete local resection
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<0·001
Distance tumour from anal verge
 ≥10·1 cm












































The randomized controlled TME trial after a median follow-up of 6 years 121
local recurrence risk at fi ve years being 5·6% in the group assigned to radiotherapy before 
surgery and 10·9% in TME alone patients (P < 0·001), implying a relative risk reduction of 49% 
in patients assigned to preoperative radiotherapy. In the univariate analyses (table 2), treat-
ment group assignment, tumour location, type of surgery, TNM stage and circumferential 
resection margin (CRM) involvement were predictors of local recurrence risk. Multivariate Cox 
regression analysis revealed that randomisation arm, tumour location, TNM stage and (CRM) 
were independent predictors of local recurrence risk (table 3). Univariate log-rank analyses 
of 5 year local recurrence risk is displayed in table 4. According to these subgroup analyses, 
radiotherapy did not have a signifi cant eff ect in patients with proximal and distal lesions, 
in patients who underwent a abdominoperineal resection or Hartmann procedure, nor in 
patients with TNM stage I,II or IV disease. However, interaction analyses in the Cox regres-
sion analysis between the respective covariates and randomisation revealed no signifi cant 
interaction between type of surgery and treatment group assignment, nor between TNM 
Table 4. Univariate log-rank analyses of 5 year local recurrence risk according to randomisation arm 
among 1748 eligible patients who underwent macroscopically complete local resection
RT+TME TME alone P-value P-value
Interaction
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Figure 3. Rates of distant recurrence among all eligible patients who did not have distant metastasis at 
the time of surgery
Figure 4. Rates of overall survival among 1805 eligible patients according to randomisation
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stage and treatment group assignment. This suggests that the eff ects of radiotherapy did not 
diff er between these subgroups.
Distant recurrence was diagnosed in 201 cases that were assigned to radiotherapy com-
pared to 222 patients in the surgery alone arm. Distant recurrence risk at fi ve years was 25·8% 
and 28·3%, respectively (P = 0·387) (fi gure 3).
As of November 1st 2005, 748 patients had died. Of these patients, 374 (50·2%) died with 
recurrent disease. At fi ve years, overall survival rates in irradiated patients were 64·2% which 
did not diff er signifi cantly from survival rates in patients who underwent TME alone (63·5%, 
P = 0·902, see fi gure 4). Respective cancer specifi c survival rates were 75·4% and 72·4% (P = 
0·260) (Figure 5).
DISCUSSION
Short term preoperative radiotherapy results in improved local control for patients with re-
sectable rectal cancer undergoing TME. Local control was chosen as primary endpoint in the 
present trial, since local recurrence is responsible for substantial morbidity and death. Local 
recurrence rates are signifi cantly lower in irradiated patients, with a relative risk reduction 
of 49% when compared to TME surgery alone. This risk reduction at 5 years is smaller when 
compared to the relative risk reduction of 71% at a median follow-up of 2 years.24 Figure 
2 shows that a signifi cant number of local recurrences occur beyond a follow-up period of 
3 years in case of preoperative radiotherapy. This is in contrast to previously released data 
Figure 5. Rates of cancer specifi c survival among 1805 eligible patients according to randomisation
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that indicated that the majority of local recurrences become overt within three years after 
surgery.25,26 In fact, in patients assigned to TME alone, only 9 (10%) out of 87 local recurrences 
appeared after 3 years of follow-up, compared to 13 (31%) out of 42 local recurrences in case 
of preoperative radiotherapy. Apparently, in a proportion of irradiated patients, radiotherapy 
does not prevent but merely postpones local recurrence. Hypothetically, radiotherapy de-
creases tumour burden, prolonging the time to macroscopically outgrowth. These results are 
in contrast to long-term follow-up data on the Swedish Rectal Cancer Trial where no delay 
was seen in irradiated patients.27 In the Swedish trial, only a total 5 patients developed a local 
recurrence at 5 years after surgery. Four of these did not undergo radiotherapy. An explana-
tion for this discrepancy might be the fact that, unlike the present trial, no TME was performed 
in the Swedish study. Conventional surgery results in a larger postoperative residual tumour 
burden that possibly needs less time to become apparent as a clinically recurrence.
In our study, increased local control in irradiated patients does not lead to a detectable 
improved overall survival. Although local recurrences are known to be an important cause 
of death, apparently, an absolute diff erence in local recurrence rates of 5·3% is too small to 
have a signifi cant impact on survival. For comparison, in the Swedish Rectal Cancer Trial, an 
absolute reduction of 16% in local recurrence risk in irradiated patients (from 27% to 11%, 
P < 0·001) was related to a signifi cant improvement in 5 year overall survival (58% vs. 48%, 
respectively, P = 0·004)28, presuming local failure to be an important cause of death. In a 
recent survey of the Swedish Rectal Cancer Trial with a minimum follow-up of 14 years the 
diff erence in local recurrence rate is persistent (9% vs. 26%, P<0·001) and this continues to 
improve overall survival after a long follow-up period (38% vs. 30%, P = 0·008).27
In the recently published German randomized trial comparing preoperative to postopera-
tive chemoradiation in patients with locally advanced disease, local recurrence rates were 
comparable to those of the current study (6% vs. 13% in favour of preoperative treatment, P 
= 0·006). In parallel, there was no diff erence between the two randomisation arms in fi ve year 
overall survival rates (76% resp. 74%, P = 0·80).29 Although trial results should be compared with 
care due to diff erences in case mix, it has to be noted that survival rates in the German study 
appear more favourable, despite the advanced stage of disease at presentation. However, the 
fact that as much as 18% of the patients, assigned to postoperative treatment turned out at 
pathological examination to have stage I disease, indicates that not only patients with locally 
advanced disease were included. Moreover, in the German study there was an upper age limit 
of 75 years excluding trial participation compared to no age limit in the TME trial. Diff erences 
in patient selection due to diff erent staging techniques hinder adequate comparison of trial 
results. For example, the Polish trial comparing short term preoperative radiotherapy (5x5 
Gy) to chemoradiation (50·4 Gy, 1·8 Gy per fraction plus bolus 5FU/LV) in patients with lo-
cally advanced rectal cancer accessible to digital examination, showed no diff erence in local 
recurrence risk (9% vs. 14%, P=0·17)30, despite the fact that there was more downsizing after 
prolonged treatment.31 These results demonstrate that for the patients selected in this trial, 
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a short course of radiotherapy is at least as good as chemoradiation, indicating that not all 
patients with locally advanced tumours require a prolonged radiotherapy schedule. Accord-
ing to the EORTC 22921 trial, response rate is increased by the addition of chemotherapy to 
prolonged irradiation (14% vs. 5%, complete pathological response)32, leading to a signifi cant 
reduction in local recurrence risk (17·1% vs. 8·7% at 5 years).33 This is in line with data from 
the FFCD 9203 trial that showed not only more complete responses after combined treat-
ment (11·7% vs. 3·7%, P<0·001), but also a 2-fold reduction in local recurrence risk (16.5% vs. 
8%, no P-value mentioned.34 Although the addition of chemotherapy to radiotherapy seems 
justifi able on the basis of these data, acute and late toxicity may be more pronounced after 
combined treatment. 
Discrepancies between trial results are most likely related to selection biases due to sub-
optimal staging, rather than to diff erences in biological behaviour. Preoperative clinical stag-
ing applying digital rectal examination and/or endorectal ultrasonography is increasingly 
replaced by magnetic resonance imaging, facilitating appropriate selection for the right type 
of neoadjuvant therapy.35 Thus, the diff erences in patient characteristics between all these 
trials are diffi  cult to appreciate, applying the current standards of local staging.
A potential advantage of prolonged neoadjuvant treatment over short term preoperative 
irradiation is tumour shrinkage and thus, sphincter preservation for distal rectal lesions. A 
prolonged overall time of irradiation, as well a protracted interval between radiotherapy 
and surgery is considered to be associated with downsizing, facilitating low-lying anasto-
mosis. However, the aforementioned randomized trial comparing conventionally fraction-
ated chemoradiation to preoperative short-term irradiation showed no diff erence in rates 
of sphincter preservation (58% vs. 61%, P = 0·57).31 This might relate to the hypothesis that 
surgeons were reluctant to alter their initial surgical planning on the basis of response to 
neoadjuvant treatment. Sphincter preservation and thus, avoidance of a permanent stoma 
are thought to be of benefi t for rectal cancer patients. However, in a recent study of our 
group investigating the late toxic eff ects of radiotherapy on functional outcome, patients 
with a (permanent) stoma were more satisfi ed with bowel functioning than patients who had 
undergone a low anterior resection and had no stoma.36
Clinical practise should not be based on the results of subgroup analyses: power is often 
too low to detect clinically relevant diff erences, and it is diffi  cult to diff erentiate between 
subgroups prior to treatment. Nevertheless, subgroup analyses may be of interest for the 
development of future trials. According to the univariate analyses of local control (table 4), 
only patients with positive lymph nodes (i.e. TNM stage III) benefi ted from radiotherapy. 
Apparently, with the involved nodes having removed, preoperative radiotherapy is able 
to treat (microscopic) nodal disease beyond the plane of surgical resection. Lateral pelvic 
lymphadenectomy, as favoured in Japan37-40 seems unnecessary with radiotherapy treating 
nodal spread suffi  ciently in a non-invasive manner. Preferably, patients with lymph node 
involvement are to be identifi ed prior to treatment in order to avoid overtreatment. Although 
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the use of novel MRI contrast agents to predict nodal involvement prior to treatment seems 
promising41, presently, the use of these agents is merely experimental and requires further 
investigation, especially for suspected nodes smaller than 5 millimeters.42 Although subgroup 
analyses indicate a nonsignifi cant eff ect of radiotherapy for TNM stage I,II and IV, caution is 
warranted not to irradiate these patients considering the absence of signifi cant interaction 
between TNM stage and treatment group assignment.
The effi  cacy of the investigated radiotherapy regimen depends on the location of the 
tumour: patients with proximal tumours do not benefi t signifi cantly from radiotherapy as be-
comes clear in table 3. Apart from the absence of a statistical diff erence, the number of events 
is rather low in patients with proximal lesions, making the number of patients needed to 
treat to prevent one local recurrence considerably high. Surprisingly, in the aforementioned 
German trial, there is no diff erence in local relapse risk between patients with tumours in 
the middle and upper part.43 Possibly, the completeness of mesorectal excision that might 
be less in case of proximal lesions is an explanatory factor. For patient with low tumours 
up to 5 centimetres from the anal verge, there is neither a signifi cant eff ect to the benefi t 
of short course irradiation. This contradicts data from the Swedish Rectal Cancer Trial that 
showed an eff ect of radiotherapy for this group of patients.27 Also, the Swedish Rectal Cancer 
Register has demonstrated a signifi cant eff ect on local recurrence rates by applying 5 x 5 
Gy preoperatively for patients with low lying rectal cancer. (Swedish Rectal Cancer Register 
(2004) http://www.SOS.se/mars/kvafl ik.htm (Swe). A possible important confounding factor 
for this patient subset is the substantial proportion of patients with positive CRM involve-
ment. Unfortunately, Swedish data on margin involvement are not available, but hypotheti-
cally, CRM involvement occurs less often in Sweden. Especially for patients with distal lesions, 
incomplete resection constitutes a major problem: as shown earlier, positive CRM is the most 
important independent predictor for local failure.44 Table 4 shows unacceptable high rates of 
local recurrence in case of positive CRM. For these patients, radiotherapy has no signifi cant 
eff ect (19·7% vs. 23·5%, P = 0·393). In particular, for patients requiring APR, complete resec-
tion seems a major challenge: in this subgroup, as much as 30% had involved CRM compared 
to 11% of the patients undergoing LAR (P < 0.001). Hypothetically, a cylindrical resection in 
stead of “coning in” towards the distal margin is appropriate in an attempt to avoid incom-
plete resection. Alternatively, as mentioned before, prolonged (chemo)radiation may result in 
downsizing facilitating curative resection. Again, speculations based upon subgroup analyses 
require validation in future studies. Precise tumour location is often diffi  cult to assess prior to 
treatment: discrepancies between coloscopy measurements, CT and MRI imaging and intra-
operative fi ndings are often encountered and indicate the diffi  culty of determining exact 
tumour position and the a priori chance of local failure. Therefore, these subgroup analyses 
provide limited support to withhold radiotherapy from patients with proximal rectal cancer 
or to apply a prolonged radiotherapy schedule for patients with distal rectal cancer.
The randomized controlled TME trial after a median follow-up of 6 years 127
In conclusion, with increasing follow-up, there is still a highly signifi cant eff ect of short 
term preoperative radiotherapy on local recurrence rates. There is no detectable eff ect on 
overall survival. TME surgery contributes signifi cantly to superior local control and survival 
compared to results from conventional blunt dissection. Future eff orts should be directed 
towards optimal preoperative imaging in order to diff erentiate between rectal cancers where 
a free CRM can be obtained or not. In the latter a more aggressive approach is warranted. In 
the future, adjuvant chemotherapy might gain a role for patients with clinically resectable 
rectal cancer in an attempt to improve survival, now that local treatment has been optimised 
by both TME and short term preoperative radiotherapy.
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Objective of this article is to evaluate the current multimodality treatment for locally ad-
vanced rectal cancer (LARC) and to gain more insight in tumour biology. 
Patients
A group of 201 single institution multimodality treated LARC patients with T4 and T3 tumours 
growing less than 2 mm from the mesorectal fascia were compared with a second group con-
sisting of 316 patients with a T3 resectable rectal tumour, included in the Dutch TME trial. 
Results 
Overall survival after 3 years was not diff erent (76% for TME, 67% for LARC, p = 0.071). Local 
recurrence rate (LR) was signifi cantly lower in TME patients than in LARC patients at 3 years: 
5% and 17% (p = 0.0001). In 83% of the LARC patients a negative circumferential resection 
margin could be realised, compared to 75% of the TME patients (p=0.037). Both circumfer-
ential margin status and lymph node status were important outcome parameters in both 
groups.
Conclusion 
In both groups circumferential margin involvement and nodal positivity are independent 
prognostic factors in local control and survival. Outcome for a LARC patient is similar to 
resectable TME patients in absence of these factors. However, when chemoradiation did not 
result in achieving tumour regression and subsequent negative resection margins and nega-
tive lymph nodes, prognosis of LARC patients is signifi cantly worse.
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INTRODUCTION
For planning of surgical treatment, rectal carcinomas growing through the muscularis 
propria of the bowel wall (tumour invasion classifi cation T3), are the most diffi  cult group, 
since these are inhomogeneous. A large majority of these tumours present themselves 
as mobile at rectal examination. Mobility is considered a surrogate for the probability of 
freedom of involvement of the circumferential margin (CRM). These tumours can adequately 
be treated with short-term preoperative radiotherapy (5x5 Gy), followed by Total Mesorectal 
Excision (TME). However, a small proportion of T3 tumours infi ltrate into or nearly into the 
circumferential fascia, and even with appropriate performed TME surgery free circumferen-
tial margins are not likely to be obtained. As these tumours are often less mobile at rectal 
examination, they are often referred to as being fi xed. Fixity is a subjective measure, and 
cannot always be assessed properly. Infi ltration into the vaginal septum or seminal vesicles 
may be underestimated at rectal examination and the same accounts for tumours out of 
the reach of the palpating fi nger. Large tumours may be over-staged merely due to their 
physical dimensions. The development of the Magnetic Resonance Imaging (MRI) has made 
it possible to distinguish a likely involved or free CRM (1, 2). In this paper locally advanced 
rectal cancer (LARC) refers to the close relation of the tumour to the circumferential margin 
based on MRI. 
The treatment of patients with LARC is diffi  cult. Short-term radiotherapy, followed by 
immediate surgery, does not result in down-staging of tumours (3) and is not eff ective in 
patients with a positive CRM (4). A positive CRM has been repeatedly showed to be one of 
the most important prognostic factors for local recurrence, next to invasion depth and nodal 
status in both mobile and LARC tumours (5-9). This has led to the development of neoadju-
vant multimodality treatments with preoperative downsizing as main goal, in order to help 
the surgeon to achieve a radical resection. 
Recently, several multimodality strategies have been investigated, but controversies remain 
to exist. At present, practice diff ers in Europe and in the USA, between countries in Europe, 
and even between institutions within the same country. It is obvious that current results are 
superior compared to historical controls. However, large diff erences in patient selections and 
treatment strategies make interpretation of the results diffi  cult.
The current study compares the mobile or “not locally advanced” rectal cancer pa-
tients, treated with short-term radiotherapy with LARC patients, treated with long term 




The Catharina Hospital in Eindhoven is a national referral centre for rectal cancer patients in 
whom a R0 resection is not likely to be obtained. Multimodality treatment of patients with 
primary locally advanced rectal cancer is applied since 1994 (10). This study group consists 
of 201 consecutive patients with locally advanced primary rectal adenocarcinoma treated 
in the Catharina Hospital Eindhoven between 1994 and 2004. Patients presenting with a 
rectal tumour infi ltrating into the mesorectal fascia or within proximity of less than 2 mm on 
MRI were eligible. Most of these tumours were referred as being fi xed at rectal examination. 
Sometimes fi xity was established by bimanual palpation during a staging laparotomy.  All 
patients had biopsy-proven rectal adenocarcinoma. Patients with recurrent rectal cancer 
and distant metastasis at fi rst presentation were excluded. The data were collected prospec-
tively. Mean age was 62,1 years (36-86 years), 122 patients were male and 79 female. Median 
follow up of the survivors in this group was 36 months. The fi rst 71 patients were treated 
with long course of preoperative radiotherapy consisting of 50,4 Gy (1,8 Gy fraction). Later, 
chemotherapy was added to the radiotherapy. In 109 patients daily bolus injections 5FU 350 
mg/sqm and leucovorin 20 mg/sqm were administered two hours before irradiation in the 
fi rst and fi fth week of irradiation. In 2003 21 patients received a continuous scheme: 825 
mg capecitabine/sqm bid every irradiation day and oxaliplatin 50 mg/sqm every fi rst day of 
each irradiation week, total irradiation dose 45 Gy/1.8 Gy fractions in fi ve weeks. After 6-8 
weeks patients underwent radical surgery. During this surgery intraoperative radiotherapy 
(IOERT; 10-15 Gy) was applied as a boost at the area of risk. Details about this procedure were 
published before (10). Standard pathological analysis was performed on all rectal resection 
specimens.
TME study group
Data from patients included in the Dutch TME trial were the basis of this study. The TME trial 
is a large prospective randomized multicentre trial that compared short term (5x5 Gy) pre-
operative radiotherapy and TME surgery with TME surgery alone which has been extensively 
described (11, 12). Informed consent had been obtained from all included patients and the 
medical ethics committees of all participating hospitals have approved the trial.
For the current study, data of the eligible Dutch patients in the trial as described earlier were 
analyzed (11) . The following patients were excluded from the analysis: no resection, tumour 
left behind, distant metastases at operation, TNM stage IV and no tumour at operation. For 
the current analysis, patients with pT1 or pT2 tumours were also excluded. Of the remaining 
patients only those who were randomized to the arm with 5x5 Gy preoperative irradiation 
(n=316) acted as benchmark, since these patient represent optimal standard treatment in the 
Netherlands. Mean age was 63,2 years (26-88 years), 214 patients were males and 102 were 
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females. Accrual for the TME study was from 1995 until 2005 and the mean follow up of the 
survivors at the time of analysis was 58 months
Statistics
Patient characteristics were compared using the chi-square test. Prognosis (overall survival 
(OS), distant metastasis free survival (MFS) and local recurrence free survival) were calculated, 
using the Kaplan-Meier method. Log rank testing was used to compare these diff erent patient 
groups. The starting point for the analyses of survival and recurrence was the day of surgery. 
Multivariate proportional hazard regression analysis (Cox regression) was performed to 
identify independent risk factors for the primary outcome variables, using the parameters 
with a p-value of less than 0.05 in the univariate analysis. A prognostic model for the outcome 




Table 1 shows the survival characteristics of CRM involvement, lymph node involvement and 
surgical procedure in the LARC population and irradiated patients of the TME trial. In T3-LARC 
and T4-LARC patients a similar outcome was observed in all investigated variables, therefore 
LARC patients will be reported as one group. 
Prognosis in both patient populations was similar for OS en MFS (fi gure 1). However, the 
local recurrence rate (LR) was signifi cantly lower in TME patients than in LARC patients at 3 
years: 5% versus 17% (p = 0.0001). In contrast, more positive CRMs were present in the TME 
group (25% versus LARC 17%, p = 0.037). In patients with negative margins, local recurrence 
rates were 2% (TME) versus 10% (LARC); in patients with positive margins 14% (TME) versus 
53% (LARC), p < 0.0001. Figure 2 shows the infl uence of positive margins on local recurrence 
for both the TME and LARC patients. Nodal status was an important prognostic parameter. 
In patients with negative lymph nodes local recurrence rates after 3 years were 3% (TME) 
versus 12% (LARC, p = 0.004). In patients with positive nodes: 7% (TME) versus 28% (LARC, p 
= 0.0007). Development of metastases and overall survival were predicted by nodal status as 
well, but there were no diff erences between both patient populations (fi gure 3).
Type of surgery and location of the tumour:
With a tumour below 5 cm from the anal verge 20% of the patients underwent a low anterior 
resection (LAR) and 80% an abdomino-perineal resection (APR). Irrespective the location of 
the tumour AP resected specimens showed signifi cantly more positive circumferential mar-
gins (31% versus 15%, p<0.0001). When TME patients were compared to LARC patients, the 
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latter had signifi cantly less positive margins after APR (43% vs 19%, p=0.0001). In contrast, 
after LAR there was no signifi cant diff erence between the two patient groups (LARC 10% vs 
TME 17%, p= 0.133). Overall survival and metastases-free survival were similar in both treat-
ment groups, if stratifi ed for surgical technique. However, LR-rate for LAR patients was much 
lower in TME patients than in LARC patients: at 3 years 2% versus 18% (p=0.000). 
Multivariate analysis.
Table 2 summarizes the results of the Cox regression multivariate analysis. The location of the 
tumour and the type of operation showed no longer prognostic value. Nodal status, CRM and 
patient population remained important factors for prognosis. 
Based on these results we created four prognostic groups for each patient population 
(table 3, fi gures 4a, 4b, 4c). These fi gures illustrate the good prognosis of LARC patients in 
case of a negative CRM and negative lymph nodes. The TME patients with both positive 
lymph nodes and a positive CRM show a poor prognosis, just like the LARC patients with 
these characteristics. 
Table 1. Kaplan-Meier (log-rank) Univariate calculated 3 year survival analysis
Overall survival Local recurrence Distant metastasis free 
survival
TME LARC TME LARC TME LARC TME LARC
n n 3yr % (n) 3yr % (n) p 3yr % (n) 3yr % (n) p 3yr % (n) 3yr % (n) p
All patients 316 201 76% (232) 67% (75) 0.0706 5% (227) 17% (73) 0.0001# 69% (191)67% (59) 0.2337
CRM neg 238 167 81% (188) 74% (66) 0.1103 2% (184) 10% (65) 0.0096# 77% (162)70% (54) 0.0519
CRM pos 78 34 60% (44) 40% (9) 0.1180 14% (43) 53% (8) 0.0000# 44% (29) 51% (6) 0.9844
p 0.0000# 0.0002# 0.0001# 0.0000# 0.0000# 0.0143#
LAR 220 97 77% (166) 69% (35) 0.1968 2% (163) 18% (34) 0.0000# 72% (138)62% (27) 0.0601
APR 96 90 73% (66) 70% (33) 0.3293 12% (64) 15% (32) 0.5811 63% (53) 69% (25) 0.9694
p 0.7149 0.7015 0.0022# 0.8138 0.2905 0.5735
pN neg 166 132 84% (135) 75% (52) 0.0999 3% (131) 12% (51) 0.0042# 85% (120)77% (41) 0.0611
pN pos 150 69 67% (97) 54% (23) 0.0629 7% (96) 28% (22) 0.0007# 52% (71) 49% (18) 0.2319
p 0.0000# 0.0025# 0.0044# 0.0163# 0.0000# 0.0000#
CRM: circumferential resection margin, LAR: low anterior resection, APR: abdomino-perineal resection, pN: 
pathological lymph node status, # signifi cant (log rank < 0.05)
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DISCUSSION
We demonstrated that in a group of locally advanced rectal carcinomas with a poor pre-treat-
ment prognosis the majority of cases will end up with a prognosis comparable to mobile T3 
tumours. The applied multimodality treatment resulted in a relatively low percentage of CRM 
positive cases (17%). Survival rate in CRM negative LARC tumours are similar to the results in 
TME treated mobile rectal tumours after preoperative radiotherapy.
In recent years the treatment of mobile, or primary resectable, rectal cancer has improved 
dramatically. The hypothesis that the introduction of TME surgery would result in an improve-
ment of overall survival (13) in addition to improved local control, was confi rmed in the Dutch 
        
fig. 1 0 12 24 36 48 60 months
        
TME T3 316 288 264 232 166 98 at risk 
 100 91 84 76 67 62 % surv 
        
LARC T3 89 81 48 32 16 13 at risk 
 100 93 75 68 58 58 % surv 
        
LARCT4 112 86 67 43 22 15 at risk 
 100 85 76 67 56 48 % surv 
        
      p=0,630 log rank
Figure 1. Kaplan-Meier: Overall survival for the diff erent patient populations.
No diff erence is observed between T3 and T4 LARC tumours. TME treated patients show the same survival 
as LARC patients (p = 0.630)
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TME trial (12). Local control was further improved by the introduction of 5 times 5 Gy preop-
erative radiotherapy. This combination resulted in very low local recurrence rates; in fact, local 
recurrence does not contribute signifi cantly to mortality anymore. From subgroup analyses 
it became clear that prognosis of patients with an involved CRM is signifi cantly worse (14). 
Locally advanced patients are by defi nition patients with a visceral mesorectal fascia exposed 
to the threat of tumour involvement. TME surgery in those patients, even after short course of 
preoperative irradiation, will inevitably lead to a high percentage of irradical resections and 
        
fig. 2 0 12 24 36 48 60 months
        
TME 238 220 208 184 140 81 at risk 
CRM neg 0 0 1 2 4 5 % LR 
        
TME 78 64 53 43 24 14 at risk 
CRM pos 0 6 10 14 18 18 % LR 
        
LARC 167 135 91 65 36 26 at risk 
CRM neg 0 4 10 10 10 10 % LR 
        
LARC 34 23 13 8 3 2 at risk 
CRM pos 0 23 49 53 53 53 % LR 
        
      p=0,000 log rank
Figure 2. Kaplan-Meier: Local recurrence in both patient population in relation to circumferential margin 
involvement
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subsequent higher local recurrence rate (12, 15). In this study a multimodality treatment for 
patients with locally advanced rectal cancer was benchmarked against a comparable group 
of patients from the TME study. The only diff erence was the initial estimation of the circum-
ferential margin.One of the primary questions of the current study was, whether the use of 
multimodality treatment could reduce the number of irradical resections and subsequently 
contribute to an improved outcome.In both groups circumferential margin involvement is an 
important predictor of local recurrence. Long course preoperative radiotherapy eff ectively 
lowers the rate of positive surgical margins. In fact, in these patients the a priori high risk on a 
       
fig. 3 0 12 24 36 48 60 months
        
TME 166 147 141 120 95 54 at risk 
pN neg 100 96 92 85 82 79 %meta 
        
TME 150 115 90 71 52 30 at risk 
pN pos 100 81 64 52 49 45 %meta 
        
LARC 132 103 68 41 26 20 at risk 
pN neg 100 92 83 77 73 70 %meta 
        
LARC 69 45 31 18 6 6 at risk 
pN pos 100 74 61 49 30 30 %meta 
        
      P=0,0000 log rank
Figure 3. Kaplan-Meier: Metastatic free survival in both patient populations, in relation to lymph node 
status
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positive CRM was lowered to a level signifi cantly lower than in TME patients (17% versus 25%). 
The importance of a negative surgical margin is highlighted by the fi nding that prognosis for 
survival is equal to TME patients with negative margins. 
Table 2. Cox regression Multivariate analysis
Overall survival Local recurrence Distant metastasis
HR 95% CI p HR 95% CI p HR 95% CI p
CRM neg 1 1 1
CRM pos 2.13 1.54-2.93 0.000# 4.50 2.41-8.41 0.000# 2.39 1.71-3.34 0.000#
LAR 1 1 1
APR 1.01 0.74-1.38 0.935 1.35 0.72-2.52 0.346 1.08 0.77-1.50 0.671
pN neg 1 1 1
pN pos 1.93 1.44-2.59 0.000# 2.48 1.32-4.66 0.005# 3.10 2.23-4.32 0.000#
TME 1 1 1
LARC 1.50 1.09-2.06 0.013# 3.75 2.00-7.02 0.000# 1.49 1.06-2.09 0.020#
CRM: circumferential resection margin, LAR: low anterior resection, APR: abdomino-perineal resection, pN: 
pathological lymph node status, HR: hazard ratio, 95% CI: 95% confi dential interval, # signifi cant (p< 0.05)
Table 3. Hazard ratio Circumferential resection margin and lymph node status combined
TME group LARC group
CRM neg CRM pos CRM neg CRM pos
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Overall survival
pN neg 1 0.98 0.46-2.09 1 2.94 ## 1.37-6.30
pN pos 1.41 0.91-2.18 4.40 ## 2.80-6.89 2.06 # 1.19-3.56 3.95 ## 2.00-7.83
Local recurrence
pN neg 1 0.00 * 1 5.23 ## 1.71-16.01
pN pos 1.16 0.31-4.32 10.52 ## 3.60-10.75 1.49 0.49-4.55 11.20 ## 4.40-28.48
Distant metastasis
pN neg 1 1.26 0.518 1 2.19 0.82-5.83
pN pos 2.44 ## 1.48-4.03 8.64 ## 5.18-14.44 2.71 ## 1.49-4.94 4.20 ## 1.97-8.95
CRM: circumferential resection margin, pN: pathological lymph node status, HR: hazard ratio, 95% CI: 95% 
confi dential interval, # p<0.05, ## p<0.01, * no events (n=30)
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Nodal status in TME and LARC patients are diff erent entities. Whereas in TME patients the 
initial nodal status is recognised, in LARC patients an unknown number will have had positive 
nodes that have been sterilized due to the neoadjuvant therapy. In this case, pN0 consists of 
an heterogeneous group of patients who were initially node negative and patients whose 
metastatic tumours responded well to treatment. In all patients, node positivity was associ-
ated with a higher local recurrence risk. However, node positive LARC patients had a signifi -
cantly higher risk than their TME counterparts. This might be explained by the presence of 
non-responders in the node positive LARC group. These patients have a worse prognosis due 
to the therapy-resistance in addition to their lymph node status. Another possible explana-
tion for the higher risk of local recurrence in more advanced stages of nodal involvement was 
Figure 4a. Cox regression: overall survival, 
categorized in treatment, margin and lymphnodes
Figure 4b. Cox regression: local recurrence, 
categorized in treatment, margin and lymphnodes
Figure 4c. Cox regression: metastatic free survival, categorized in treatment, margin and lymph nodes
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published by Steup and Fujita (16, 17). They demonstrated a positive correlation between 
nodal stage and lateral nodal involvement. A higher local recurrence rate in node positive 
LARC patients, especially in the midrectal segment, where most of the lateral nodes reside in 
the obturator fossa, suggest a higher nodal stage contributing to the development of local 
recurrence originating in this lateral nodal depot. Indirectly, the absence of this phenomenon 
in low rectal cancer may support the theory that low tumours do not drain preferably in the 
lateral lymph nodes. The diff erences between lymph node positive LARC and TME patients 
with respect to the development of local recurrence refl ects the higher stage of the LARC 
patients. 
Another interesting point is the prognostic value of CRM involvement in node negative 
T3 patients. In the patients treated with short-term radiotherapy (TME group), no local 
recurrence occurred during follow up, whereas LARC patients have a high chance on local 
recurrence (HR 5.23, p<0,00001). This suggests that 5 x 5 Gy eff ectively prevents local recur-
rences in positive margin patients without nodal disease, but not in CRM+ patients with nodal 
metastases. This conclusion is supported by the fact that in the control arm of the TME study 
without 5x5 Gy preoperative irradiation local recurrence rate equal was in node negative and 
node positive patients. In addition, it underlines that LARC patients who still have a positive 
CRM after chemoradiation are poor responders and have a very poor prognosis. 
Above mentioned demonstrates that both circumferential margin and nodal status play 
an important role in the local control after rectal cancer surgery. With this regard, mobile 
and advanced rectal cancers obey to the same rules. Success of multimodality treatment for 
advanced rectal cancer depends on how well these primary unfavourable variables are con-
trolled. Our results demonstrate that outcome for a LARC patient is similar to TME patients 
when these unfavourable parameters have been controlled by chemoradiation. The key 
role in recent progress in the treatment of locally advanced rectal cancer is the cooperation 
between the diff erent modalities. Several multimodality strategies have been developed and 
evaluated. Due to lack of randomised trials, there are still controversies in what treatment 
and especially which sequence off ers the best survival. However, some agreement seems 
to be present: at this moment long-term radiotherapy (50 Gy) with concomitant fl uoroucil 
(5-FU) based chemotherapy is becoming the most used neoadjuvant therapy (18-20).
Last years preoperative combined adjuvant therapy has gained acceptance as standard 
therapy in favour of postoperative regimens (21-24). Key factor in this development is the 
improved possibility of preoperative imaging and thus staging (25, 26).
CONCLUSION
Insight into the tumour biology of progressing rectal cancer has been gained by the com-
parison of the response to two diff erent treatment strategies. The interaction between two 
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independent variables i.e. positive circumferential surgical margin and positive lymph nodes 
and its relevance for the development of local recurrence is obvious. Another observation 
was, that local recurrences, at least partly could be explained as metastatic disease in the 
lateral lymph node compartment. The question that remains to be answered is whether fur-
ther intensifi cation of neoadjuvant local or more attention to systemic treatment will help to 
control this type of recurrence. Especially in low rectal cancer, 5x5 Gy preoperative irradiation 
followed by immediate surgery cannot prevent a relatively high positive circumferential mar-
gin rate (27). In more advanced T3 and T4 cases long course neoadjuvant treatment (LCNT) 
eff ectively reduces the number of positive margins, and therefore LCNT may also play an 
important role in T3 low rectal cancer. Selection for either treatment requires high-resolution 
preoperative imaging. Overall LCNT is able to restrain progressing rectal cancer. In the future, 
the isolated local recurrence without the development of distant metastatic disease will be 
very rare. Most patients will develop distant metastatic disease and one out of three will die 
of metastatic disease. The focus of upcoming studies also will have to include proper patient 
selection for adjuvant treatment.
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SUMMARY
Lymph node dissection plays an important role in staging and treatment of cancer patients 
with solid tumors. Sentinel node biopsy (SNB) has been introduced to minimize the extent of 
surgery and to enable minimal residual disease (MRD) assessment without compromising ac-
curate staging and survival. This review addresses the variation in technical aspects and out-
come of SNB and MRD assessment in patients with breast and gastrointestinal cancer. There 
is a need for quality control leading to standardization of SNB and consecutive pathological 
examination to enable reliable comparison of studies, leading to consensus of diagnostic and 
therapeutic strategies.
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INTRODUCTION
The histological status of lymph nodes is one of the most important prognostic indicators in 
patients with cancer originating from solid tumors. Staging patients to determine the need 
for adjuvant therapy presently occurs through lymphadenectomy. Apart from lymphad-
enectomy as a staging tool, it may also serve a therapeutic aspect, even in patients without 
nodal involvement1,2. Overall survival of colorectal cancer patients without nodal involve-
ment, improves with increasing number of lymph nodes recovered3. Also in invasive bladder 
cancer, both node-negative and node-positive patients had prolonged overall survival with 
an increasing number of lymph nodes examined4. This benefi t is possibly due to the presence 
of MRD in H&E-negative lymph nodes. 
Lymphadenectomy may be associated with considerable morbidity, especially in breast 
cancer and melanoma patients. To minimize the extent of lymphadenectomy without 
compromising accurate staging and survival, SNB has been introduced. Sentinel nodes are 
known as the fi rst possible sites of metastasis along the route of lymphatic drainage from a 
primary tumor. The histopathological state of the sentinel node is presumed to refl ect that of 
all regional lymph nodes. SNB can be performed by injecting either a vital dye, a radioactive 
colloid or both around the primary tumor. Techniques vary, however, substantially between 
institutions and researchers, which complicates reliable assessment of the role of SNB.
An amenity of the SNB is the lower number of lymph nodes that have to be examined 
compared to regional lymph node dissection. Laborious and expensive focused examina-
tion techniques like immunohistochemistry (IHC) and reverse transcriptase polymerase 
chain reaction (RT-PCR) can therefore be applied in a limited number of sentinel nodes to 
detect the presence of so-called minimal residual disease, also known as micrometastases. 
Micrometastases are defi ned as a cohesive cluster of malignant cells, greater than 0.2 mm 
and up to 2.0 mm in diameter, that are usually not detected with conventional pathological 
examination techniques. The prognostic signifi cance of micrometastases and the thera-
peutical consequences of upstaging by MRD assessment, however, are far from clear yet. 
Nevertheless, in some countries treatment decisions are already based on MRD assessment, 
implying possible over treatment. This review addresses the role of SNB and MRD in (sentinel) 
lymph nodes in breast, gastric and colorectal carcinoma and pleads for standardized and 
randomized trials in this fi eld. 
BREAST CANCER
Axillary lymph node dissection (ALND) contributes to both treatment and staging. Over-
gaard reported large diff erences in local recurrence rates in a trial investigating the effi  cacy 
of radiotherapy following total mastectomy5. There were clear variations in the extent and 
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quality of surgery since more than half of the local recurrences appeared on the chest wall. It 
was concluded that radiotherapy improved local control with the current surgery. However, 
if surgical procedures would improve, the benefi ts of standard application of radiotherapy 
might be questionable. It is clear that the quality of surgery dictates the value of adjuvant 
treatment. This stresses the need for standardized and quality-controlled SNB as staging 
and treatment decisions depend on removing and investigating only one or a few sentinel 
nodes. Currently, most centres agree on using the combination of a radioactive tracer and 
blue dye, which improves the identifi cation of multiple sentinel lymph nodes compared to 
the use of one tracer alone6. Table 1 highlights studies published since 1998 on SNB in breast 
cancer patients, with more than 100 patients included. Most centres use the combination of 
blue dye and radioactive colloid to detect sentinel nodes. In the displayed studies consider-
able variation exists in the volume of tracer used and the technique of examination of the 
resected sentinel nodes, which might lead to diff erent success and false negative rates. The 
site of injection is often inaccurately reported and it remains unclear whether massage has 
been performed. 
In focused examination studies of H&E negative lymph nodes, there is considerable 
variation in the applied technique, marker or antibody used and data analysis. Dowlatshahi 
showed upstaging by serial sectioning and immunohistochemistry of 9 to 33%7,8. The clinical 
relevance of MRD assessment is debatable. Studies that showed survival disadvantage due 
Table 1. An overview of the SNB studies in breast cancer








Nwariaku et al36 Tc + blue dye 1.84 81 s.s. 4
Borgstein et al37 Tc 1.2 100 IHC 2
Krag et al38 Tc 2.6 91 - 11
Hill et al39 Tc + blue dye 2.1 100 IHC 11
Veronesi et al40 Tc + blue dye 1.4 99 s.s. 7
Winchester et al41 Tc  3.1 90 s.s. 8
Bass et al42 Tc + blue dye 2.0 93 IHC 2
Morrow et al43 Tc + blue dye 1.8 79 - 13
Fraile et al44 Tc 2.0 96 IHC 4
Kollias et al45 Tc + blue dye 1.4 81 IHC 6
Tafra et al46 Tc + blue dye 2.2 87 IHC 13
Nano et al47 Tc + blue dye - 87 IHC 7
Tc = 99m Technetium; s.s. = serial sectioning; IHC = immunohistochemistry
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to the presence of micrometastases included larger patient populations (range 147-921) and 
had more prolonged follow-up (at least 6 years) than studies that did not prove any survival 
diff erence. Moreover, most studies did not take the size of the micrometastases into account, 
whereas data already exist that the size of nodal metastases linearly correlates with survival8. 
Also the role of isolated tumor cells in lymph nodes has not been elucidated yet9. It might be 
diffi  cult to distinguish isolated tumor cells from mesenchymal cells, mesothelial cells, transfer 
(contamination) artefact, and transport of benign or malignant epithelium. Many investiga-
tors probably often encounter these technical diffi  culties, but reports on these issues are 
remarkably scarce. 
MRD assessment in sentinel nodes with immunohistochemistry and serial sectioning re-
veals a higher detection rate of micrometastases in sentinel nodes than in the regional lymph 
nodes10. This is in line with the sentinel node hypothesis. An overview study showed that in 
38-67% of patients with breast cancer the sentinel node is the only involved lymph node11. 
When the sentinel node is the only involved lymph node it can be argued that ALND is not nec-
essary. In the AMAROS trial (After Mapping of the Axilla Radiotherapy Or Surgery), coordinated 
by the European Organization for Research and Treatment of Cancer, patients with positive 
sentinel nodes are randomized to ALND or axillary radiotherapy. The presence of any tumour 
deposit, detected with either HE staining or IHC, has consequences for the local treatment of 
the axilla (i.e. surgery or radiotherapy) but not for systemic treatment. Recently, concern has 
been expressed that many pathology laboratories have adopted IHC techniques and many 
oncologists recommend adjuvant chemotherapy upon IHC detected metastases only12. Giving 
patients a toxic and often expensive treatment with possibly limited benefi ts, based upon IHC 
fi ndings alone, is not backed up by the literature and should therefore not be encouraged. 
It can be concluded for breast cancer patients, that the SNB is presently performed with 
acceptable success rates and low false negative rates despite considerable variation in SNB 
techniques. Special techniques to detect micometastases can lead to upstaging in a consid-
erable number of patients, but it remains unclear whether these fi ndings should aff ect the 
choice of adjuvant treatment.
GASTRIC CANCER
The widespread use of gastroscopy has led to increasing chance of identifying gastric cancer 
at an early stage. Nodal involvement occurs only in 2 to 18% in T1 tumors and in about 50% 
in T2 tumors13. This means that a larger than necessary lymphadenectomy is performed in a 
substantial number of patients. The debate on the benefi ts of D1 compared to D2 lymph node 
dissection is still ongoing. Also, the value of adjuvant therapy in relation to the extent of sur-
gery is intensely discussed14. An extended lymphadenectomy is associated with considerable 
postoperative morbidity and mortality, especially in western countries15,16. However, reliable 
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tools are lacking to predict nodal involvement. SNB and its investigation might however gain 
a role in minimizing the surgical procedure and predicting the status of non-sentinel nodes. 
The studies on feasibility of SNB in gastric cancer are rather limited. Table 2 shows that diff er-
ent types of tracers are being used and a ranging number of SNs are retrieved. Moreover, only 
in one SNB study upstaging techniques were applied17. Endoscopic submucosal injection has 
shown to be a feasible route of administration of a radioactive tracer or a dye. Identifi cation 
of the sentinel node using a radiolabelled colloid and perioperative detection with a gamma-
ray detection probe has the drawback of detecting not only radiation from lymph nodes, but 
also from the adjacent injection site. Therefore, most experience has been gained so far with 
the application of dyes. All the displayed studies, initiated in the Far East, showed acceptable 
feasibility in early stage disease (i.e. T1 or T2). In Western countries however, gastric cancer is 
often diagnosed at an advanced stage, which questions the role of SNB in these patients. 
Table 3 displays that two out of fi ve IHC studies, using anticytokeratin antibodies showed 
an adverse eff ect of the presence of micrometastases. Remarkable are the diff erences in 
Table 2. An overview of the SNB studies in gastric cancer











Hiratsuka et al48 72 Indocyanine green 5 2.6 (1-9) 99 10
Aikou et al17 18 Tc + blue dye 2 (Tc) 3 94 17
Yasuda et al49 26 Tc 2 4 (2-8) 100 18
Ichikura et al50 62 Indocyanine green 4 or 8 4.5 (1-12) resp. 
8.6 (1-25)
100 13
Kitagawa et al51 145 Tc 2.0 3.6 (1-8) 95 8
Miwa et al52 211 Blue dye 0.8 6 (1-19) 96 11
Tc = 99m Technetium
Table 3. Immunohistochemistry studies on H&E-negative lymph nodes in gastric cancer
Reference Antibody No of H&E-node-
negative patients








Maehara et al53 CAM 5.2 34 12.4 single 23.5 adverse
Cai et al54 CAM 5.2 69 24.6 single 25 controversial
Morgagni et al55 MNF 116 139 10.7 multi 17 no diff erence
Fukagawa et al56 AE1/AE3 107 41.9 single 35.5 no diff erence
Lee et al57 AE1/AE3 70 23.7 single 40 adverse
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antibodies used, the number of resected lymph nodes and proportion of patients upstaged. 
Noguchi et al used RT-PCR with keratin 19 as a marker to detect micrometastases and found 
that this was a more sensitive method than histological examination for the detection of 
gastric micrometastases in lymph nodes18. The prognostic signifi cance of micrometastases, 
detected with this technique, was however not addressed.
The majority of the reports on gastric carcinoma originate from specialized centers that 
have been able to gain experience with the technical demanding procedure in a patient 
population less prone to postoperative morbidity and mortality than in Europe and the 
USA. 
In conclusion, the initial and limited experience in SNB has a potential value in staging and 
treating gastric cancer patients. However, only patients with early stage disease, a patient 
category not very often encountered in Western population, may benefi t from SNB. More-
over, the existing variation in technical aspects of SNB and MRD assessment hampers the 
introduction of treatment decisions based on MRD assessment. 
COLORECTAL CANCER
The treatment of node-negative colorectal cancer consists of surgical resection of the pri-
mary tumor without adjuvant therapy. However, up to 30% of these patients will develop 
metastases possibly due to micrometastases in the regional lymph nodes. We showed that 
patients with CEA RT-PCR negative lymph nodes had a signifi cantly better fi ve-year disease-
free survival than patients with positive lymph nodes (91 versus 50%, p=0.02)19. Three other 
RT-PCR studies20-22 also showed an adverse eff ect on the prognosis whereas only three of 
ten immunohistochemistry studies showed an adverse eff ect22,23. Again, the IHC studies 
show clear variation in the number of resected lymph nodes, the use of serial sectioning 
and antibodies, and the degree of upstaging, which ranges from 10 to 76%22,24-32. Noura 
et al studied the same paraffi  n-embedded lymph nodes with CEA RT-PCR and cytokeratin 
immunohistochemistry and showed that CEA RT-PCR had prognostic value whereas immu-
nohistochemistry did not22. 
SNB in colorectal cancer patients is still in childhood. In contrast to breast cancer patients, 
SNB in colorectal cancer is not performed to avoid unnecessary lymphadenectomy but to en-
able focused examination of few lymph nodes. An important consequence of intraoperative 
SNB in colorectal cancer patients is the identifi cation of aberrant lymphatic drainage pat-
terns occurring in up to 14% of the patients leading to an adjustment of the initial surgical 
resection plan33,34. Table 4 summarizes SNB studies on colorectal cancer patients, with more 
than 25 patients included. Blue dye is used in most of the studies with moderate variation 
in volume and site of injection. However, the number of detected SNs ranges widely. Suc-
cess rates, false-negative rates and upstaging techniques vary and are infl uenced by disease 
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stage. In rectal cancer, the dye method has its limitations because of the restricted visibility 
of the transit of dye into the SNs35.
In summary, SNB in colorectal cancer patients is a technical demanding procedure with 
variable success rates. Although MRD assessment can lead to profound upstaging, there is no 
clear evidence yet that it should aff ect adjuvant treatment decisions. Still, in some countries 
colorectal cancer patients with sentinel node micrometastases are already receiving systemic 
adjuvant therapy. SNB and MRD assessment techniques are currently being optimised, which 
may lead to more tailored adjuvant treatment, based upon MRD assessment.
CONCLUSION
Limiting the extent of surgery in the treatment of solid tumors through SNB is technically 
feasible. However, when comparing studies investigating the role of SNB, there is a large 
variation in patient selection, and type and volume and location of tracers injected around 
the tumor. This variety complicates trial comparison, which hampers application of SNB into 
daily practise. Minimal residual disease assessment by serial sectioning, immunohistochem-
istry and RT-PCR is possible and may lead to considerable upstaging. The results from studies 
Table 4. An overview of the SNB studies in colorectal cancer
















Joosten et al58 50 15 70 3 IHC 60
Wiese et al59 83 5-10 99 1.9 s.s. and IHC 9
Feig et al60 48 - 98 2.6 IHC 38
Wong et al61 26 2-5 92 2.8 s.s. and IHC 6
Saha et al62 203 1-5 98 (1-4) s.s. and IHC 6
Merrie et al63 26 20*; 26 – 106** 88 3
(0-8)
RT-PCR 45
Esser et al.64 31 - 58 - - 33
Broderick-Villa et al65 51 - 92 1.5 IHC 50
Wood et al66; 
Bilchik et al67
100 - 97 2 s.s. and IHC 11
Fitzgerald et al68 26 5-10 88 2.5 s.s. and IHC 40
Paramo et al69 55 5 82 1.9 s.s. and IHC 7
Kitagawa et al35 56 120 91 3.5 - 18
Minimal residual disease assessment in sentinel nodes of breast and gastrointestinal cancer 155
addressing the prognostic role of micrometastases are often contradictory, which might be 
due to the use of diff erent examination techniques, markers, antibodies and diff erences in 
sample size and length of follow-up. This variation in techniques of SNB and MRD assessment 
precludes the availability of evidence-based diagnostic and therapeutical guidelines in the 
near future. Quality control leading to standardization of SNB and MRD assessment is neces-
sary to enable reliable comparison of diff erent studies. In this way only, we can determine the 
prognostic role of MRD and develop tailored adjuvant treatment, based upon MRD assess-
ment of lymph nodes retrieved after limited surgery.
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GENERAL DISCUSSION
Gastric cancer
In 2002, 933,900 cases of gastric cancer were diagnosed world wide (http://info.cancerre-
searchuk.org/cancerstats/). Gastric cancer ranks second after lung cancer when it comes to 
cancer mortality: there are 700,300 gastric cancer deaths per year. Treatment is based on 
surgical resection of the tumour. In case of localised disease, surgical resection off ers favour-
able survival rates. The problem is however that localised disease is rare in Western countries: 
only in case of advanced stage, signs and symptoms may indicate the likelihood of gastric 
cancer. Furthermore, mass screening programs that are helpful in diagnosing early stage are 
successfully employed in Japan, but are not common in Europe or the United States.
Surgery
Apart from stage disease, the quality and extent of surgery is a prognostic factor as well. In 
Japan (as much as 19% of all malignancies are gastric cancers), surgery does not only involve 
tumour resection. Extended lymph node dissection is performed on a routine basis as well. 
The extent of lymphadenectomy focuses on the main question: are the lymph nodes the 
tumour is draining to merely indicators or also governors of disease? In other words: does 
lymphadenectomy only serve staging purposes (opinion in Western countries) or has it also a 
therapeutical goal (reducing the likelihood of distant spread, 1-4opinion in the Eastern Asia)? 
To answer this question, several randomised trials have been performed. Remarkably, in Ja-
pan no prospective randomised trial was ever performed to substantiate their own practise: 
convinced of the benefi ts of D2 dissection, setting up such trial has always been considered 
unethical by both patients and doctors. The two large European trials with adequate design, 
power and execution, were the British MRC5,6 and the Dutch Gastric Cancer D1D2 trial4,7,8. Both 
trials failed to show any benefi t from extended surgery. In the editorial accompanying Henk 
Hartgrink’s fi nal report on the Dutch D1D2 trial, Petrelli9 concluded that the debate on the 
benefi ts of D2 dissection is over: there is no survival benefi t of extended surgery after a median 
follow-up 11 years, and therefore no reason perform this kind of surgery on Western gastric 
cancer patients (“it’s time to move on”). However, Petrelli’s conclusion might be premature: 
postoperative morbidity and mortality of D2 dissection was considerable in both European 
trials and might have obscured a survival benefi t of extended surgery. Indeed, subgroup 
analyses from the D1D2 trial show improved survival in patients who were assigned to D2 
dissection and did not undergo organ resection. (During trial accrual, resection of spleen and 
pancreatic tail was not only preformed in case of organ involvement. It was also performed 
assuming that organ resection was necessary in order to achieve adequate nodal clearance 
(stations 10 and 11) in case of proximal gastric cancer). More recent reports show that organ 
preservation techniques can safely performed in Western patients, with low morbidity and 
mortality without compromising the extent of lymph node dissection.10-14 Moreover, recently 
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the fi rst prospective randomised trial was published showing a survival benefi t of extended 
lymph node dissection: patients undergoing D3 gastrectomy had better 5 year overall sur-
vival rates than patients who were treated with D1 dissection. (59.5% vs. 53.6%, P = 0.041).15 
These interesting results were obtained in a single-center study, indicating that high-volume 
surgery in experienced centers might be an explanatory factor. Moreover, there is another 
subset of patients that benefi t from D2 dissection: subgroup analyses from the D1D2 trial 
indicate a trend for better survival in N2 patients after a D2 dissection (lymph nodes are 
probably not only indicators but also governors of disease). It is likely that performing a D1 
dissection without splenectomy and resection of the pancreatic tail, together with dissection 
of at least 15 nodes (a so-called over D1 (D1+) resection) results in better outcome.16
Another way of reducing overall morbidity and mortality is to tailor surgery to the indi-
vidual gastric cancer patient. It is known from the D1D2 trial that patients older than 70 years 
of age, subjected to D2 dissection are more likely to suff er from postoperative complications.4 
Performing this kind of extended surgery in the elderly seems inadvisable.
A fi nal and promising way of tailoring surgery involves resecting only those lymph nodes 
that are most likely to be involved by tumour. Prediction of nodal involvement by preopera-
tive imaging has limited value. The concept of the Maruyama Index of Unresected Disease17,18 
(MI, see Chapter 3) may off er new opportunities: by collecting individualised patient and 
tumour characteristics prior surgery, the chance of nodal involvement of the D1 and D2 sta-
tions can be predicted by comparing these individual data to a large database of close to 
4,000 Japanese gastric cancer patients. In this manner, unnecessary lymphadenectomy of 
uninvolved lymph nodes is prevented, thus reducing the likelihood of postoperative compli-
cations. The value of the MI has been established retrospectively in both the US Intergroup 
trial 011619 and the Dutch Gastric Cancer trial18: performing individualised “low-Maruyama-
index-surgery” is probably better than dissecting the complete N2 echelon in every gastric 
cancer patient; postoperative complications are reduced and long term survival improves. Of 
course, it is premature to introduce the Maruyama concept before testing it in a prospective 
fashion. The newly designed CRITICS study (see later) off ers the opportunity.
(Neo-)adjuvant treatment
Because the results of surgery alone are poor in case of locally advanced disease (i.e. exten-
sion through the gastric wall and involvement of peri-gastric nodes), attempts have been 
made to improve treatment outcome applying adjunctive treatment regimens. In contrast 
to colon cancer, adjuvant chemotherapy has not shown to be eff ective.20-23 The addition 
of radiotherapy however (external-beam radiation delivered to the site of surgery and its 
draining lymph nodes) to fl uorouracil and leucovorin after surgery is benefi cial: the US SWOG 
trial showed that patients after multi-modality treatment had better median survival than 
patients treated with surgery alone (36 vs. 27 months, P = 0.005).24 Also disease-free survival 
was superior (30 vs. 19 months, P<0.001). This trial was criticised on some points however, 
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the most important one being the fact that the majority of the patients (54%) had not even 
undergone a resection of the peri-gastric nodes (D1 level). The important confounding role 
of surgery was stressed earlier, and keeping this in mind, the question whether postopera-
tive chemoradiation is of any value after optimal surgery remains largely unanswered. There 
are however some reports from non-randomised studies that adjuvant chemoradiotherapy 
in D2-resected gastric-cancer patients is tolerable25 and can prolong survival and decrease 
recurrence.26
Another way of adjuvant treatment concerns peri-operative treatment. Theoretical ad-
vantages of preoperative treatment include increasing the chances for curative resection 
and relief from tumour–related symptoms, both through the mechanism of downstaging. 
Moreover, tumour response to chemotherapy can be determined. The British MRC trial tested 
in a prospective randomised trial whether peri-operative epirubicin, cisplatin and infused 
fl uorouracil (ECF) could improve overall survival in patients with resectable adenocarcinoma 
of the stomach, esophagogastric junction, or lower esophagus.27 Rates of postoperative com-
plications did not diff er between the perioperative-chemotherapy group and the surgery 
alone group (46 percent and 45 percent, respectively), neither did the numbers of deaths 
within 30 days after surgery. With a median follow-up of four years, the perioperative-che-
motherapy group had a higher likelihood of overall survival (hazard ratio for death, 0.75; 
P=0.009; fi ve-year survival rate, 36 percent vs. 23 percent). Interestingly, the resected tumors 
were signifi cantly smaller (median size 3 cm vs. 5 cm, P<0.001) and less advanced in the 
perioperative-chemotherapy group (proportion T1/T2 tumours 52% vs. 37%, P = 0.002, pro-
portion N0/N1 disease 84% vs. 71%, P = 0.01). These fi ndings favour preoperative treatment 
considering the diffi  culty to achieve curative resection in case of locally advanced disease 
(a patient category often encountered in Western countries). A disadvantage of infusional 
fl uorouracil however, is the implantation of central venous catheter devices and the use of 
portable infusion pumps that bare the risk of complications such as thrombosis and wound 
infection. An alternative might be capecitabine, a prodrug and oral analogue of 5-FU that is 
believed to mimic continuous infusion of 5-FU. Capecitabine has demonstrated to be equally 
eff ective in tumor control and to be less toxic than intravenous 5-FU in patients with stage III 
and IV colon cancer.28-30
Data from the well designed MAGIC and SWOG/Intergroup studies raise the important 
question whether postoperative chemoradiotherapy improves survival and/or locoregional 
control in patients that receive neoadjuvant chemotherapy followed by a D1+ gastric resec-
tion. The recently developed CRITICS trial (ChemoRadiotherapy after Induction chemoTherapy 
In Cancer of the Stomach, leading group Dutch Colorectal Cancer Group) randomises gastric 
cancer patients between 2 arms: 1. 3 courses of ECC chemotherapy prior to D1+ surgery fol-
lowed by 3 additional ECC courses or 2. 3 courses of ECC chemotherapy prior to D1+ surgery 
followed chemoradiotherapy (45 Gy in 25 fractions plus capecitabin and cisplatin). Primary 
endpoint is overall survival. The trial is to be launched in 2007.
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A fi nal comment needs to be made on the role of sentinel node biopsy (SNB) and the 
clinical relevance of minimal residual disease (MRD) in gastric cancer patients. SNB, a concept 
pioneered by Morton et al.31 in melanoma patients, has gained wide acceptance in the treat-
ment of breast cancer patients: analysis of the sentinel node is used to predict the presence 
of metastasis in the corresponding nodal basin. In this manner, morbidity of unnecessary 
lymph node dissection is reduced without compromising locoregional control. To avoid 
inaccurate mapping, SNB should only be performed in early gastric cancer lesions: distor-
tion of lymphatic pathways in locally advanced disease hinders reliable mapping. Japanese 
data show encouraging data, although the rate of accurate detection might be low for large 
tumours.32,33 The fact that results in Western patients are less favourable is probably due to 
the more advanced stages of disease diagnosed in the West.
As mentioned before, disease recurrence is a major problem in gastric cancer patients. 
The current method for staging in gastric cancer is insuffi  cient: not only are often too few 
lymph nodes removed leading to systematic understaging, also routine investigation of 
the removed nodes applying hematoxylin and eosin staining may not be accurate enough. 
To illustrate this inaccuracy, even after a complete tumor resection many patients who are 
considered to be node-negative suff er from disease recurrence. Searching for occult tumour 
cells (OTC) in these lymph nodes may identify this high-risk subset of patients. OTC comprise 
micrometastases with its size being more than 0.2 mm but less than 2.0 mm, and isolated tu-
mor cells (size less than 0.2 mm). A recent case-control study by Doekhie et al.34 showed that, 
although identifi cation of OTC is technically possible, it can not predict disease recurrence. 
This is line with Japanese data that showed that the presence of immunohistochemically de-
tected micrometastases in the regional lymph nodes did not aff ect the survival of pT2N0M0 
gastric cancer patients who had undergone gastrectomy with D2 lymph node dissection.35 
The number of lymph nodes removed may serve as a more reliable predictor, stressing again 
that lymph node dissection has therapeutical value.36
RECTAL CANCER
In 2002, 1,023,200 patients were diagnosed with colorectal cancer worldwide (http://info.
cancerresearchuk.org/cancerstats/). In Europe 11% of all cancer cases were bowel malignan-
cies. It is the fourth most common cause of death from cancer worldwide accounting for 8% 
of all deaths from cancer. There have been steady increases worldwide in the numbers of 
people being diagnosed with bowel cancer over the last 25 years. Approximately one third of 
the colorectal cancers are rectal cancers.
As for gastric cancer, local recurrence is important issue for concern. Again, well-performed 
surgery is an important prognostic variable. It is increasingly acknowledged that local failure 
is more a matter of surgical technique rather than of aggressive biological tumour behavior. 
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Incomplete tumour resection with involvement of the circumferential resection margin 
by tumour and/or lymph nodes is the most important risk factor for local recurrence. The 
importance of complete resection is stressed by the fact that postoperative radiotherapy is 
not eff ective in case of irradical resection and therefore does not compensate for low-quality 
surgery.37 This emphasizes the need for precise staging during the initial work-up for each 
rectal cancer patient. By accurate MR imaging, tumours can be classifi ed according to the risk 
or local recurrence. Involvement of the mesorectal fascia calls for prolonged irradiation prior 
to surgery, leading to downstaging and –sizing, facilitating curative (R0) resection.
The benefi ts of short term preoperative radiotherapy (5x5 Gy)
The Swedish rectal Cancer Trial showed that 5x5 Gy followed by conventional surgery of 
operable surgery increased both local control and overall survival38, also in the long run at 
a median follow-up of 13 years.39 The effi  cacy of this regimen in TME treated patients was 
unknown until the early data of the TME trial were released: at a median follow-up of 2 years, 
local recurrence rate was lower in irradiated patient (2.4% vs. 8.2%, P<0.001).40 There was 
however no eff ect on overall survival, hypothetically due to the rather short period of fol-
low-up. With a median follow up of 6 years, irradiated patients still have signifi cant lower 
recurrence risk compared to non-irradiated patient. (5.6% vs. 10.9%, P<0.001), chapter 8). The 
benefi ts of preventing local failure need to be stressed: intractable pain, incontinence due to 
sphincter ingrowth and rectal blood loss are prevented in many rectal cancer patients. In this 
respect 5x5 Gy is a valuable regimen. Moreover, the short term adverse eff ects of this radio-
therapy are only minor, although perineal wound dehiscence after irradiating the perineum 
is a matter of concern.41 On the long run however, fecal incontinence occurs more often in 
irradiated patients: 62% vs. 38%, P < 0.001 (chapter 7).42 Moreover, satisfaction with bowel 
function is signifi cantly lower and the impact of bowel dysfunction on daily activities was 
greater in irradiated patients compared to patients who underwent TME alone. This should 
prompt the medical community to tailor radiotherapy to those patients that are most likely 
to benefi t from it. Not every rectal cancer patients has equal benefi t from radiotherapy: the 
effi  cacy depends partly on the height of the rectal tumour. Therefore, it is tempting to per-
form subgroup analyses from the TME trial on tumour height in order to narrow the indica-
tions for 5x5 Gy. Caution is warranted: statistical power is often insuffi  cient to detect clinical 
relevant diff erences. Furthermore, daily practice tells us that it is diffi  cult to determine exact 
tumour position prior to surgery: discrepancies between endoscopy fi ndings, CT/MRI imag-
ing and intra-operative fi ndings are not uncommon. Nevertheless, one may wonder about 
the implications of these analyses for rectal cancer treatment. Subgroup analyses do provide 
a degree of evidence, especially when the analyses are derived from the largest study so far 
on TME treated patients. Local failure after treatment of proximal tumours is relatively rare, 
making the number of patients needed to irradiate in order to prevent one local recurrence 
substantial. Moreover, the diff erence in local recurrence rate between the two randomisation 
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arms is non-signifi cant (3.7% vs. 6.2%, P=0.122). For low-lying rectal cancers there is neither 
any signifi cant eff ect of radiotherapy (10.7% vs. 12.0%, P = 0.578). An import confounding 
factor in distal rectal cancers is the rate of CRM involvement. As it appears from the TME 
trial, APR patients have undergone more often irradical resection than patients treated with 
anterior resection (26.5% v 12.6%, P < .001). Also, survival is substantial lower (38.5% v 57.6%, 
P = .008).43 This is in line with a retrospective series from Leeds involving 190 APR and 371 AR 
patients, local recurrence was higher in case of APR (22.3% versus 13.5%, P = 0.002), overall 
survival lower (52.3% vs. 65.8%, P = 0.003).44 Even after introduction of TME the incidence of 
CRM involvement in the APR group (41%) was much higher than in the AR group (12%) (P 
= 0.006). Finally, the Norwegian Rectal Cancer Group stipulated the same problem: in their 
prospective observational cohort study involving 2,136 patients with rectal cancer within 12 
cm of the anal verge, 10 percent local recurrence after anterior resection and 15 percent after 
abdominoperineal resection was seen (P=0.008).45
Future challenges in rectal cancer treatment
Establishing resection without involved margins
Preoperative imaging with the aim to distinct operable from locally advanced disease is 
crucial. MRI scanning is the only reliable tool to assess mesorectal fascia involvement and 
should be done in each rectal cancer patient.46 Of course, scanning a patient is not enough, 
gaining the radiological expertise to interpret the images is important as well. In case of 
suspected mesorectal fascia involvement, 5x5 Gy is not a good option. Hypofractioned 
preoperative radiotherapy followed by immediate surgery does not lead to downsizing47 and 
does therefore not facilitate complete resection. Prolonged irradiation (25x2Gy) followed by 
surgery carried out 4-8 weeks following the completion of radiotherapy, reduces tumour size 
and therefore increases the chances for radical resection. According to several phase II stud-
ies48-50 the addition of continuous infusion fl uorouracil (FU) chemotherapy to external-beam 
radiation therapy potentates this downsizing and –staging eff ect. The addition of oxaliplatin 
to intravenous continuous infusion FU and radiotherapy for patients with locally advanced 
rectal cancer may be associated with even a higher pathologic complete response rate51 
up to 25%, but is associated with more acute toxicity than when FU is used alone.52 Apart 
from acute side eff ects, late morbidity should be a matter of concern as well. In chapter 7 
we showed the detrimental long-term eff ect of 5x5 Gy on bowel function.53 The impact of 
prolonged chemoradiation is probably substantial as well, but still needs to be clarifi ed.
APR patients constitute a separate category of patients; in the TME trial CRM involvement 
was unacceptable high (26.5%) and tumour perforation occurred frequently (13.7%)54 The 
diffi  culty to obtain margins in distal lesions is understandable: when the mesorectal plane 
is followed completely down onto the sphincter apparatus, the risk of involved margins 
increases as the mesorectum is a only a thin structure when it closes into the sphincters. 
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This “coning in” into the tumour is prevented when the perineal phase is commenced earlier 
during rectal cancer surgery: by performing a cylindrical resection with removing the levator 
muscles en bloc, the risk of inadvertent perforation due to excessive manipulation during 
the abdominal phase is reduced. This radical resection may lead to less margin involvement 
but leaves a substantial defect that calls for closure using for example myocutaneous fl aps in 
order to facilitate wound healing.55-58
Minimising the morbidity from rectal cancer treatment
TME off ers the opportunity to work under close vision of nerves that are important for bladder 
and sexual function. Yet, there is still room for further improvement considering the degree of 
dysfunction that many patients report, even if they did not undergo radiotherapy. Although 
rectal cancer surgery may inevitably cause a certain level of dysfunction, all eff orts should be 
directed towards optimal identifi cation and preservation of important nerve structures. This 
might imply further training of surgeons in order to obtain maximum exposure of the opera-
tive fi eld. We have to keep in mind however that bowel, bladder and sexual dysfunction is 
partly physiological in the elderly and therefore cannot be ascribed solely to the detrimental 
eff ects of rectal cancer treatment. 
In contrast to (neo-)adjuvant treatment surgery is the mainstay of cure of rectal cancer, 
making a certain level of side eff ects acceptable. Short term preoperative radiotherapy 
however is responsible for “only” a relatively small, but statistically signifi cant reduction in 
local recurrence risk compared to surgery.(chapter 8) Considering the severe symptoms that 
accompany local failure the administration of preoperative radiotherapy seems justifi ed. 
Moreover, it has to be stressed that local recurrence was chosen as primary endpoint of he 
TME trial, and not overall survival. The fact however, that there is hardly any eff ect of radio-
therapy on overall survival at a median follow-up of 6 years (63.5% vs. 64.2%, P=0.260), raises 
the question whether every rectal cancer patient should be off ered this toxic radiotherapy 
regimen. As we know from subgroup analyses from the TME trial, local recurrences are rela-
tively rare when rectal cancer is located more than 10 centimeters from the anal verge. One 
could argue not to irradiate these patients, especially when it concerns (elderly) patients 
with already moderate bowel function prior to surgery: fecal incontinence is considerable in 
irradiated patients, even when it concerns proximal cancer. The impact of bowel dysfunction 
on daily activities and quality of life should be counterbalanced at the reduction in local 
recurrence risk. One has to be bare in mind however that accurate determination of tumour 
height is crucial. This implies that there is a need for standardizing endoscopy. When in doubt 
a soluble water-enema might give valuable information.
Another category patients that are possibly overtreated by 5x5 Gy are patients with early 
(stage I, pT1/2N0) rectal cancers. Again from subgroup analyses of the TME trial, we know 
that local recurrence is extremely rare and the impact of radiotherapy is non-signifi cant 
(0.4% vs. 1.7%, P=0.091). An absolute diff erence of only 1.3% seems not enough to irradiate 
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every stage I rectal cancer patient. The problem is however that accurate diagnosis of early 
lesions prior to treatment is diffi  cult.59 Therefore, it is diffi  cult during pre-treatment work-
up to estimate the risk of local failure and the possible benefi ts of radiotherapy. Not only 
radiotherapy, but also major surgery might imply overtreatment for early lesions. It is known 
that lymph node metastases are seldomly engaged in this subset of rectal cancers indicat-
ing that lymphadenectomy serves hardly therapeutical or staging purposes. By performing 
local excision of early lesions the morbidity of laparotomy is avoided. This would imply a 
major step in reducing late morbidity as a large proportion of long-term dysfunction can be 
ascribed to TME surgery, and not to radiotherapy. Local excision of even pT1 tumours may 
however be associated with unacceptable high local recurrence rates up to 26%.60 Ending up 
with a local failure after treatment of an early lesion is hard to sell. To minimise the risk of such 
catastrophes, accurate staging is of utmost importance in order to avoid local procedures for 
advanced lesions.61-63
Improving survival
As mentioned earlier, pre-operative radiotherapy decreases local recurrence risk but has no 
survival benefi t in TME treated patients. Local recurrence is thought to aff ect survival, but 
apparently, an absolute diff erence of “only 5.3%” is too small to impact on survival. Moreover, 
distant failure is accountable for mortality and is substantial regardless radiotherapy (25.8% 
vs. 28.3%, P=0.387). So far it is unknown whether adjuvant chemotherapy which is standard in 
colon cancer patients with nodal involvement, may improve survival in rectal cancer patients 
that have been treated with 5x5 Gy and TME. In the past adjuvant treatment has proven to be 
ineff ective for rectal cancer patients.64 This was however in the era of conventional surgery 
when local recurrence risk was major. Now that local failure is no longer a confounding 
factor due to the benefi cial eff ects of both TME and radiotherapy, the matter needs to be 
addressed again. The SCRIPT (Simply Capecitabine in Rectal Cancer after Irradiation Plus Tme) 
Trial randomises stage II/III rectal cancer patients that have had 5x5 Gy plus TME between 
oral capecitabine and observation. Unfortunately, trial accrual is slow leaving this important 
question unanswered. In the mean time more eff ective chemotherapeutics have been intro-
duced in the fi eld of colon cancer65,66, opening possibilities for new clinical trials. An important 
diff erence with previous trials in the past decades is that pre-operative work up has become 
more accurate. Digital examination has been replaced by endoultrasound and MRI in many 
centers, leading to distinction between lesions that may be removed by either local excision, 
laparotomy or only after short term or prolonged neoadjuvant treatment. This development 
calls for inventive trial designs with adequate power to answer multiple questions.
Minimising the risk of symptomatic anastomotic leakage
Multimodality treatment of rectal cancer aims for adequate local control and prolonged sur-
vival. Apart from side late side eff ects on bowel, sexual and bladder function, acute morbidity 
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is important as well. In chapter 2 the acute side eff ects of radiotherapy using a 2 portal tech-
nique are extensively described. In the mean time, technique has changed substantially and 
Marijnen et al.67 concluded, after describing the acute side eff ects of 5x5 Gy in the TME trial 
that “preoperative hypofractionated radiotherapy is a safe procedure in patients treated with 
TME surgery, despite a slight increase in complications when compared with TME surgery 
only.” Indeed, apart from perineal wound dehiscence in APR patients, there are no signifi cant 
clinical acute side eff ects that can be ascribed to radiotherapy. Apart from postoperative 
death, the most important complication after rectal surgery is anastomotic failure. There 
was no signifi cant diff erence between irradiated and non-irradiated patients (10.9% versus 
12.3%, P = 0.517).68 Nevertheless, the rate of leakage is substantial, calling for further action. 
According to the multivariate analysis of the TME trial, both the construction of a temporary 
stoma and the placement of a drain in the presacral space are the only two factors correlated 
with a lower risk for leakage. It is noteworthy that there is no unanimous policy considering 
these two issues among surgeons in the Netherlands. Therefore, a national working party has 
been installed in order to reduce the morbidity and mortality associated with symptomatic 
leakage throughout the Netherlands. Guidelines will be evidence-based. Important ques-
tions that need to be asked for the individual rectal cancer patient are: what is the estimated 
risk for leakage prior to surgery (location of the tumour, gender, nutritional state etc.)? Is 
it possible to decide prior to surgery and not during surgery whether a stoma needs to be 
constructed (bowel function prior to multimodality treatment, likelihood of stoma reversal in 
a second procedure etc.)?
Laparoscopic resection of rectal cancer
Without elaborating on this hot topic, few words must be side on laparoscopy as surgical treat-
ment of colorectal disease. For both benign and malignant diseases of the colon, laparoscopy 
is increasingly performed. The reported advantages are earlier recovery of bowel function and 
shorter hospital stay, improved quality of life without compromising oncological outcome.69,70 
Even despite perioperative optimization of open surgery using enhanced recovery programs, 
length of hospital stay is lower following laparoscopic surgery.71 Moreover, the costs of the 
laparoscopic approach are only marginally higher than of open surgery.72 Schwenk et al.73 
recently stated in a Cochrane systematic review including 25 randomised controlled trials 
that laparoscopic colonic resection “shows clinically relevant advantages in selected patients”. 
Indeed, it is likely to assume that laparoscopy, especially in the early phase of the individual 
surgeon’s learning curve, is only proposed to patients who are not likely to suff er from major 
postoperative complications. Moreover, many reports are from single-center institutions 
that have been able to gain a wide experience in laparoscopic colon resections. Finally, not 
only length of hospital stay should be of interest. The local infrastructure for postoperative 
care after hospital discharge should be accounted for as well: is the patient staying at home 
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without any (para)medical help or is he staying at “recovery hotels” hiring qualifi ed nurses, 
therapists and home aides to meet all the patient’s needs?
Rectal cancer seems a diff erent entity. Considering its location in the lesser pelvis, it’s a 
technically more demanding procedure requiring a long learning curve. Reports on laparos-
copy are almost exclusively from non-randomised studies executed in experienced centers. 
Nevertheless, short term outcome may not always be as favourable (anastomotic leakage 
up to 17%)74, and functional outcome may be unsatisfactory.75 Laparoscopy is said not entail 
any oncological disadvantages.74 However, focussing on the technical aspects of laparoscopy 
should not obscure the need for detailed preoperative work up, leading to unacceptable 
rates of palliative resection up to 25%76, increased rates of positive resection margins77 and 
local recurrence rates of 21%78, putting us back in time when blunt dissection of rectal cancer 
was the norm. In conclusion, prior to introduction of laparoscopy for rectal cancer on a large 
scale, randomised controlled trials need to be awaited (COLOR II amongst others), surgeons 
need extensive training, and preoperative work-up should be standardized.
QUALITY ASSURANCE
Everyone involved in the treatment of cancer aims for improved treatment outcome. A 
tool to accomplish this goal is to increase the quality of the services that are delivered to 
cancer patients. For both gastric and rectal cancer, quality is increased by achieving good 
locoregional control. Achieving adequate local control is a matter of team work: radiologists 
play a profound role in preoperative imaging of rectal cancer, radiation and medical oncolo-
gists decrease tumor burden in case of locally advanced disease by administering prolonged 
chemoradiation, increasing the likelihood that the surgeon can perform a curative resec-
tion.
For gastric cancer, there are wide variations in outcome, calling for intervention. One pos-
sible way to improve quality, is to increase case volume, especially as surgery is the corner-
stone of the treatment of gastric cancer. The literature on the relationship between volume 
and outcome is extensive and beyond the scope of this concluding chapter. It was Luft79 
who fi rst explored the relationship in 1979 and concluded that there was a strong inverse 
relationship between hospital volume and mortality. Not many years ago, Birkmeyer80 et al. 
investigated cardiovascular procedures and major cancer surgery and concluded accord-
ingly. The mechanism of this persistent relationship is not completely understood. Possible 
confounding factors are the availability of well equipped staff  and medical services, high 
quality of postoperative (intensive) care, and last but not least training of medical staff . 
Considering the latter, well-trained expert surgeons tend to work more often in high-volume 
hospitals, being prepared to focus on a relatively small area of surgical practise, troubling 
the volume-outcome relationship. Now that surgery for benign gastric diseases has become 
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a rarity and the incidence of gastric cancer is dropping, it is diffi  cult to gain a certain level 
of expertise in gastric cancer treatment All together, for gastric cancer, concentrating cases 
in expert institutions seems the most logic means to improve nationwide outcome. Before 
appointing these expert centers, insight must be gained in the results of each treating center. 
In the United States the National Cancer Data Base (NCDB) collects detailed information on 
demographic and tumour statistics as well as treatment outcome for each cancer case in the 
US. Each year, every participating hospital receives a detailed and confi dential report indicat-
ing how “good or bad” the center performs in comparison to regional and national bench-
marks. This national non-governmental initiative has been a resource of cancer epidemiology 
throughout the years81,82 and serves as a huge source of information for the benefi t of quality 
assurance initiatives. Noteworthy is the low budget of 1-2 million dollars for maintaining this 
nationwide database.
In parallel, in Sweden, the Swedish Cancer Register has been introduced, making it manda-
tory by law(!) for each surgeon and pathologist to report each new cancer case including 
the surgeon and assistant surgeon who are involved in the treatment as well as information 
on surgical treatment (i.e. type of resection, curative intent, general and surgery-related 
postoperative complications etc.) Moreover, follow-up must be reported each year. Each year 
feedback on treatment outcome is given to all units. The Rectal Cancer Registry in Sweden 
has run for 9 years now and has included over 13.000 patients, from each center at least 
hundreds of patients. Now it has become possible to draw conclusions for each center, based 
on median results of specifi c endpoints. When centers do not reach standards, set by the 
surgical community, they may consider stop treating rectal cancer patients or seek additional 
training. Working in this way, treatment outcome improves. Although it is encouraging to 
see that trial results are superior to historical controls83, it is important to realise that the 
majority of cancer patients is treated outside the framework of clinical trials. These patients 
also need to benefi t from ongoing developments as well.84,85 Finally, extensive training by 
experts is a prerequisite of improving treatment outcome: the acknowledgement that local 
recurrence of rectal cancer was a major problem in Sweden urged the medical community to 
acquire the TME technique by building up a training program and hiring Mr Heald, pioneer in 
TME surgery who teached this new surgical technique throughout Sweden. Similar initiatives 
were undertaken successfully in the Netherlands and Norway.86,87 Yet, there is major room for 
further improvement, illustrated by the aforementioned challenges in rectal cancer treat-
ment. In an attempt to meet challenges, a multidisplinary approach is necessary as is being 
employed currently in the Pelican Center Foundation, Basingstoke UK88,89, off ering training 
courses on colorectal malignancies applying MRI scanning in the preoperative work-up. Also, 
from economic point of view, it makes common sense to invest more in multidisciplinary 
training: Phil Quirke90 calculated that the costs of multidisciplinary training in rectal cancer 
treatment amount only £200 per patient. Evidence shows a 20% reduction in cancer deaths 
through extensive training, making the total costs of each life saved £1000. For comparison, 
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by the introduction of novel chemotherapeutics as irinotecan and oxaliplatin the median 
survival of patients with metastastic colorectal cancer has improved over the past decade 
from 12 months (fl uorouracil) up to 21 months.91 Although these advances are commend-
able, the costs of the initial 8 weeks of treatment have increased 340(!)-fold from US$ 63 to 
US$ 21.033.92 
In order to employ our resources in our struggle against cancer eff ectively, national cancer 
plans are crucial. Urged by the long waiting lists and worst treatment records in Europe, the 
United Kingdom launched the NHS Cancer Plan in 2000. Australia, Canada and New Zealand 
also have plans in place. France acknowledged the need for a comparable plan in 2003 and 
set up the National Cancer Institute (known as the INCa) employing 185 staff  members within 
6 months. The INCa initiated a cancer plan with a total of 70 key areas, all being precisely 
funded and evaluated. An expert committee lead by David Kayat, a medical oncologist and 
leading fi gure in France, calculated how much execution of the plan would cost. They asked 
the government for 1.7 billion euros, and they received the grant. It is a major plan including 
various measures: centralisation of basic research into 7 large regional research centers and 
structural coordination of cancer care. There is also room for raising the price of tobacco and 
buying the tobacco industry off , as well as for funding of television campaigns on the dangers 
of sun exposure. In 2004, a national plan against cancer was formulated in the Netherlands 
focusing on prevention, screening and treatment. Although the initiative is laudable, no 
concrete measures are taken considering organisation, funding and implementation. Putting 
pens to paper is not enough, long term vision and adequate funding is the key.
In conclusion, now that cancer mortality will overtake death from cardiovascular disease 
within a couple of years (http://www.kwfkankerbestrijding.nl/), it is time to decide how we 
will strike back as eff ectively as possible. When treating solid malignancies, setting up mul-
tidisciplinary teams involving organ-related specialists seems the key, with an emphasis on 
surgical training in technically demanding procedures as gastric and rectal cancer surgery. 
Within the EORTC, unfortunately there are no longer funds available for surgical quality as-
surance. The importance is however acknowledged: the European Journal of Surgical Oncol-
ogy devoted a complete issue in august 2005 to the benefi ts of surgical QA. Recently, the 
European Society of Surgical Oncology released additional funds for surgical fellows, backing 
up this important area of surgical research. If governments are seriously willing to meet the 
challenge of combating cancer, investing in meaningful cancer plans and multidisciplinary 
training seems the only way.
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SUMMARY
Cancer is a world wide health problem. Each year 10.9 million people are diagnosed with can-
cer. It is estimated that worldwide 24.6 million people are alive who have received a diagnosis 
of cancer in the last fi ve years. In Western countries cancer incidence is increasing rapidly. 
In 2002, there was a cancer incidence in Europe of 873,700 cases, in Northern America of 
1,570,500 patients (http://info.cancerresearchuk.org/cancerstats/). Of all malignancies solid 
tumours constitute the vast majority. Bowel, breast, lung and prostate cancer account for 
nearly half of all new cases.
Improving the quality of care aims at improving locoregional control, and thus survival. 
Numerous initiatives have been successfully employed in order to improve quality of radio-
therapy and medical oncology. Although surgery is generally acknowledged as the mainstay 
of the treatment of solid tumours, surgical research encounters important diffi  culties: 
pharmaceutical companies do not release substantial funds to promote surgical research, 
neither seem governmental institutions willing to support trials investigating diff erences 
in surgical techniques. This possibly relates to the fact that every operation is considered a 
unique event which may hinder standardisation, a vital part of research when testing new 
treatment regimens. There is however a need for standardisation and uniforming surgical 
treatment: by controlling surgery, heterogeneity in patient outcome, caused by variation in 
surgical treatment, is removed as much possible. There are not many clinical trials that have 
made serious eff orts to standardize surgery in order to reduce its confounding infl uence of 
surgery on treatment outcome. The Dutch D1D2 Gastric Cancer Trial4,93 and the TME trial94, 
both prospective randomised trials, have done their utmost to instruct surgeons onsite, 
to teach and control surgical treatment and to record every vital treatment detail.95,96 The 
D1D2 trial investigated the role of extended lymph node dissection (D2) compared to limited 
lymph node dissection (D1) in patients with gastric cancer. The Dutch TME trial tested short 
term preoperative radiotherapy in rectal cancer patients who were treated with TME (Total 
Mesorectal Excision). The current thesis focuses on both trials.
Chapter 1 serves as a general introduction, describing the background and the outline of this 
thesis.
Chapter 2 is a review of the various aspects of gastric and rectal cancer treatment. Although 
the need for standardised and quality-controlled surgery is emphasized, the value of adjunc-
tive treatment regimens is discussed as well.
Chapter 3 is an editorial that was released in the Journal of Clinical Oncology, refl ecting upon 
a Japanese study (published in that same issue) that investigated the value of adjuvant 
chemotherapy in gastric cancer patients. 252 serosa negative gastric cancer patients were 
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randomised in a phase III trial between intravenous mitomycin, fl uorouracil and cytarabine, 
twice weekly for the fi rst 3 weeks after surgery followed by oral FU for the next 18 months 
(arm 1) versus surgery alone (arm 2). The primary end point was relapse-free survival. Accord-
ing to Japanese practise, 98% underwent extended lymphadenectomy (D2 dissection) and 
relapse-free survival was impressive: 88.8% resp. 83.7%. Remarkably, only 2 patients (none 
in the combination-treatment group, 2 in the surgery alone group) developed a local recur-
rence. These favourable results are beyond any expectation when treating Western gastric 
cancer patients. The editorial deals with diff erences in disease stage, surgical technique and 
type of chemotherapy that may explain these gross diff erences between Japan and Western 
countries.
In chapter 4 the value of the “Maruyma Index of Unresected Disease” is studied. It was 
concluded in both the British MRC trial as well as the Dutch Gastric Cancer Trial (both large 
prospective randomised phase III trials) that there was no benefi t from extended lymph node 
(D2) dissection in gastric cancer patients. However, postoperative mortality was substantial 
in the D2 arms of both trials, which possibly obscured a survival benefi t of extended lymph 
node dissection. There are several ways to reduce the risk of postoperative mortality: ac-
cording to subgroup analyses of the Dutch Gastric Cancer Trial, patients older than 70 years 
have substantial risk for postoperative mortality, making them less suitable candidates for 
extended surgery. Also, the risk of postoperative complications is reduces when spleen and 
pancreatic tail are preserved. Meanwhile, organ preservation techniques have been intro-
duced successfully.Moreover, resection of these organs is no longer considered necessary for 
adequate nodal clearance. Finally, prevention of unnecessary resection of tumour negative 
nodes minimises the risk of postoperative complications as well. The question is however, 
how nodal clearance can be limited without compromising both staging and survival. The 
Maruyama program off ers a possible solution. The program requires entry of 7 patients and 
tumour characteristics of an individual patient and then simply matches this case with very 
similar cases previously treated at the National Cancer Center Hospital in Tokyo, Japan. In this 
manner the computer gives a prediction of the likelihood of nodal involvement of each of 
the 16 lymph nodes stations. The Maruyama Index of Unresected Disease (MI) was defi ned 
as the sum of regional nodal disease percentages for stations that were not removed by the 
surgeon. The MI was introduced for the fi rst time by the investigators of the SWOG trial that 
showed that postoperative chemoradiation was benefi cial in gastric cancer patients. The MI 
turned to be a prognostic factor and stressed that there was substantial undertreatment in 
this US trial. Chapter 4 describes the value of the MI in 648 patients of the Dutch Gastric Cancer 
Trail who underwent a curative resection. According to the multivariate regression analysis, 
MI turned out to be a signifi cant independent predictor of overall survival and disease-free 
interval. (HR 1.45, P = 0.016 resp. HR 1.72,, P = 0.010). The MI enables the surgeons to match 
the extent of surgical resection with the extent of regional disease. Obtaining a low MI seems 
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preferable in stead of dissecting the complete N2 echelon, exposing patients to substantial 
risks of postoperative death. The next step is prospective testing of the value of the MI.
Chapter 5 has tested a model that serves as a predictor of survival after gastric cancer treat-
ment. Apart from treatment (surgery and its extent, adjuvant (chemo)radiotherapy etc.), 
there are other factors such as age, sex, the stage of disease at presentation and tumour 
location and morphology that determine a patient’s prognosis. Current staging modalities 
focus solely on tumour depth (T stage) and the presence of nodal involvement (N stage). 
Nomograms are models that integrate other prognostic factors as well. One could argue that 
the need for adequate prognosis clinically irrelevant, as there is no role (yet) for adjuvant 
treatment in the Netherlands. However, both patients and doctors have a growing interest 
for individual-based specifi c information on survival prognosis. The nomogram sees to this 
need. The nomogram that was developed for gastric cancer was tested in only one high-vol-
ume US center (Memorial Sloan Kettering Cancer Center, NY, USA). We attempted to validate 
the nomogram in patients included in the Dutch Gastric Cancer Trial. Also, the discriminating 
value of the nomogram was studies in relation to the AJCC staging system.
There were 459 eligible patients with available information for the nomogram calculation. 
Nomogram discrimination was superior to that of AJCC stage grouping (concordance index 
0.77 vs. 0.75, P < 0.001, Z-test) and proved to be an accurate predictor of 5- and 9 year dis-
ease-specifi c survival. Moreover, patients within diff erent AJCC stages with heterogeneous 
prognosis were successfully discerned, using the nomogram. In comparison, the AJCC stag-
ing system that is presently used is unable to identify subsets of patients with homogeneous 
prognoses. By classifying patients according to diff erences in prognosis, suitable candidates 
for novel adjuvant treatment regimens may be identifi ed. The nomogram is freely available 
in software from www.nomograms.org.
Chapter 6 describes a study that investigated risk factors for symptomatic anastomotic 
leakage after TME for rectal cancer. The benefi ts of TME are beyond any dispute: both local 
control and survival are superior compared to historical controls, and functional outcome 
(bladder and sexual function) has improved substantially through working under close vision 
of important nerve structures. Anastomotic failure remains however a signifi cant problem. 
As anastomotic failure causes substantial morbidity and even mortality, all eff orts should be 
directed towards the reduction of risk of anastomotic dehiscence.
Nine hundred twenty-four patients undergoing low anterior resection with primary anat-
omises were included in this study. Of all possible risk factors known from the literature, the 
presence of a diverting stoma (8.2% vs. 16.0%, RR 1.89 (1.24-2.90), P=0.003) as well as the 
placement of a drain in the pelvic area (9.6% vs. 23.5%, RR 2.53 (1.57-4.09, P<0.001) were cor-
related with a decreased risk of anastomotic failure. Interestingly, there were wide variations 
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in the policy regarding stoma construction and pelvic drainage, emphasizing the need for 
standardisation in order to avoid this major complication after TME.
Chapter 7 reports on the late side eff ects of both TME and short term radiotherapy. In the past, 
preoperative short term radiotherapy followed by conventional blunt dissection of the rectal 
tumour has been held responsible for increased bowel frequency, incontinence, urgency and 
emptying diffi  culties. We examined the late side eff ects in patients included in the TME trial. 
A questionnaire was sent to 708 patients who were alive and had no evidence of recurrent 
disease. 597 patients (87%) returned the questionnaire; the median follow up of responding 
patients was more than 5 years.
There was no diff erence between irradiated and non-irradiated patients regarding urinary 
function, stoma function and hospital treatment. However, irradiated patients reported in-
creased rates of fecal incontinence (62% vs. 38%, P < 0.001), pad wearing due to incontinence 
(56% vs. 33%, P < 0.001), anal blood loss (11% vs. 3%, P = 0.004) and mucus loss (27% vs. 15%, 
P = 0.005). These data urge doctors to inform their rectal cancer patients reliably about the 
side eff ects of both radiotherapy and. Compared to radiotherapy, TME surgery is the main 
contributor to late bowel dysfunction. However, surgery is the only option that can lead to 
cure in contrast to radiotherapy that has merely benefi ts in terms of increased local control. 
The substantial additional long term side eff ect of radiotherapy on bowel dysfunction urges 
to tailor radiotherapy to those patients only who are most likely to benefi t from it. However, 
pretreatment staging modalities presently used are not capable enough to accurately iden-
tify patients at risk for local failure.
Chapter 8 reports on the results of the TME trial after a median follow-up of 6 years. Early 
results after a median follow-up of 2 years showed a decrease in local recurrence risk (2.4 vs. 
8.2%, P<0.001) in irradiated patients without any survival benefi t (82.0% vs. 81.8%, P=0.84). It 
was hypothesized that there was no survival benefi t yet due to a short period of follow-up.
There was a persistent signifi cance in local recurrence risk at 5 years to the benefi t of ir-
radiated patients (5.6% vs. 10.9%, P < 0.001), yet there was still no survival benefi t (64.2% 
vs. 63.5%, P = 0.902). Local failure is presumed to be a cause of death. However, an absolute 
diff erence of “only” 5.3% is perhaps too small to aff ect survival signifi cantly. Moreover, distant 
failure occurs often regardless the administration of radiotherapy (25.8% vs. 28.3%, P = 0·387) 
and is an important cause of death.
In order to minimise the late side eff ects as described in chapter 7, subgroup analyses may 
be valuable. According to these analyses only tumours between 5 and 10 centimeters from 
the anal verge benefi t from radiotherapy (3.7% vs. 13.7%, P<0.001). Local failure is uncom-
mon in proximal lesions and the eff ect of radiotherapy is not signifi cant (3.7% vs. 6.2%, 
P=0.122), making the “numbers needed to treat” in order to prevent one local recurrence 
substantial. For distal lesions there is neither any signifi cant eff ect of radiotherapy (10.7% vs. 
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12.0%, P=0.578). An important confounding factor in distal rectal cancer is the considerable 
rate of circumferential resection margins. When tailoring the indications for radiotherapy by 
performing subgroup analyses on tumor height, it must be stressed that exact determination 
of tumour location, and thus the a priori chance of local failure is diffi  cult.
The eff ect of radiotherapy depends also the stage of disease. According to subgroup 
analyses, only pTNM stage III rectal cancer (nodal involvement) benefi t from radiotherapy. 
Apparently, with the involved nodes having removed, preoperative radiotherapy is able to 
treat (microscopic) nodal disease beyond the plane of surgical resection. Unfortunately, there 
are presently no reliable means that can be used in the preoperative work up that can identify 
patients with nodal involvement.
Short term preoperative radiotherapy achieves a relative risk reduction of 49% in local 
recurrence risk. Although there is no detectable survival benefi t, this radiotherapy regimen 
remains a valuable treatment modality as the severe symptoms associated with local failure 
are prevented in many rectal cancer patients.
Chapter 9 reports on a benchmark study that was performed in order to evaluate multimo-
dality treatment of locally advanced rectal cancer. The Catharina Hospital in Eindhoven, the 
Netherlands, is a national referral centre for rectal cancer patients in whom a radical resec-
tion is not likely to be obtained. All consecutive patients with a rectal tumour infi ltrating 
into or less than 2 mm distance to the mesorectal fascia on MRI were included (n=252). For 
these lesions multimodality treatment is given involving prolonged radiotherapy of 50,4 
Gy (1,8 Gy per fraction) and intra-operative radiotherapy (10-15 Gy) at the area of risk. Also, 
chemotherapy was administered (5FU and leucovorin, later replaced by oral capecitabine 
and oxaliplatin). Results of this multimodality treatment were compared to data from TME 
trial: patients with operable, mobile pT3/4 disease without distant failure at time of operation 
were used as a benchmark.
Three year local recurrence rate was signifi cantly lower in TME trial patients: 5% and 17% 
(P = 0.0001). Interestingly, in as much as 83% of the patients wit locally advanced cancer a 
negative circumferential resection margin could be realised, compared to 75% of the TME 
trial patients (P = 0.037). Overall survival after 3 years was similar (76% for TME trial patients 
and 67% in case of locally advanced lesions, P = 0.071). Both circumferential margin status as 
lymph node status were important outcome parameters in both groups, for overall survival, 
metastases free survival and local recurrence. When chemoradiation is not able to achieve 
suffi  cient tumour down sizing and –staging, resulting in positive resection margins, the 
prognosis of patients of locally advanced lesions is considerably worse than of patients with 
operable disease with positive margins.
Chapter 10 is a review dealing with the role of sentinel node biopsy (SNB) in breast, gas-
tric and colorectal cancer. SNB has been introduced to reduce the extent of axillary lymph 
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node dissection and thus the associated postoperative morbidity without compromising 
adequate staging, locoregional control and survival (breast cancer). Another advantage 
is the possibility to search the sentinel node for the presence of minimal residual disease 
(MRD) that might have prognostic infl uence. The review addresses the variation in technical 
aspects and outcome of SNB and MRD assessment. Considering the substantial variation in 
reported techniques there is a need for quality control leading to standardization of SNB and 
pathological examination to enable reliable comparison of studies. Only then a consensus 
regarding diagnostic and therapeutic strategies may arise.
Chapter 11 is a general discussion on future directions of gastric and rectal cancer treatment. 
Also a summary of the thesis is given.
Chapter 12 provides a summary in Dutch. Also, all centers that participated in the Dutch 
Gastric Cancer Trial and the TME trial are acknowledged.
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De kwaliteit van de gezondheidszorg staat onder voortdurende aandacht van de media. Rang-
lijsten van de “beste ziekenhuizen in Nederland” worden met enige regelmaat gepubliceerd 
en patiënten worden aangemoedigd met zorg hun dokter en/of ziekenhuis uit te kiezen. Ook 
de medewerkers in de gezondheidszorg zelf hebben kwaliteit hoog op de agenda gezet. De 
Inspectie voor de Volksgezondheid heeft in samenwerking met de Nederlandse Vereniging 
van Ziekenhuizen, de Nederlandse Federatie van UMC’s en de Orde van Medisch Specialisten 
een aantal prestatie-indicatoren geformuleerd. Volgens de Inspectie zijn dit ‘meetbare aspec-
ten van de zorg die een aanwijzing geven over de kwaliteit, de veiligheid, de doelmatigheid en 
de toegankelijkheid van de zorg in ziekenhuizen.’ Voorbeelden van prestatie-indicatoren zijn 
decubitusregistratie en –preventie, registratie van postoperatieve wondinfecties, percentage 
patiënten met een heupfractuur dat binnen één kalenderdag geopereerd wordt, percentage 
patiënten dat binnen 5 dagen na het eerste polikliniek bezoek voor een afwijking in de borst 
de uitslag goed- of kwaadaardig krijgt etc. Elk ziekenhuis is verplicht deze indicatoren te 
meten en rapporteren zodat deze voor (potentiële) patiënten, zorgverzekeraars en toezicht-
houders openbaar zijn. Men mag veronderstellen dat deze indicatoren bruikbaar zijn mits zij 
een natuurgetrouwe afspiegeling vormen van de kwaliteit van zorg, en bovendien aanzetten 
tot activiteiten die de kwaliteit van zorg vervolgens doen toenemen. Ten aanzien van het 
eerste is gesuggereerd dat dit op zijn minst twijfelachtig is gezien de beperkte kwaliteit van 
de aangeleverde data, de geringe accuraatheid van de meetmethode, de afwezigheid van 
correctie voor ziekteverscheidenheid en tenslotte de toevalsvariatie die een correcte inter-
pretatie van prestatie-indicatoren bemoeilijkt.
Hoewel er uitvoerig gediscussieerd kan worden over de wijze waarop kwaliteit van de zorg 
het best gemeten kan worden, is het een aanlokkende en wellicht logische gedachte dat er 
enig verband bestaat tussen de kwaliteit en de uitkomst van de zorg. Echter, vooraleer men 
spreekt van kwaliteitsmeting in de zorg, is het wellicht verstandig het begrip kwaliteit eerst te 
defi niëren. De ‘van Dale’ omschrijft kwaliteit als een ‘bepaalde gesteldheid, een hoedanigheid, 
mate waarin iets geschikt is om voor een bepaald doel gebruikt te worden’. Indien men een 
medische behandeling tracht te kwalifi ceren is vergelijking met een standaard onontbeer-
lijk. Binnen de oncologische zorg zijn vele standaarden ontwikkeld die hun beslag hebben 
gekregen in richtlijnen en/of protocollen. Deze standaarden zijn gebaseerd op een multidis-
ciplinaire consensus en gestoeld op wetenschappelijk verkregen bewijs. Een voorbeeld ter 
verduidelijking: specialisten in Europa die vanuit meerdere disciplines betrokken zijn bij de 
behandeling van patiënten met endeldarmkanker, zijn recentelijk overeengekomen dat het 
vervaardigen van een MRI scan, voorafgaand aan de behandeling, van groot belang is om de 
lokale uitgebreidheid van de kwaadaardigheid vast te stellen. Men zou kunnen stellen dat 
het achterwege laten van een MRI scan een slechte kwaliteit van zorg impliceert. Indien er op 
188 Chapter 12
vergelijkbare wijze consensus wordt bereikt over meerdere diagnostische en therapeutische 
trajecten, ontstaat er een referentiekader waarbinnen het medisch handelen getoetst kan 
worden. Het ontwikkelen van een standaard vereist de nodige inspanningen, maar kan 
grotendeels van achter het bureau plaats vinden. Echter, het vervolgens introduceren en 
handhaven van een tevoren vastgesteld kwaliteitsniveau is een veeleisende taak. Hiertoe zal 
een scala maatregelen nodig zijn variërend van goede registratie van behandeltrajecten, trai-
ning van medewerkers in de zorg en, indien noodzakelijk, kwaliteit verhogende interventies. 
‘Quality assurance’ oftewel ‘kwaliteitsborging’ omvat alle maatregelen die nodig zijn om een 
van tevoren vastgesteld kwaliteitsniveau te introduceren en vervolgens te handhaven.
Het behandelen van kankerpatiënten is ‘team work’. Een optimale planning van het di-
agnostische en behandeltraject (inhoudelijk en logistiek) vereist de inbreng van meerdere 
specialisten. In geval van endeldarmkanker heeft de radioloog een belangrijke rol in het 
beoordelen van de MRI scan van het kleine bekken: de lokale uitgebreidheid van de tumor 
kan op deze wijze nauwkeurig beoordeeld worden waardoor van tevoren (tot op zekere 
hoogte) kan worden bepaald of de tumor volledig verwijderd kan worden (met negatieve 
(circumferentiële) resectie marges). Indien dit het geval is, zal de radiotherapeut conform de 
huidige landelijke richtlijn kortdurende radiotherapie (5x5 Gy) toedienen waarna de chirurg 
een TME (Totale Mesorectale Excisie) zal uitvoeren (zie later). Indien er volgens de MRI scan 
sprake is van lokale uitgebreidheid, komt de patiënt in aanmerking voor langdurige radio-
therapie (50.4 Gy, 1.8 Gy per fractie), hetgeen de tumor in volume doet afnemen waardoor 
resectie met negatieve marges beter mogelijk wordt. In toenemende mate wordt aan dit 
radiotherapieschema chemotherapie toegevoegd, hetgeen het eff ect van de radiotherapie 
doet toenemen. Hierdoor ontstaat er ook een verantwoordelijkheid voor de medisch onco-
loog in de diagnostische “work up’. Nadat de preoperatieve behandeling is voltooid, opereert 
de chirurg volgens de TME techniek waarbij onder zicht van belangrijke zenuwstructuren in 
het kleine bekken, de tumor inclusief het vet daaromheen wordt verwijderd. De patholoog 
onderzoekt het verwijderde weefsel en beoordeelt onder andere de doorgroei door de 
darmwand, de aanwezigheid van eventuele lymfkliermetastasen, en de radicaliteit van de 
resectie. Het mag duidelijk zijn dat een dergelijke multidisciplinaire benadering resulteert in 
een behandeling die duidelijk op de individuele patiënt is toegespitst.
De specialisten die in engere zin betrokken zijn bij de behandeling van patiënten met 
solide tumoren zijn de chirurg, de radiotherapeut en de medisch oncoloog. De chirurg le-
vert, om begrijpelijke redenen, de grootste bijdrage aan de genezing van kankerpatiënten: 
het grootste deel van de ‘tumour load’ kan immers niet anders dan op chirurgische wijze 
verwijderd worden. De radiotherapeut en de medisch oncoloog dragen “slechts” bij aan een 
relatief geringe toename van locoregionale controle en overleving. Kwaliteitsverbetering 
door protocollering en standaardisatie vindt reeds lange tijd plaats bij de radiotherapeuten 
en medisch oncologen. Voor de chirurgie ligt dat beduidend anders. Het toedienen van een 
bestraling dan wel chemotherapie is redelijk uniform en in zekere zin goed reproduceer-
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baar. Een operatie echter is een vorm van behandeling die onvoorspelbare elementen in 
zich draagt: elke patiënt is uniek met de nodige anatomische varianten. Bovendien kunnen 
onverwachte gebeurtenissen het beloop en resultaat van een operatie beïnvloeden. Dit 
zou het idee kunnen oproepen dat chirurgie niet te standaardiseren is en derhalve niet aan 
zekere kwaliteitstoetsing onderworpen zou kunnen worden. Het tegendeel is echter waar: 
in verschillende Europese landen (waaronder Nederland) is de TME techniek op grote schaal 
geïntroduceerd door middel van het trainen van chirurgen. TME resulteert in vergelijking 
met conventionele chirurgie (stomp verwijderen van de rectumtumor uit het kleine bekken) 
in lagere lokaal recidief percentages en verbeterde overleving, en is bovendien geassocieerd 
met betere postoperatieve blaas- en seksuele functie ten gevolge van het identifi ceren en 
sparen van belangrijke zenuwstructuren. Lange tijd is gedacht dat veel van de lokaal reci-
dieven die ontstonden na de behandeling van endeldarmkanker, toe te schrijven waren aan 
het (agressieve) biologische gedrag van deze tumoren. Nu is het inmiddels duidelijk dat de 
kwaliteit van de (chirurgische) behandeling van grotere betekenis is. De resultaten van TME 
vormen het referentiekader waarbinnen de chirurgische behandeling dient te worden ge-
toetst. Standaardisatie van chirurgie is niet alleen nodig om de kwaliteit van de behandeling 
te vergroten, te objectiveren en te toetsen. Het dient ook ter vermindering van de verschillen 
in de uitkomst van de behandeling. Dit is temeer nodig indien klinische studies worden 
geïnitieerd die de waarde van nieuwe chemotherapeutica moeten vaststellen. Nieuwe che-
motherapeutica worden vaak opgenomen indien zij een relatief geringe verbetering laten 
zien ten opzichte van de tot dan toe geldende behandeling. (MOSAIC trial: toevoeging van 
oxaliplatin aan 5FU als adjuvante behandeling voor stadium II en III coloncarcinoom levert 
een toename op van 1.1% overall survival na 3 jaar: van 86.6% naar 87.7%, niettemin wordt 
dit regime in toenemende mate als standaardbehandeling toegediend). Het verstorende ef-
fect van de variatie in de chirurgische behandeling belemmert het accuraat vast stellen van 
het ‘netto’ eff ect van nieuwe, vaak veelbelovende maar ook dure geneesmiddelen.
Het huidige proefschrift kwam tot stand met fi nanciële ondersteuning door de European 
Organisation of Research and Treatment (EORCT) te Brussel dat een fellowship ter beschik-
king stelde ten behoeve van “Quality assurance in surgical oncology”. De Dutch Gastric Cancer 
Trial and de TME studie vormen de basis van dit proefschrift. De eerstgenoemde studie heeft 
de waarde van uitgebreide lymfklierdissectie onderzocht bij patiënten met maagkanker. 
Kwaliteit van de chirurgie werd gewaarborgd door intensieve training van chirurgen, ‘on-site’ 
instructie door ervaren chirurgen en gedetailleerde controle van chirurgische en pathologi-
sche gegevens door speciaal daartoe aangestelde trial coördinatoren. Uitgebreide dissecties 
worden veelvuldig toegepast in Japan, alwaar maagkanker de meest voorkomende vorm van 
kanker is. Kortweg geformuleerd, laten de resultaten van deze studie zien dat uitgebreide 
chirurgie (D2 dissectie) geassocieerd is met meer complicaties en postoperatieve sterfte dan 
beperkte chirurgie. Er is bovendien geen overlevingsvoordeel van D2 chirurgie. Wellicht dat 
er enig voordeel van D2 dissectie is indien postoperatieve sterfte gereduceerd kan worden. 
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De TME studie heeft de waarde van kortdurende preoperatieve radiotherapie (5x5 Gy) on-
derzocht bij patiënten met een mobiel rectumcarcinoom die geopereerd werden volgen de 
TME principes. Analoog aan de D1D2 studie werden de chirurgen uitgebreid getraind in deze 
nieuwe techniek. Bovendien werden ook de andere disciplines (radiotherapie en pathologie) 
onderwerpen aan een strikt kwaliteitsborgingprogramma.
Hoofdstuk 2 bevat een overzichtartikel over de diverse aspecten van de behandeling van 
maag- en endeldarmkanker. De noodzaak en voordelen van kwaliteitsborging van chirurgie 
worden benadrukt. Er is echter ook aandacht voor de veelbelovende ontwikkelingen op het 
gebied van radio- en chemotherapie.
Hoofdstuk 3 is een ‘editorial’, handelend over een Japanse prospectief gerandomiseerde stu-
die die de waarde heeft onderzocht van adjuvante chemotherapie in maagkanker patiënten 
die uitgebreide chirurgie (D2 dissectie) hadden ondergaan. In totaal werden 252 patiënten 
gerandomiseerd tussen ‘chirurgie-alleen’ of chirurgie gevolgd door chemotherapie. Opval-
lend was dat van alle geïncludeerde patiënten er slechts 2 een locoregionaal recidief kregen, 
een uitstekend resultaat dat ongetwijfeld grotendeels valt toe te schrijven aan de uitgebreid-
heid van de lymfklierdissectie. Het editoreal bespreekt de ontwikkelingen op het gebied van 
maagkanker, bediscussieert waarom er een grote discrepantie bestaat tussen de Japanse en 
Westerse behandelresultaten, en beschouwt de rol van (neo-)adjuvante therapie in relatie tot 
de kwaliteit en uitgebreidheid van chirurgie.
Het verkrijgen van locoregionale controle bij de behandeling van patiënten met een 
maagcarcinoom is van groot belang. In Japan wordt dit gerealiseerd door het toepassen 
van uitgebreide lymfklierdissectie. Ondanks het feit dat de lange termijn resultaten van 
de D1D2 studie geen overlevingsvoordeel van uitgebreide dissectie aantonen, is er niet-
temin een voordeel van de D2 dissectie denkbaar indien de postoperatieve sterfte verder 
gereduceerd zou kunnen worden. Behoud van de pancreasstaart en milt lijken hieraan bij 
te kunnen dragen. Een alternatief behelst het voorkómen van onnodige dissectie van niet 
aangedane lymfklieren. Dit impliceert het preoperatief kunnen identifi ceren van de status 
van de regionale lymfklieren. Het zogenaamde “Maruyama Program” biedt hiertoe een 
mogelijkheid: het bestaat uit een Japanse database van 3843 maagcarcinoom patiënten en 
koppelt 7 patiëntkarakteristieken die allen pre-/peroperatief te bepalen zijn aan de waar-
schijnlijkheid dat de afzonderlijke lymfklierstations zijn aangedaan. Van alle patiënten in de 
D1D2 trial is bekend welke lymfklierstations werden gereserceerd. Als afgeleide hiervan werd 
voor elke patiënt de zogenaamde Maruyama Index of Unresected Disease (MI) berekend: een 
kwantitatieve maat voor de achtergebleven tumor load. De prognostische betekenis van de 
MI werd reeds eerder aangetoond in een grote Amerikaanse prospectief gerandomiseerde 
studie naar de waarde van adjuvante radio-chemotherapie. In hoofdstuk 4 werd nagegaan of 
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ten eerste, deze MI van prognostische betekenis was in de D1D2 trial en ten tweede of het 
Maruyama Program dus gebruikt zou kunnen worden voor een op het individu toegespitste 
chirurgische behandeling.
Op grond van de beschikbare gegevens kon de MI berekend worden voor 648 van de 711 
patiënten die curatief behandeld werden. De minimale follow-up bedroeg 11 jaar. De MI in 
D1D2 trial was aanzienlijk lager dan in de eerder genoemde Amerikaanse trial, wijzend op 
minder resttumor in de Nederlandse dan in de Amerikaanse trial. Bovendien bleek de MI, in 
tegenstelling tot de uitgebreidheid van de lymfklierdissectie (D1 vs. D2), van prognostische 
betekenis voor zowel de algehele overleving als de ziektevrije overleving.
Concluderend bleek de MI een maat voor de achterbleven tumor load. Bovendien had deze 
index prognostische betekenis. Aangezien de MI pre-/peroperatief bepaald kan worden, kan 
deze als leidraad gebruikt worden om niet aangedane lymfklieren in situ te laten. Zodoende 
kan postoperatieve morbiditeit en mortaliteit beperkt worden zonder de locoregionale con-
trole en overleving te compromitteren. Met nadruk moet gesteld worden dat de waarde van 
de MI slechts retrospectief is vastgesteld, prospectief valideren is de volgende stap.
De uitgebreidheid en kwaliteit van de behandeling van patiënten met maagkanker bepaalt 
in grote mate de prognose van deze patiënten. Ook andere factoren zoals leeftijd, uitgebreid-
heid van ziekte, tumorlocatie en –diff erentiatie spelen echter een grote rol. De huidige wijze 
van stageren (TNM classifi catie) concentreert zich ‘slechts’ op doorgroei van de tumor door 
de maagwand (T-stadium) en de eventuele aanwezigheid van lymfkliermetastasen. Zowel 
patiënten als artsen hebben in toenemende mate behoefte aan zo nauwkeurige prognose-
bepalingen. Het zogenaamde nomogram biedt soelaas: een nomogram is een voorspellend 
model waarin alle factoren worden meegewogen waarvan bekend is (op grond van multiva-
riate analyses) dat zij prognostische betekenis hebben. Het nomogram voor maagcarcinoom 
patiënten werd ontwikkeld in het Memorial Sloan Kettering Cancer Center, New York, VS. 
Hoofdstuk 5 beschrijft een validatiestudie waarbij het nomogram dat zijn waarde slechts had 
getoond in 1 Amerikaans ziekenhuis, werd getest in patiënten uit de D1D2 studie (patiënten 
afkomstig uit 80 ziekenhuizen). Tevens werd het discriminerend vermogen van het nomo-
gram vergeleken met die van de tegenwoordig gehanteerde AJCC stadiering.
Er waren 459 patiënten van wie allen gegevens beschikbaar waren die nodig waren voor 
het calculeren van het nomogram. Het nomogram bleek een beter discriminerend vermogen 
te hebben dan de AJCC stadiëring (concordantie index 0.77 vs. 0.75, P < 0.001, Z-test). Het 
bleek bovendien een nauwkeurige voorspeller van de ziekte-specifi eke overleving. Bovendien 
was het nomogram in staat om patiënten die door de AJCC stadiëring een zelfde prognose 
toegedicht kregen maar die feitelijk niet hadden, afzonderlijk te identifi ceren. Kortom, het 
nomogram is een goede voorspeller met adequaat discriminerend vermogen en kan wellicht 
in de toekomst gebruikt worden om high risk patiënten te identifi ceren die in aanmerking 
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zouden kunnen komen voor adjuvante therapie. Bovendien zijn nomogrammen bijzonder 
gebruiksvriendelijk en te downloaden via www.nomograms.org.
Hoofdstuk 6 beschrijft een studie naar factoren die risicoverhogend zijn voor het optreden van 
klinisch manifeste naadlekkage na TME. Hoewel TME resulteert in betere lokale controle en 
overleving in vergelijking met conventionele chirurgie, zijn er aanwijzingen dat er een groter 
risico is op naadlekkage. Dit hangt mogelijk samen met het verwijderen het mesorectum 
waardoor de bloedvoorziening van de naad gecompromitteerd kan raken. Een andere mo-
gelijke verklaring is het feit dat ten gevolge van TME een ruimte achterblijft in de presacrale 
ruimte die opgevuld raakt met geïnfecteerd hematoom dat vervolgens doorbreekt in de 
genezende naad, hetgeen leidt tot een naadlekkage. Naadlekkage is verantwoordelijk voor 
veel morbiditeit en zelfs mortaliteit. Dientengevolge is het zaak alle mogelijke maatregelen 
te treff en teneinde het risico op naadlekkage te reduceren.
Van 924 patiënten uit de TME studie die een laag anterieure resectie hadden ondergaan 
werden alle mogelijke risicofactoren in kaart gebracht en bezien of er een correlatie bestond 
met het optreden van naadlekkage. Uit de multivariaat analyse bleek de aanwezigheid van 
een ontlastend stoma, alsmede de plaatsing van een drain in de presacrale ruimte de enige 
2 signifi cante factoren die waren gecorreleerd met een minder vaak optreden van naadlek-
kage (8.2% vs. 16.0%, RR 1.89 (1.24-2.90), P=0.003 resp. 9.6% vs. 23.5%, RR 2.53 (1.57-4.09, 
P<0.001). Bovendien waren deze 2 factoren geassocieerd met een gunstig beloop in geval 
van naadlekkage. Het is opmerkelijk te noemen dat er een sterk wisselend beleid bestaat 
beleid bestaat in chirurgisch Nederland ten aanzien van het aanleggen van stoma’s en het 
plaatsen van drains. Er bestaat derhalve een noodzaak om meer standaardisatie aan te bren-
gen teneinde de kans op het optreden van klinisch manifeste naadlekkage terug te dringen.
Hoofdstuk 7 handelt over de late eff ecten van preoperatieve radiotherpie (5x5 Gy) en TME 
bij patiënten die zijn behandeld wegens een rectumcarcinoom. Naast “harde” eindpunten 
zoals overleving en locoregionale controle ontstaat er in toenemende mate aandacht voor 
de functionele resultaten van de multidisciplinaire behandeling van patiënten met een 
rectumcarcinoom. Er werd onderzocht in welke mate defecatie- en blaasfunctiestoornissen 
bestaan bij patiënten met een mobiel rectumcarcinoom, die behandeld werden middels 
TME, al dan niet in combinatie met kortdurende preoperatieve radiotherapie. Tevens werd 
stomafunctie onderzocht en de tevredenheid van patiënten met defecatie en blaasfunctie. 
Lange termijn morbiditeit werd geanalyseerd bij patiënten die gerandomiseerd werden in 
de TME trial. Nederlandse patiënten zonder een lokaal en/of afstandsrecidief kregen een 
vragenlijst toegestuurd.
Vijfhonderd en zevenennegentig van de 708 aangeschreven patiënten (84%) retourneerden 
een ingevulde vragenlijst. Incontinentie voor feces kwam vaker voor bij bestraalde patiënten 
(62% vs. 38%, P < 0.001), evenals de het dragen van opvangmateriaal wegens deze inconti-
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nentie(56% vs. 33%, P < 0.001). Bovendien was er vaker sprake van rectaal bloedverlies (11% 
vs. 3%, P = 0.004) en slijmverlies (27% vs. 15%, P = 0.005) in geval van radiotherapie. Boven-
dien voelden bestraalde patiënten zich meer beperkt ten gevolge van defecatiestoornissen 
in het ondernemen van dagelijkse activiteiten dan niet bestraalde patiënten. Er bestonden 
aanzienlijke blaasfunctiestoornissen die echter niet statistisch verschilden tussen bestraalde 
en niet-bestraalde patiënten.
Hoewel TME de mogelijkheid biedt tot het identifi ceren en sparen van zenuwen die van 
belang zijn voor een adequate blaasfunctie en defecatie, is er blijkbaar een aanzienlijke lange 
termijn morbiditeit van TME. Bovendien leidt kortdurende preoperatieve radiotherapie tot 
additionele defececatiestoornissen. Er dient echter opgemerkt te worden dat in deze studie 
een gezonde controlegroep ontbrak. Wellicht is een deel van de gerapporteerde functie-
stoornissen fysiologisch en derhalve leeftijdgebonden van aard. Niettemin kan worden 
gesteld dat er meer aandacht moet komen voor zenuwidentifi catie en –sparing, en dat er 
nagegaan moet worden of het additionele nadelige eff ect van radiotherpie deels voorkomen 
kan worden door patiënten met een rectumcarcinoom selectiever te bestralen.
Hoofstuk 8 rapporteert de resultaten van de TME studie na een mediane follow-up van 6 jaar. 
De vroege resultaten na een follow-up van 2 jaar toonden een signifi cante reductie in lokaal 
recidieven (2.4 vs. 8.2%, P<0.001) ten gunste van bestraalde patiënten. Er was echter geen 
overlevingswinst (82.0% vs. 81.8%, P=0.84), mogelijk ten gevolge van een korte follow-up 
duur.
Na 6 jaar bleek er sprake te zijn van persisterend signifi cant verschil in lokale controle 
(5-jaars getallen: 5.6% vs. 10.9%, P < 0.001), echter nog altijd niet resulterend in een over-
levingsverschil (64.2% vs. 63.5%, P = 0.902). Het is mogelijk dat een verschil van ‘slechts’ 
5.3% in lokaal recidief percentages te klein om de overleving in gunstige zin te beïnvloeden. 
Bovendien komen prognosebepalende afstandsmetastasen veel voor, ongeacht of er sprake 
is van voorbestraling of niet (25.8% vs. 28.3%, P = 0.387).
Subgroep analyses kunnen van belang zijn om de waarde van preoperatieve radiotherapie 
beter te kunnen inschatten teneinde selectiever te kunnen bestralen. Er kleven echter ook 
nadelen aan subgroup analyses: de ‘power’ is vaak onvoldoende om statistische signifi cantie 
aan te tonen dan wel te ontkrachten en ‘subgroups’ zijn bovendien voorafgaand aan de 
behandeling niet als zodanig betrouwbaar te onderscheiden. Derhalve dienen de resultaten 
van subgroup analyses niet zonder meer geëxtrapoleerd te worden naar de dagelijkse prak-
tijk in een poging de indicaties voor preoperatieve radiotherapie te versmallen. Niettemin 
vormen deze analyses een vorm van ‘evidence’. Volgens deze analyses hebben alleen patiën-
ten met tumoren tussen de 5 en 10 centimeter van de anaalring baat bij radiotherapie (3.7% 
vs. 13.7%, P<0.001). Bij proximale laesies (tussen 10 en 15 centimeter) zijn lokaal recidieven 
relatief zeldzaam en is er bovendien geen signifi cant voordeel van bestraling (3.7% vs. 6.2%, 
P=0.122). Bij distaal gelegen afwijkingen (tussen 0 en 5 centimeter) is er evenmin een eff ect 
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(10.7% vs. 12.0%, P=0.578). Bij deze laatste categorie patiënten is er echter vaak sprake van 
irradicale resecties (technisch moeilijke chirurgie laag in het kleine bekken), hetgeen een 
verstorend eff ect heeft op de waarde van preoperatieve radiotherapie: het is immers bekend 
dat radiotherapie niet eff ectief is indien er sprake is van positieve resectiemarges. Er moet 
echter benadrukt worden dat de exacte positie van de tumor en dus de a priori kans op een 
lokaal recidief moeilijk vast te stellen is: met enige regelmaat is er sprake van discrepantie 
tussen de bevindingen van endoscopie, CT, MRI en de bevindingen tijdens operatie.
Het eff ect van radiotherapie hangt mede af van het ziektestadium. Volgens de subgroup 
analyses hebben alleen de patiënten met lymfkliermetastasen (stadium III) baat bij radiothe-
rapie. Blijkbaar is radiotherapie in staat om na resectie van aangedane lymfklieren micros-
copische restziekte buiten het chirurgische resectievlak adequaat te bestrijden. Helaas zijn 
er op dit moment onvoldoende (radiologische) middelen om de aan- of afwezigheid van 
lymfkliermetastasen voorafgaand aan de behandeling nauwkeurig te kunnen vaststellen.
Concluderend resulteert preoperatieve radiotherapie in een relatieve risicoreductie van 
49% wat betreft lokaal recidieven (van 10.9% naar 5.6%). Gezien het ernstige klachtenpatroon 
dat samenhangt met een lokaal recidief, blijft kortdurende preoperatieve radiotherapie een 
waardevolle behandeling.
Hoofdstuk 9 beschrijft een ‘benchmark’ studie teneinde de gecombineerde behandeling met 
uitgebreide (chemo)radiatie, eventueel aangevuld met intra-operatieve radiotherapie te 
evalueren bij patiënten met een lokaal voortgeschreden rectumcarcinoom. Het Catharina 
Ziekenhuis in Eindhoven fungeert als verwijscentrum voor patiënten bij wie een radicale 
resectie (zonder voorafgaande behandeling) niet waarschijnlijk is. Patiënten met een tumor 
op een afstand van 2 of minder millimeter van de mesorectale fascie werden bestudeerd 
(n=252). De preoperatieve behandeling bestond uit langdurige radiotherapie met 50.4 Gy 
(1.8 Gy per fractie) en intra-operatieve radiotherapie (10-15 Gy) op het tumorgebied. Boven-
dien werd er neoadjuvant chemotherapie gegeven: aanvankelijk 5FU met leucovorin, later 
capecitabine and oxaliplatin. De resultaten van deze multi-modaliteit behandeling werden 
vergeleken met de resultaten van patiënten met pT3 rectumcarcinomen uit de TME trial die 
voorbestraald waren met 5x5 Gy.
Het lokaal recidief percentage na 3 jaar was signifi cant lager in patiënten afkomstig van 
de TME trial: 5% vs. 17% (P = 0.0001). Opmerkelijk was dat 83% van de patiënten met locally 
advanced’ laesies negatieve circumferentiële resectie marges (CRM) hadden versus 75% bij 
de patiënten uit de TME trial (P = 0.037). Overleving op 3 jaar verschilde niet signifi cant: 76% 
in TME trial patiënten en 67% bij de patiënten uit Eindhoven. Zowel de CRM als de lymf-
klierstatus zijn voorspellend voor zowel de kans op een lokaal recidief als voor ziektevrije 
en algehele overleving. Indien ondanks uitgebreide voorbehandeling geen radicale resectie 
wordt verricht is er sprake van een zeer slechte prognose. Deze prognose is slechter dan bij 
patiënten uit de TME trial bij wie er sprake was van een positieve CRM.
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Hoofdstuk 10 is een review die de rol van de schilwachtklierprocedure (SWP) bespreekt bij 
patiënten met een mamma-, maag- dan wel colorectaal carcinoom. Voor patiënten met een 
mamacarcinoom is de SWP geïntroduceerd teneinde de morbiditeit van een okselklierdis-
sectie te reduceren zonder de stagering, de locoregionale controle en de algehele overleving 
te compromitteren. Een bijkomend voordeel is de mogelijkheid om de schildwachtklier te 
onderzoeken op de aanwezigheid op ‘minimal residual disease’ (MRD): de aanwezigheid van 
micrometastasen en geïsoleerde tumorcellen heeft wellicht prognostische betekenis. Wel-
licht hebben de patiënten met MRD een verhoogde kans op terugkeer van de ziekte. Het 
review behandelt de uitgebreide verschillen in techniek die bestaan om de schildwachtklier 
te identifi ceren en vervolgens te onderzoeken op de aanwezigheid van MRD. Gezien de grote 
variatie in de gebruikte technieken, kunnen er (nog) geen unanieme conclusies getrokken 
worden ten aanzien van klinische consequenties van de aanwezigheid van MRD. Derhalve is 
er behoefte aan gestandaardiseerde technieken. Alleen dan kan er een adequate vergelijking 
gemaakt worden tussen de resultaten van de vele studies die er op dit gebied gepubliceerd 
worden, waardoor een behandelconsensus ontstaat voor patiënten met MRD.
Hoofdstuk 11 bevat een algehele discussie ten aanzien van de huidige ontwikkelingen op het 
gebied van maag- en rectumcarcinoom. Tevens is er in dit hoofdstuk een samenvatting van 
dit proefschrift te vinden.
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